Bifunctional compounds for degrading braf via ubiquitin proteosome pathway

Abstract

This disclosure relates to compounds of formula (I) useful for ex vivo, in vitro, or in vivo degradation of BRAF via a ubiquitin proteolytic pathway. This disclosure also provides pharmaceutically acceptable compositions comprising said compounds, and methods of using the compositions in the treatment of various diseases, conditions, and / or disorders. (I)

Description

WHAT IS CLAIMED IS: 1. A compound of Formula (I) (I) wherein R1is alkyl, aryl, amino, alkylamino, dialkylamino, cycloalkyl, or heterocycloalkyl, each unsubstituted or substituted with one or more halogen or hydroxyl; R1ais halogen; R1bis hydrogen, haloalkyl, or halogen; R2is hydrogen, alkyl, cycloalkyl, haloalkyl, or -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM; X1is carbon or nitrogen; X2is carbon or nitrogen; X3is sulfur, nitrogen, oxygen, or carbon; the bonds among X1, X2, and X3comprise single and double bonds, and the ring containing X1, X2, and X3is aromatic; X4is carbon or nitrogen; X5is hydrogen or -NR3R4; R3is hydrogen or alkyl where alkyl is unsubstituted or substituted with hydroxyl; R4is hydrogen, alkyl, cycloa -Cy1-Z3-L-UBM wherein Ar1is arylene or het bstituted or substituted with one or more alkyl or one or more h Z1is a bond or -CH2- n is zero or one; Z2is absent, -C(O)-,- -, - 0 y , 1-10 alkylene-C(Me)(Me)-, three- to six-membered cycloalkylene, three- to six-membered cycloalkylene-C1-10 alkylene, heterocycloalkylene, or -C(Me)(Me)-; Cy1is absent or heterocycloalkylene, unsubstituted or substituted with one or more alkyl or one or more halogen;Z3is absent, C1-10 alkylene, or -C(O)-; L is a linker according to –L1-L2-L3-L4– or –L4-L3-L2-L1–, wherein –L1– is absent, -N(R10)-, -C(R11)2-, -C(O)-, -C1-8 alkylene-, -C2-8 alkynylene-, -C6-10 aryl-, -C4-10 heteroaryl-, -Q1-, or -Q2-; each –L2–, –L3–, and –L4– is independently, absent, -N(R10)-, -C(R11)2-, -C(O)-, -O-, -(CH2CH2-O)1-8-, -C1-8 alkylene-, -C2-8 alkynylene-, -C6-10 aryl-, -C4-10 heteroaryl-, -Q1-, -Q2-, or -Q3-; each R10is independently, hydrogen or methyl; each R11is, independently, hydrogen, methyl, aryl, or heteroaryl; each -Q1- is a three- to seven-membered heterocycloalkylene comprising at least one nitrogen and is unsubstituted or substituted with one or more methyl, hydroxyl, or halogen; each -Q2- is a five- to thirteen-membered bicyclic heterocycloalkylene comprising at least one nitrogen, wherein the five- to thirteen-membered bicyclic heterocycloalkylene is optionally a spiro bicyclic heterocycloalkylene ring; each -Q3- is a three- to six-membered cycloalkylene; UBM is a ubiquitin ligase binding moiety; wherein at least one of R2or R4is -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM; or a stereoisomer and / or pharmaceutical salt thereof. 2. The compound of claim 1, having the following Formula (I) (I) wherein R1is alkyl, aryl, amino, alkylamino, dialkylamino, cycloalkyl, or heterocycloalkyl, each unsubstituted or substituted with one or more halogen or hydroxyl; R1ais halogen; R1bis hydrogen or halogen;R2is hydrogen, alkyl, cycloalkyl, haloalkyl, or -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM; X1is carbon or nitrogen; X2is carbon or nitrogen; X3is sulfur, nitrogen, oxygen, or carbon; the bonds among X1, X2, and X3comprise single and double bonds, and the ring containing X1, X2, and X3is aromatic; X4is carbon or nitrogen; X5is hydrogen or -NR3R4; R3is hydrogen or alkyl where alkyl is unsubstituted or substituted with hydroxyl; R4is hydrogen, alkyl, cycloalkyl, or -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM wherein Ar1is arylene or heteroarylene, each unsubstituted or substituted with one or more alkyl or one or more halogen; Z1is a bond or -CH2-; n is zero or one; Z2is absent, -C(O)-, -O- C1 10alk lene C1 10alkylene-C(Me)(Me)-, three- to six-membered cycloalkylene, t d cycloalkylene-C1-10alkylene, heterocycloalkylene, or -C(Me)( Cy1is absent or heterocy uted or substituted with alkyl; Z3is absent, C1-10alkyle L is a linker according to4-L3-L2-L1–, wherein –L1– is absent, -N( )-, -C( )2-, -C(O)-, -C1-8 alkylene-, -C2-8alkynylene-, -C6-10aryl-, -C4-10heteroaryl-, -Q1-, or -Q2-; each –L2–, –L3–, and –L4– is independently, absent, -N(R10)-, -C(R11)2-, -C(O)-, -O-, -(CH2CH2-O)1-8-, -C1-8 alkylene-, -C2-8 alkynylene-, -C6-10aryl-, -C4-10heteroaryl-, -Q1-, -Q2-, or -Q3-; each R10is independently, hydrogen or methyl; each R11is, independently, hydrogen, methyl, aryl, or heteroaryl; each -Q1- is a three- to seven-membered heterocycloalkylene comprising at least one nitrogen and is unsubstituted or substituted with methyl, hydroxyl, or halogen; each -Q2- is a five- to thirteen-membered bicyclic heterocycloalkylene comprising at least one nitrogen, wherein the five- to thirteen-memberedbicyclic heterocycloalkylene is optionally a spiro bicyclic heterocycloalkylene ring; each -Q3- is a three- to six-membered cycloalkylene; UBM is a ubiquitin ligase binding moiety; wherein at least one of R2or R4is -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM; or a stereoisomer and / or pharmaceutical salt thereof. 3. The compound of claim 2, wherein X1is nitrogen; X2is carbon, X3is sulfur; and X4is carbon or nitrogen. 4. The compound of claim 3, wherein R1is alkyl; R1ais fluoro; R2is -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM; n is zero; Z2is absent; and Cy1is an unsubstituted heterocycloalkylene. 5. The compound of claim 4, wherein Z3is -C(O)-. 6. The compound of claim 5, wherein L1is Q1. 7. The compound of claim 6, wherein L2is -C(O)-. 8. The compound of claim 7, wherein L3is Q1; and L4is absent. 9. The compound of any one of claims 4-8, wherein R1is -CH2CH2CH3. 10. The compound of claim 2, wherein X1is carbon or nitrogen; X2is nitrogen, and X3is carbon or nitrogen. 11. The compound of claim 10, wherein X1is carbon; X2is nitrogen, and X3is nitrogen. 12. The compound of claim 11, wherein R1is alkyl; R1ais fluoro; R2is -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM; Ar1is ; Z1is a bond; n is one; Z2and Z3are absent; andCy1is an unsubstituted heterocycloalkylene. 13. The compound of claim 12, wherein X4is carbon and X5is hydrogen. 14. The compound of claim 13, wherein L1is -C(R11)2-. 15. The compound of claim 14, wherein is R11hydrogen. 16. The compound of claim 15, wherein L2is Q1; and L3and L4are absent. 17. The compound of any one of claims 11-16, wherein R1is -CH2CH2CH3. 18. The compound of claim 2, wherein X1is nitrogen; X2is carbon, X3is sulfur; and X4is nitrogen. 19. The compound of claim 18, wherein R1is alkyl; R1ais fluoro; R2is alkyl; n is zero; Z2is absent; and Cy1is an unsubstituted heterocy 20. The compound of claim 19, wh- or -C(O)-. 21. The compound of claim 20, wherein L1is Q1, -C(R11)2-, or -CH2CH2CH2CH2CH2-, or Q3. 22. The compound of claim 21, wherein L2is absent, Q1, Q2, -C(R11)2-, -C(O)-, or -O-. 23. The compound of claim 22, wherein L3is absent, Q1, or -CH2CH2CH2-; and L4is absent. 24. The compound of any one of claims 19-23, wherein R1is -CH2CH2CH3. 25. The compound of claim 2, wherein UBM binds an E3 ubiquitin ligase. 26. The compound of claim 2, wherein UBM binds SCFβ-TRCP, VHL, MDM2, IAP, or CRBN. 27. The compound of claim 2, wherein UBM binds VHL. 28. The compound of claim 27, wherein UBM binds VHL and has the following chemical formula whereindesignates attachment to L; Z4is a bond, -CH2-, -C(O)-, -C(O)N(R12)-, or -N(R12)-, wherein R12is hydrogen or methyl; X6is C-H or nitrogen; R8is alkyl, alkenyl, alkylene, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, - S(O)(R13), or -S(O)2(R13); wherein R13is hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, aryl, heterocycle, or heteroaryl, wherein each alkyl, alkenyl, alkylene, alkynyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl is unsubstituted or substituted; R9is hydrogen, unsubstituted or substituted C1-8 alkyl, or -AA1-AA2-R14wherein each AA1and AA2is an amino acid residue, and R14is hydrogen or methyl. 29. The compound of claim 27, wherein UBM binds VHL and has the following chemical formula wherein designates attachment to L; Z5is a bond, -CH2-, -C(O)-, -C(O)N(R12)-, -N(R12)-, or -O-, wherein R12is hydrogen or methyl; A is phenyl or C4-heteroaryl; X7is -CH2, -NR12, oxygen, or sulfur, wherein R12is hydrogen or methyl; p is zero or one; R15is unsubstituted or substituted C1-8 alkyl, -AA1-AA2-R14, wherein each AA1and AA2is an amino acid residue, and R14is hydrogen or methyl. 30. The compound of claim 27, wherein UBM binds VHL and has the following chemical formula wherein designates attachment to L;Z6is a bond, -CH2-, -C(O)-, -C(O)N(R12)-, or N(R12), wherein R12is hydrogen or methyl; W is , , or wherein, designates attachment to X8, wherein designates attachment to X9, and wherein, designates attachment to Z6; X8is carbon or nitrogen; X9is C–H or -CH2-; R16is hydrogen, –OH, halogen, –NH2, -C1-3 alkyl, -C2-6 alkenyl, -C2-6 alkynyl, -C1-3 alkoxy, -C1-3thioalkyl, -C1-3alkylamine, -C6-10aryl, cycloalkyl, heterocycloalkyl, or heteroaryl; R17is -C(O)N(H)-C6-10aralkyl, -C(O)CH(t-butyl)-N(H)-C3-6cycloalkyl, -C(O)-CH(t-butyl)-N(H)C(O)-C3-C6cycloalkyl, , , , , or -AA1-AA2-R14, wherein each AA1and AA2is an amino acid residue and R14is hydrogen or methyl; and R18is halogen or . 31. The compound of claim 2, wherein UBM binds CRBN. 32. The compound of claim 31, wherein UBM binds CRBN and has the following chemical formulaor wherein X6absent or NR3; X7absent or -C(O)-; and X8is arylene or heteroarylene. 33. The compound of claim 32, wherein UBM binds CRBN and is selected from the group consisting of , , , , , , , , , , , , , and wherein X9is absent or halogen; and m is one, two, three, or four.34. A compound of Formula (II) (II) wherein R1is alkyl, aryl, amino, alkylamino, dialkylamino, cycloalkyl, or heterocycloalkyl, each unsubstituted or substituted with one or more halogen or hydroxyl; R1ais halogen; R1bis hydrogen or halogen; R2is -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM wherein Ar1is arylene or heteroarylene, each unsubstituted or substituted with one or more alkyl or one or more halogen; Z1is a bond or -CH2-; n is zero or one; Z2is absent, -C(O)-, -O-, C1-10alkylene, C1-10alkylene-C(Me)(Me)-, three- to six-membered cycloalkylene, three- to six-membered cycloalkylene-C1-10 alkylene, heterocycloalkylene, or -C(Me)(Me)-; Cy1is absent or heterocycloalkylene, unsubstituted or substituted with alkyl; Z3is absent, C1-10 alkylene, or -C(O)-; L is a linker according to –L1-L2-L3-L4– or –L4-L3-L2-L1–, wherein –L1– is absent, -N(R10)-, -C(R11)2-, -C(O)-, -C1-8alkylene-, -C2-8 alkynylene-, -C6-10 aryl-, -C4-10 heteroaryl-, -Q1-, or -Q2-; each –L2–, –L3–, and –L4– is independently, absent, -N(R10)-, -C(R11)2-, -C(O)-, -O-, -(CH2CH2-O)1-8-, -C1-8alkylene-, -C2-8alkynylene-, -C6-10aryl-, -C4-10heteroaryl-, -Q1-, -Q2-, or -Q3-; each R10is independently, hydrogen or methyl; each R11is, independently, hydrogen, methyl, aryl, or heteroaryl; each -Q1- is a three- to seven-membered heterocycloalkylene comprising at least one nitrogen and is unsubstituted or substituted with methyl, hydroxyl, or halogen;each -Q2- is a five- to thirteen-membered bicyclic heterocycloalkylene comprising at least one nitrogen, wherein the five- to thirteen-membered bicyclic heterocycloalkylene is optionally a spiro bicyclic heterocycloalkylene ring; each -Q3- is a three- to six-membered cycloalkylene; UBM is a ubiquitin ligase binding moiety; X1is nitrogen or oxygen; X3is sulfur when X1is nitrogen; oxygen when X1is nitrogen; or nitrogen when X1is oxygen; the bonds among X1and X3comprise single and double bonds, and the ring containing X1and X3is aromatic; X4is carbon or nitrogen; X5is hydrogen or -NR3R4; R3is hydrogen or alkyl where alkyl is unsubstituted or substituted with hydroxyl; R4is hydrogen, alkyl, or cycloalkyl; or a stereoisomer and / or pharmaceutical salt thereof. 35. The compound of claim 34, wherein X1is nitrogen; X3is oxygen; and X4is carbon or nitrogen. 36. The compound of claim 34, wherein X1is oxygen; X3is nitrogen; and X4is carbon or nitrogen. 37. The compound of claim 34, wherein X1is nitrogen; X3is sulfur; and X4is carbon or nitrogen. 38. The compound of claim 37, wherein R1is alkyl; R1ais fluoro; R2is -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM; n is zero; Z2is absent; and Cy1is an unsubstituted heterocycloalkylene. 39. The compound of claim 38, wherein Z3is -C(O)-. 40. The compound of claim 39, wherein L1is Q1. 41. The compound of claim 40, wherein L2is -C(O)-.42. The compound of claim 41, wherein L3is Q1and L4is absent. 43. The compound of any one of claims 38-42, wherein R1is -CH2CH2CH3. 44. The compound of claim 34, wherein UBM binds an E3 ubiquitin ligase. 45. The compound of claim 34, wherein UBM binds SCFβ-TRCP, VHL, MDM2, IAP, or CRBN. 46. The compound of claim 45, wherein UBM binds VHL. 47. The compound of claim 46, wherein UBM binds VHL and has the following chemical formula wherein designates attachment to L; Z4is a bond, -CH2-, -C(O)-, -C(O)N(R12)-, or -N(R12)-, wherein R12is hydrogen or methyl; X6is C-H or nitrogen; R8is alkyl, alkenyl, alkylene, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, - S(O)(R13), or -S(O)2(R13); wherein R13is hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, aryl, heterocycle, or heteroaryl, wherein each alkyl, alkenyl, alkylene, alkynyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl is unsubstituted or substituted; R9is hydrogen, unsubstituted or substituted C1-8 alkyl, or -AA1-AA2-R14wherein each AA1and AA2is an amino acid residue, and R14is hydrogen or methyl. 48. The compound of claim 46, wherein UBM binds VHL and has the following chemical formula wherein designates attachment to L;Z5is a bond, -CH2-, -C(O)-, -C(O)N(R12)-, -N(R12)-, or -O-, wherein R12is hydrogen or methyl; A is phenyl or C4-heteroaryl; X7is -CH2, -NR12, oxygen, or sulfur, wherein R12is hydrogen or methyl; p is zero or one; R15is unsubstituted or substituted C1-8 alkyl, -AA1-AA2-R14, wherein each AA1and AA2is an amino acid residue, and R14is hydrogen or methyl. 49. The compound of claim 46, wherein UBM binds VHL and has the following chemical formula wherein designates attachment to L; Z6is a bond, -CH2-, -C(O)-, -C(O)N(R12)-, or N(R12), wherein R12is hydrogen or methyl; W is , , or wherein, designates attachment to X8, wherein designates attachment to X9, and wherein, designates attachment to Z6; X8is carbon or nitrogen; X9is C–H or -CH2-; R16is hydrogen, –OH, halogen, –NH2, -C1-3alkyl, -C2-6alkenyl, -C2-6alkynyl, -C1-3alkoxy, -C1-3 thioalkyl, -C1-3 alkylamine, -C6-10 aryl, cycloalkyl, heterocycloalkyl, or heteroaryl; R17is -C(O)N(H)-C6-10 aralkyl, -C(O)CH(t-butyl)-N(H)-C3-6 cycloalkyl, -C(O)-CH(t-butyl)-N(H)C(O)-C3-C6 cycloalkyl, , ,, , or -AA1-AA2-R14, wherein each AA1and AA2is an amino acid residue and R14is hydrogen or methyl; and R18is halogen or . 50. The compound of claim 34, wherein UBM binds CRBN. 51. The compound of claim 50, wherein UBM binds CRBN and has the following chemical formula or wherein X6is absent or NR3; X7is absent or -C(O)-; and X8is arylene or heteroarylene. 52. The compound of claim 51, wherein UBM binds CRBN and is selected from the group consisting of , , , , , ,, , , , , , , and wherein X9is absent or halogen; and m is one, two, three, or four. 53. The compound of claim 2 Formula (I) or claim 34 Formula (II), wherein L comprises at least one -Q1-; at least one -Q2-; at least one -Q3-; at least one -C(R11)2-; or at least one C1-8 alkylene-. 54. The compound of claim 53, wherein L is selected from the group consisting of a. -Q1-; b. -Q1-C(O)-Q1-; c. -C(R11)2-Q1-; d. -Q1-C(R11)2-Q1-; e. -C(R11)2-O-; f. -Q3-O-; g. -C(R11)2-Q1-Q1-; h. -Q1-Q1-; i. -C(R11)2-Q2-; j. -C1-8alkylene-; k. -C(R11)2-Q1-C1-8alkylene-; l. -Q3-C(R11)2-; m. -C(R11)2-;n. -Q2-; o. -Q1-C(O)-C(R11)2-; p. -Q1-C(O)-Q3-O-; q. -Q1-C(O)-C(R11)2-Q1-; r. -Q1-C(R11)2-Q3-O-; and s. -Q1-C(R11)2-. 55. The compound of claim 54, wherein -Q1- is or wherein R19is hydrogen, hydroxyl, halogen, or unsubstituted alkyl, n1is one or two, n2is one or two, and n3is one or two. 56. The compound of claim 55, wherein -Q1- is selected from the group consisting of , , , and , wherein R19is hydrogen, hydroxyl, fluoro, or methyl. 57. The compound of claim 54, wherein -Q2- is , wherein n4is one or two, n5is one or two, and n6is one or two.58. The compound of claim 57, wherein -Q2- is selected from the group consisting of and . 59. The compound of claim 54, wherein -Q3- is , wherein n7is one or two, and n8is one or two. 60. The compound of claim 59, wherein -Q3- is selected from the group consisting of , , , and . 61. The compound of claim 54, wherein each R11is, independently, hydrogen or methyl. 62. The compound of claim 61, wherein both R11are hydrogen; one R11is hydrogen and one R11is methyl; or both R11are methyl. 63. The compound of claim 54, wherein -C1-8alkylene- is selected from the group consisting of -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, - CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2CH2-, and -CH2CH2CH2CH2CH2CH2CH2CH2-. 64. The compound of claim 54, wherein the linker L is selected from, , , , , , , , , , , , , , , , , , , , , , , , , ,, , , , , , , , , , , and , wherein indicates attachment to Z3, and indicates attachment to UBM. 65. The compound of any one of claims 2-9, 31-33, or 53-64 selected from the group consisting of (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(1-(1-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(1-(1-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(1-(1-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(1-(1-(4- (2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(1- (1-(1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (S)-N-(3-(2-(1-(1-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, and (S)-N-(3-(2-(1-(1-(1-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5- (pyridin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide. 66. The compound of any one of claims 2, 31-33, or 53-64 selected from the group consisting of (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4-yl)propyl)piperazin-1-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)- 2-fluorophenyl)propane-1-sulfonamide, N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-((1S,4r)-4-((6- ((S)-2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)cyclohexane-1- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(1- (1-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(2-(4-(2-(2,6-dioxopiperidin-3-yl)- 1,3-dioxoisoindolin-5-yl)piperazin-1-yl)acetyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(2-(1'-(2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-[1,4'-bipiperidin]-4-yl)acetyl)-4- methylpiperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(1-(1-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidine-4-carbonyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-((1-(2-(6- (2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(1H)-yl)acetyl)piperidin-4- yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-3- azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2- (1-(1-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyridin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(2-(1'-(2-(2,6-dioxopiperidin-3-yl)- 1,3-dioxoisoindolin-5-yl)-[1,4'-bipiperidin]-4-yl)acetyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(2-(4-(2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)acetyl)piperidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(1-(1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4- yl)azetidine-3-carbonyl)piperidin-4-yl)propan-2-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-((1-((1R,4r)-4-(3-((R)-2,6- dioxopiperidin-3-yl)phenoxy)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4- yl)-2-(3-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)-3- azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5- (2-aminopyrimidin-4-yl)-2-(1-(1-(2-(1-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)- 4-hydroxypiperidin-4-yl)acetyl)azetidin-3-yl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(1-(2-(1-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)acetyl)piperidin-4-yl)phenyl)thiazol-4- yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-((1- (4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)thiazol-4- yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(1-(2- (1-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4-yl)acetyl)piperidin-4- yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(4-(1-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(4-(1-((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, N-(3- (5-(2-aminopyrimidin-4-yl)-2-(3-(((1S,4r)-4-((5-((S)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)oxy)cyclohexyl)methyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(1-(4- (2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperazin-1-yl)phenyl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-5-(4-(9-(5-(2-aminopyrimidin-4-yl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-2-yl)-3-azaspiro[5.5]undecane-3-carbonyl)piperidin-1- yl)-N-(2,6-dioxopiperidin-3-yl)picolinamide, N-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-((S)-1- (5-((S)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)-3-azaspiro[5.5]undecan-9- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)- 2-(1-(1-(2-(1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)acetyl)azetidin-3- yl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide,(S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(1-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (S)-N-(3-(2-(1-(1-(1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4- carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyridin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(1-(1-((1-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2- (methylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3- (5-(2-aminopyrimidin-4-yl)-2-(2-(2-(1'-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)-[1,4'-bipiperidin]-4-yl)acetyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(1-(1-(1-(5-(2,6-dioxopiperidin-3- yl) i i 2 l i i i 4 l i i i 4 l i i i 4 l i in-4- yl)-4-yl)-2- (1-((1-(((1S,4r)-4-(4-((S)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexyl)methyl)piperidin-4- yl)meth l i idi 4 l thi l 4 l 2 fl h nyl)propane-1-sulfonamide, (R)-N-(3-(5- (2-amridin-3-yl)-1,3-dioxoisoindolin-5- yl)piperidine-4-carbonyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (S)-N-(3-(2-(1-(1-(2-(1-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4- yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2- fluoropheny pane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(1-(1-(1-(5- (2,6-dioxopidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin- 4-yl)ethyl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)piperazin-1-yl)acetyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(1-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperazin-1-yl)phenyl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(1-(1-(1-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4- yl)-2-(1-(1-(1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamidef, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(4-(4-((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-1-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(1-((1-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(2-(1-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)acetyl)piperazin-1-yl)phenyl)thiazol-4- yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(1'- (2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-[1,4'-bipiperidin]-4-yl)acetyl)-3- azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5- (2-aminopyrimidin-4-yl)-2-(1-(1-((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidine-4-carbonyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(1-(1-(1-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(2- (isopropylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)piperazin-1-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1-sulfonamide, N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-((1-((1R,4r)-4-(4-((R)-2,6- dioxopiperidin-3-yl)phenoxy)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)piperidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-(6-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-2- azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, N-(3-(2-(1-(1- (1-(5-((S)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(2-(((R)-1-hydroxypropan-2-yl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-((1- (5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)thiazol- 4-yl)-2-fluorophenyl)propane-1-sulfonamide, rac-(3R)-3-{6-[4-(4-{4-[5-(2-aminopyrimidin- 4-yl)-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-1,3-thiazol-2-yl]piperidine-1- carbonyl}piperidine-1-carbonyl)piperidin-1-yl]pyridin-3-yl}piperidine-2,6-dione, rac-(3R)-3- {6-[4-(4-{4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-5-{2-[(propan-2- yl)amino]pyrimidin-4-yl}-1,3-thiazol-2-yl]piperidine-1-carbonyl}piperidine-1- carbonyl)piperidin-1-yl]pyridin-3-yl}piperidine-2,6-dione, (S)-N-(3-(5-(2-aminopyrimidin-4- yl)-2-(1-(1-((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(1-(1-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperidin-4-yl)methyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(2-(2-(2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-4- methylpiperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)piperidine-4-carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1-sulfonamide, (R)-N-(3-(2-(1-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)- 2,7-diazaspiro[3.5]nonan-7-yl)acetyl)piperidin-4-yl)-5-(2-(methylamino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4- yl)-2-(3-(6-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-3- azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5- (2-aminopyrimidin-4-yl)-2-(1-(1-(2-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(1-(1-(1-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2- (methylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3- (5-(2-aminopyrimidin-4-yl)-2-(1-(1-(2-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin- 4-yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (S)-N-(3-(2-(1-(1-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2-(isopropylamino)pyrimidin-4-yl)thiazol- 4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-(cyclopropylamino)pyrimidin-4- yl)-2-(1-(1-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(1- (1-(1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, N-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-((R)-1-(4-((S)-2,6-dioxopiperidin-3- yl)phenyl)pyrrolidin-3-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(2-(2-(2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-2- azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(1-((1-(2-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)piperidin-4-yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(1-(1-(2,6- dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)piperidine-4- carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2-(1-(1-((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(2-(methylamino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(1-(1-(2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)azetidine-3- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(2-(1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)piperidin-4-yl)azetidine-3-carbonyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(1-((1-(1- (2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)piperidin- 4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(2-(2-(2,6-dioxopiperidin-3-yl)- 1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-3-azaspiro[5.5]undecan-9- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-(1-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7- diazaspiro[3.5]nonan-7-yl)acetyl)piperidin-4-yl)propan-2-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, and (R)-4-((4-(5-(2-aminopyrimidin-4-yl)-4-(2-fluoro- 3-(propylsulfonamido)phenyl)thiazol-2-yl)piperidin-1-yl)methyl)-N-(2,6-dioxopiperidin-3- yl)benzamide. 67. The compound of any one of claims 2, 18-24, 31-33, or 53-64 selected from the group consisting of (R)-4-(4-((6-((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5- yl)pyrimidin-2-yl)amino)-2-azaspiro[3.3]heptan-2-yl)methyl)piperidin-1-yl)-N-(2,6- dioxopiperidin-3-yl)benzamide, N-(3-(2-(tert-butyl)-5-(2-((2-(2-((S)-1-(5-((S)-2,6- dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)-2-azaspiro[3.3]heptan-6- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2- (tert-butyl)-5-(2-((2-(2-(1'-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-[1,4'- bipiperidin]-4-yl)acetyl)-2-azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((2-(1-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)piperidine-4- carbonyl)-2-azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((2-(1-(1-(2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)azetidine-3-carbonyl)-2- azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((2-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-2-azaspiro[3.3]heptan-6- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2- (tert-butyl)-5-(2-((2-(6-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-2- azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((2-((1-((1-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)-2-azaspiro[3.3]heptan-6- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2- (tert-butyl)-5-(2-((2-(2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4- yl)propyl)piperazin-1-yl)acetyl)-2-azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((2-(1-((1-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-4-fluoropiperidine-4-carbonyl)-2- azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((2-((1-(1-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidine-4-carbonyl)piperidin-4-yl)methyl)-2-azaspiro[3.3]heptan-6- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2- (tert-butyl)-5-(2-((1'-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)- [1,4'-bipiperidin]-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((7-(2-(4-(4-((2,6-dioxopiperidin-3- yl)amino)phenyl)piperidin-1-yl)acetyl)-7-azaspiro[3.5]nonan-2-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((7- (((1S,4r)-4-(4-((S)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexyl)methyl)-7- azaspiro[3.5]nonan-2-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((7-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxo-1,2- dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-7-azaspiro[3.5]nonan-2-yl)amino)pyrimidin- 4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((7- ((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-7-azaspiro[3.5]nonan-2- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, and (R)-N-(3-(2-(tert-butyl)-5-(2-((7-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin- 1-yl)acetyl)-7-azaspiro[3.5]nonan-2-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide. 68. The compound of any one of claims 2, 31-33, or 53-64 selected from the group consisting of (S)-N-(3-(2-(tert-butyl)-5-(2-((4-(1-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-3-yl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((4-(1-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3- dioxoisoindolin-5-yl)oxy)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((4-(1-(2-((2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)acetyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N- (3-(2-(tert-butyl)-5-(2-((4-(1-(2-(4-(4-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperazin-1- yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((4-(1-(2-((S)-1-(5-((S)-2,6-dioxopiperidin-3- yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-4-(4-((4-(4-((4-(2-(tert-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)phenyl)piperidin-1- yl)methyl)piperidin-1-yl)-N-(2,6-dioxopiperidin-3-yl)benzamide, (R)-5-(4-((4-(4-((4-(2-(tert- butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2- yl)amino)phenyl)piperidin-1-yl)methyl)piperidin-1-yl)-N-(2,6-dioxopiperidin-3- yl)picolinamide, N-(3-(2-(tert-butyl)-5-(2-((4-(1-(((1S,4r)-4-((5-((S)-2,6-dioxopiperidin-3- yl)pyridin-2-yl)oxy)cyclohexyl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol- 4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(tert-butyl)-5-(2-((4-(1-((1-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((4-(1-(2- ((S)-1-(4-((S)-2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)acetyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, N-(3- (2-(tert-butyl)-5-(2-((4-(1-(2-((R)-1-(4-((S)-2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3- yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((4-(1-((R)-1-(5-((S)-2,6-dioxopiperidin-3- yl)pyridin-2-yl)pyrrolidine-3-carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(tert-butyl)-5-(2-((4-(1-(1-(4-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N- (3-(2-(tert-butyl)-5-(2-((4-(1-(2-(1'-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)- [1,4'-bipiperidin]-4-yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(tert-butyl)-5-(2-((4-(1-(1-(5-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, N-(3- (2-(tert-butyl)-5-(2-((4-(1-(2-((S)-1-(1-((R)-2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-5-yl)pyrrolidin-3-yl)acetyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N- (3-(2-(tert-butyl)-5-(2-((4-(1-(1-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro- 1H-benzo[d]imidazol-4-yl)piperidine-4-carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(tert-butyl)-5-(2-((4-(1- (1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)azetidine-3-carbonyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N- (3-(2-(tert-butyl)-5-(2-((4-(1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)piperidine-4-carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((4-(1-(2-(2-(2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7- yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((4-(1-(6-(2-(2,6-dioxopiperidin-3-yl)-3- oxoisoindolin-5-yl)hexanoyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((4-(1-(2-(4-(2-(2,6- dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)acetyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-5- (4-((4-(((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2- yl)amino)methyl)piperidin-1-yl)methyl)piperidin-1-yl)-N-(2,6-dioxopiperidin-3- yl)picolinamide, (S)-5-(4-((4-(1-((4-(2-(tert-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-2-methylpropan-2- yl)piperidin-1-yl)methyl)piperidin-1-yl)-N-(2,6-dioxopiperidin-3-yl)picolinamide, (R)-N-(3- (2-(tert-butyl)-5-(2-(((1-((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidin-4-yl)methyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((2-(1-((1-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)-2-methylpropyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, 5-(4-(((R)-3-(((4-(2-(tert-butyl)-4-(2- fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)methyl)pyrrolidin-1- yl)methyl)piperidin-1-yl)-N-((S)-2,6-dioxopiperidin-3-yl)picolinamide, N-(3-(2-(tert-butyl)- 5-(2-(((1r,4r)-4-((4-((1-(4-((S)-2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-1-yl)methyl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-(((1s,4s)-4-(4-(1-(5-((S)-2,6- dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperazin-1- yl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, N- (3-(2-(tert-butyl)-5-(2-(((1r,4r)-4-(4-(1-(5-((S)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidine-4-carbonyl)piperazin-1-yl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-(((1r,4r)-4-(4-((1-(5-((S)-2,6- dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1- yl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, N- (3-(2-(tert-butyl)-5-(2-(((1s,4s)-4-(4-((1-(5-((S)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperazin-1-yl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (3R)-3-{4-[4-({4-[6-({4-[2-tert-butyl-4-(3- {[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-1,3-thiazol-5-yl]pyrimidin-2- yl}amino)pyridin-3-yl]piperazin-1-yl}methyl)piperidin-1-yl]phenyl}piperidine-2,6-dione, (3S)-3-{4-[4-({4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-1,3-thiazol-5-yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazin-1- yl}methyl)piperidin-1-yl]phenyl}piperidine-2,6-dione, rac-(3S)-3-{6-[4-({4-[6-({4-[2-tert- butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-1,3-thiazol-5-yl]pyrimidin-2- yl}amino)pyridin-3-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridin-3-yl}piperidine-2,6- dione, rac-(3S)-3-(2-{[(1r,4r)-4-{4-[6-({4-[2-tert-butyl-4-(3- {[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-13-thiazol-5-yl]pyrimidin-2- yl}amino)pyridin-3-yl]piperazine-1-car hyl}-1,2,3,4- tetrahydroisoquinolin-6-yl)piperidine-2, (2-{[(1r,4r)-4-{4-[6-({4-[2-tert- butyl-4-(3-{[ethyl(methyl)sulfamoyl]am 1,3-thiazol-5-yl]pyrimidin-2- yl}amino)pyridin-3-yl]piperazine-1-car hyl}-1,2,3,4- tetrahydroisoquinolin-7-yl)piperidine-2, 2-(tert-butyl)-5-(2-((2-(2-(4-(4- ((2,6-dioxopiperidin-3-yl)amino)phenyly y -1,2,3,4-tetrahydroisoquinolin-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-5-(4-(6- ((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2- yl)amino)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidin-1-yl)-N-(2,6-dioxopiperidin-3- yl)picolinamide, N-(3-(2-(tert-butyl)-5-(2-((2-((R)-1-(5-((S)-2,6-dioxopiperidin-3-yl)pyridin- 2-yl)pyrrolidine-3-carbonyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(tert-butyl)-5-(2-((2-(2- (4-(4-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperazin-1-yl)acetyl)-1,2,3,4- tetrahydroisoquinolin-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (S)-N-(3-(2-(tert-butyl)-5-(2-((1-((1-(2-(6-(2,6-dioxopiperidin-3-yl)-3,4- dihydroisoquinolin-2(1H)-yl)acetyl)piperidin-4-yl)methyl)-1H-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert- butyl)-5-(2-((1-((1-((1S,4r)-4-(4-((S)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexane-1- carbonyl)piperidin-4-yl)methyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((1-((1-((1S,4r)-4-((5-((S)-2,6- dioxopiperidin-3-yl)pyridin-2-yl)oxy)cyclohexane-1-carbonyl)piperidin-4-yl)methyl)-1H- pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)- N-(3-(2-(tert-butyl)-5-(2-((1-((1-(2-(4-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin- 1-yl)acetyl)piperidin-4-yl)methyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- ropane-1-sulfonamide, (R)-5-(4-(4-((4-((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-1H-pyrazol-1- yl)methyl)piperidine-1-carbonyl)piperidin-1-yl)-N-(2,6-dioxopiperidin-3-yl)picolinamide, N- (3-(2-(tert-butyl)-5-(2-((1-((1-((R)-1-(5-((S)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine- 3-carbonyl)piperidin-4-yl)methyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(tert-butyl)-5-(2-((1-((1-(2-(4-(4-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)piperazin-1-yl)acetyl)piperidin-4-yl)methyl)-1H-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert- butyl)-5-(2-((1-((1-(2-((S)-1-(4-((S)-2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3- yl)acetyl)piperidin-4-yl)methyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((1-((1-(2-((R)-1-(4-((S)-2,6- dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)acetyl)piperidin-4-yl)methyl)-1H-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert- butyl)-5-(2-((1-(1-((1S,4r)-4-(4-((S)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexane-1- carbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfona utyl)-5-(2-((1-(1-((1S,4r)-4-((5-((S)-2,6- dioxopiperidin-3-yl)pyridin-2-y carbonyl)piperidin-4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol l)propane-1-sulfonamide, (R)-N-(3-(2- (tert-butyl)-5-(2-((1-(1-(2-(4-(4-3-yl)amino)phenyl)piperidin-1- yl)acetyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-5-(4-(4-(4-((4-(2-(tert-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-1H-pyrazol-1-yl)piperidine- 1-carbonyl)piperidin-1-yl)-N-(2,6-dioxopiperidin-3-yl)picolinamide, N-(3-(2-(tert-butyl)-5- (2-((1-(1-((R)-1-(5-((S)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine-3- carbonyl)piperidin-4-yl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((1-(1-(2-((S)-1-(4-((S)-2,6- dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)acetyl)piperidin-4-yl)-1H-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2- (tert-butyl)-5-(2-((3-(1-(2-(6-(2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(1H)- yl)acetyl)piperidin-4-yl)p ol-4-yl)-2-fluorophenyl)propane- 1-sulfonamide, (1-(2-(4-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-1-yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((3-(1-((R)-1-(5-((S)- 2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine-3-carbonyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N- (3-(2-(tert-butyl)-5-(2-((3-((1-(2-(6-(2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(1H)- yl)acetyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(tert-butyl)-5-(2-((3-((1-(1-(4-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(tert-butyl)-5-(2-((3 piperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((3-((1-((1S,4r)-4-(4-((S)-2,6- dioxopiperidin-3-yl)phenoxy)cyclohexane-1-carbonyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thia (3-(2-(tert-butyl)-5-(2-((3-((1-((1S,4r)-4- yl)oxy)cyclohexane-1-carbonyl)piperidin yl)-2-fluorophenyl)propane-1-sulfonamid( namide, ( -5-dioxopiperidin-3-yl)picolinamide, N-(3-(2-(tert-butyl)-5-(2-((3-((1-((R)-1-(5-((S)-2,6- dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine-3-carbonyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(tert-butyl)-5-(2-((3-((1-(2-(4-(4-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperazin- 1-yl)acetyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((3-((1-(2-((S)-1-(4-((S)-2,6- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((4-(1- ((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4 yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-e, (S)-N- (3-(2-(tert-butyl)-5-(2-((4-(4-((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-1-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((4-(4-((1-(4-(2,6- dioxopiperidin-3-yl)phenyl)pip yl)-3- fluorophenyl)amino)pyrimidin yl)propane-1-sulfonamide, (2S,4R)-1-((S)-2-(5-(4-(4-((4-( (propylsulfonamido)phenyl)thi phenyl)piperidin-1-yl)-5- oxopentanamido)-3,3-dimethyl4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2-carboxamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((2-((1-(2-(2,6- dioxopiperidin-3-yl)-1-oxo-1,2-dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-1,2,3,4- tetrahydroisoquinolin-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((1-((1-(((1S,4r)-4-(4-((S)-2,6-dioxopiperidin-3- yl)phenoxy)cyclohexyl)methyl)piperidin-4-yl)methyl)-1H-pyrazol-4-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((1-((1-((1-(2-(2,6-dioxopiperidin-3-yl)-1-oxo-1,2-dihydroisoquinolin-6-yl)piperidin-4-1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((3-(1-(2-((R)-1-(5-((S)-2,6-dioxopiperidin-3- yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4- e-1-sulfonamide, N-(3-(2-(tert-butyl)-5-(2-((3-(1-(2-((S)-1-(5-((S)- ridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4- -4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N- (1-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidin- )phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-p y p p - - ulfonamide, N-(3-(2-(tert-butyl)-5-(2-((3-((1-(((1S,4r)-4-(4-((S)-2,6- dioxopiperidin-3-yl)phenoxy)cyclo yl)oxy)phenyl)amino)pyrimidin-4- nyl)propane-1-sulfonamide, (R)-N-(3-(2-(tert-butyl)-5-(2-((3-(( -3-yl)-1-oxo-1,2- dihydroisoquinolin-6-yl)piperidin- xy)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)pro -(2-(tert-butyl)-5-(2-((3-((1-(2-((R)-1-(5-((S)-2,6-dioxopi yrrolidin-3-yl)ethyl)piperidin-4- yl)oxy)phenyl)amino)pyri fluorophenyl)propane-1-sulfonamide, N- (3-(2-(tert-butyl)-5-(2-((3- oxopiperidin-3-yl)pyridin-2- yl)pyrrolidin-3-yl)ethyl)pi mino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-s 3-(2-(tert-butyl)-5-(2-((3-((1-((1-(5-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)methyl)piperidin-4- yl)oxy)phenyl)amino)pyrimid rophenyl)propane-1-sulfonamide, (R)-5-(4-((4-(4-((4-(2-(tert-bu ulfonamido)phenyl)thiazol-5- yl)pyrimidin-2-yl)amino)-1H- l)methyl)piperidin-1-yl)-N-(2,6- dioxopiperidin-3-yl)picolinam -((4-((4-(2-(tert-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)th amino)-1H-pyrazol-1-yl)methyl)piperidin-1-yl)methyl)piperidin-1-yl)-N-(26-dioxopiperidin-3-yl)picolinamide, (S)-N-(3-(2-(tert-butyl)-5-(2-((4-( -3-yl)phenyl)piperidine-4- carbonyl)piperazin-1-yl)-3-fluoro -yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonam -(1-((1-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidin-4-yl)methyl) o)pyrimidin-4-yl)-2- methylthiazol-4-yl)-2-fluorophen(R)-N-(3-(5-(2-((4-(1-((1-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4 henyl)amino)pyrimidin-4- yl)-2-methylthiazol-4-yl)-2-fluorophen (S)-N-(3-(5-(2-((5-(4-((1- (5-(2,6-dioxopiperidin-3-yl)pyridin-2-y perazin-1-yl)pyridin-2- yl)amino)pyrimidin-4-yl)-2-methylthia ropane-1-sulfonamide, (S)- N-(3-(5-(2-((5-(4-((1-(4-(2,6-dioxopipe -4-yl)methyl)piperazin-1- yl)pyridin-2-yl)amino)pyrimidin-4-yl)-- e y a o - -y - - uorophenyl)propane-1- sulfonamide, (R)-N-(3-(5-(2-((5-(4- 3-yl)phenyl)piperidin-4- yl)methyl)piperazin-1-yl)pyridin-2-yl)ami lthiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, -5-(2-((4-(4-((1-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl) yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1- -(tert-butyl)-5-(2-((4-(4-((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazin-1- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N- (3-(2-(tert-butyl)-5-(2-((4-(4-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)piperazin-1-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, rac-(3R)-3-[6-(4-{4-[6-({4-[2-tert-butyl-4-(3-{[ethy -2-fluorophenyl)-1,3-thiazol-5-y yl}am 1-carbonyl}piperidin-1-yl)pyrid dione, (1-(1-(5-(2,6-dioxopiperidin-3-y carbon ino)pyrimidin-4-yl)-2-methylth fluoro ide, N-(3-(2-(tert-butyl)-5- dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine-3-carbonyl)piperazin-1-yl)-3- fluorophenyl)amino)pyrimidin- yl)propane-1-sulfonamide, (R)- N-(3-(5-(2-((4-(1-((1-(5-(2,6-di piperidin-4- yl)methyl)piperidin-4-yl)pheny hylthiazol-4-yl)-2- fluorophenyl)propane-1-sulfon -5-(2-((4-(4-((R)-1-(5-((R)-2,6- dioxopiperidin-3-yl)pyridin-2-y zin-1-yl)-3- fluorophenyl)amino)pyrimidin-yl)propane-1-sulfonamide, rac- 2(1H)-yl)acetyl)piperazin-1-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-s yl)-5-(2-((4-(4-((1S,4r)-4-((5-((S)-2,6- dioxopiperidin-3-yl)pyridi bonyl)piperazin-1-yl)-3- fluorophenyl)amino)pyrim rophenyl)propane-1-sulfonamide, (R)- N-(3-(2-(tert-butyl)-5-(2-( idin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)piperazin-1-yl)-3 in-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(tert-butyl)-5-(2-((4-(4-((1-(5-(26- dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperaz yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)p - (3-(2-(tert-butyl)-5-(2-((4-(4-(2-(1-(4-((2,6-dioxopiperidin-3-yl yl)acetyl)piperazin-1-yl)-3-fluorophenyl)amino)pyrimidin-4-yl fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(tert- dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-3- fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)- N-(3-(5-(2-((4-(1-(2-(1-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4-yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl) fluorophenyl)propane-1-sulfonamide, {4-[4-(3- {[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-2-m din-2- yl}amino)pyridin-3-yl]piperazin-1-yl}methyl)piperidin 2,6- dione, rac-(3S)-3-[6-(4-{4-[6-({4-[2-tert-butyl-4-( mino}-2-fluorophenyl)-1,3-thiazol-5-yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazine-1-carbonyl}-4- methylpiperidin-1-yl)pyridin-3-yl]piperidine-2,6-dione, - {[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-2-methyl-1, yl}amino)pyridin-3-yl]piperazin-1-yl}methyl)piperidin-1-yl]ph rac-(3S)-3-[6-(4-{4-[6-({4-[4-(3-{[ethyl(methyl)sulfamoyl]ami methyl-1,3-thiazol-5-yl]pyrimidin-2-yl}amino)pyridin-3-yl]pip1-yl)pyridin-3-yl]piperidine-2,6-dione, rac-(3R)-3-{6-[4-(2-{4-[6-({4-[4-(3- [ th l(m th l) lf m l] min 2 fl r h n l) 2 m th l 13 thi z l 5 l] rimidin 21-sulfonamide, rac-(3S)-3-{6-[4-({4-[6-({4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorop imidin-2-yl}amino)pyridin-3-yl]piperazin-1- yl}met 3-yl}piperidine-2,6-dione, rac-(3S)-3-{4-[4-({4- [6-({4- o}-2-fluorophenyl)-2-methyl-1,3-thiazol-5- yl]pyri azin-1-yl}methyl)-4-fluoropiperidin-1-yl]phenyl}piperidine-2,6-dione, (S)-N-(3-(5-(2-((4-(4-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin- 2-yl)-4-methylpiperidin-4-yl)methyl)piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-2- methylthiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-((4-(4-((1-(4-(2,6- dioxopiperidin-3-yl)phenyl)-4-fluoropiperidin-4-yl)methyl)piperazin-1- yl)phenyl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2-fluorophenyl)propane-1-dione, rac-(3R)-3-[2-(2-{4-[4-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-1,3-thiazol-5 2-fluorophenyl]piperazin-1-yl}-2- oxoethyl)-1,2,3,4-tetrahydr -2,6-dione, and (3R)-3-{6-[4-({4-[6- ({4-[4-(3-{[ethyl(methyl)s enyl)-2-methyl-1,3-thiazol-5- yl]pyrimidin-2-yl}amino)p ethyl)piperidin-1-yl]pyridin-3- yl}piperidine-2,6-dione.69. The compound of any one of claims 2 10-17 31-33 or 53-64 selected from the group l)piperidin-4- nyl)propane- l)piperidin-4- nyl)propane- -yl)piperidin-fluorophenyl)propane-1-sulfonamide. 70. The compound of any one of 3-64 selected from the group consisting of (R)-N-(3-(1-(4- ridin-3-yl)phenyl)piperidine-4- carbonyl)piperazine-1-carbonyl)phenyl yrazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, 4-((1-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidin-4-yl)methyl)pipera )-3-(pyridin-4-yl)-1H-pyrazol- 4-yl)-2-fluorophenyl)propane-1-sulfona(4-(1-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidine-4-carbonyl)piperazin-1-yl)phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(1-(4-((1-(1-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4-yl)oxy)phenyl)-3-(pyridin-4-yl)-1H- pyrazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(1-(4-(4-((1-(5-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)methyl)piperazin-1-yl)phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(1-(4-(4- ((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazine-1-carbonyl)phenyl)- 3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(1-(1-(1- (1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin- 4-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(1- (4-(4-((1-(4-(2,6-dioxopiperidin-3-yl)-3-fluorophenyl)piperidin-4-yl)methyl)piperazin-1- yl)phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N- (3-(1-(4-(1-((1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)methyl)piperidin- 4-yl)phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)- N-(3-(1-(1-(1-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (S)-N-(3-(1-(4-(4-((1-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4- yl)methyl)piperazin-1-yl)phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane- 1-sulfonamide, (S)-N-(3-(1-(6-(4-((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-1-yl)pyridin-3-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(1-(4-(4-(2-(1-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidin-4-yl)a bonyl)phenyl)-3-(pyridin-4-yl)-1H- pyrazol-4-yl)-2-fluorophenyl)pr , (S)-N-(3-(1-(1-(1-((1-(5-(2,6- dioxopiperidin-3-yl)pyridin-2-y yl)piperidine-4-carbonyl)piperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(1-(4-(4- ((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(1-(6-(4- ((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)pyridin-3- yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(1-(4- (1-((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(1-(4-(1- ((1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(1-(4-(1- ((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(1-(4-(4- ( peridin-4-yl)methyl)piperazin-1-yl)phenyl)-3- ( henyl)propane-1-sulfonamide, (S)-N-(3-(1-(1-(1-(1- (5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (S)-N-(3-(1-(4-(1-((1-(4-(2,6-dioxopiperidin-3-yl)-3-fluorophenyl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)propane- 1-sulfonamide, and (R)-N-(3-(1-(4-(4-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin- 4-yl)methyl)piperazin-1-yl)phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide. 71. The compound of any one of claims 34, 37-45, or 50-54 selected from the group (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(1-(1-(5-(2,6-dioxopiperidin-3-idine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(1-(1-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(1-(1-(1-(5-( carbonyl)-4-methylpiperidine-4-carbo fluorophenyl)propane-1-sulfonamide, (2,6-dioxopiperidin-3-yl)phenyl)pipeN-(3-(2-(1- -iperidine-4- carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, and (S)-N-(3-(2-(1-(1-(1-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5- (pyridin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide. 72. The compound of any one of claims 34, 37, 44, 45, or 50-64 selected from the group consisting of (R)-N-(3-(5-(2-aminopyrimidin-4-yl 2 3 2 4 3 2 26 di i idi 3 l)- 1,3-dioxoisoindolin-4-yl)propyl)piperazin-1-yl)a 4-yl)-2-fluorophenyl)propane-1-sulfonamide, N -4-((6-((S)-2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)cyclohexane-1- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(1- (1-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin 1-(2-(1'-(2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-[1,4'-bipiperidin]-4-y 4-methylpiperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(1-(1-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidine-4-carbonyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-((1-(2-(6- (2,6-dioxopiperidin-3-yl)-3,4-d )-yl)acetyl)piperidin-4- yl)methyl)piperidin-4-yl)thiazo propane-1-sulfonamide, (S)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-((1- -3-yl)phenyl)piperidin-4-yl)methyl)-3- azaspiro[5.5]undecan-9-yl)thia l)propane-1-sulfonamide, (S)-N-(3-(2- (1-(1-((1-(5-(2,6-dioxopiperidieridin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyridin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(2-(1'-(2-(2,6-diox 1,3-dioxoisoindolin-5-yl)-[1,4'-bipiperidin]-4-yl)acetyl)piperidin-4-yl)thiazol fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)acetyl)pipe yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-am yl)-2-(2-(1-(1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperi- - y s d y y a(2-aminopyrimidin-4-yl)-2-(1-(1-(2-(1-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)- 4-hydroxypiperidin-4-yl)acetyl)azetidin-3-yl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(1-(2-(1-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)acetyl)piperidin-4-yl)phenyl)thiazol-4- yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-((1- (4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)thiazol-4-yl)- (1-( yl)p ami car (3-( yl)(5-(2-aminopyrimidin-4-yl)-2-(3-(((1S,4r)-4-((5-((S)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)oxy)cy ro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluoroph e, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(1-(4- (2,6-diox eridine-4-carbonyl)piperazin-1-yl)phenyl)thiazol-4-yl)-2- fluoroph e, (R)-5-(4-(9-(5-(2-aminopyrimidin-4-yl)-4-(2-fluoro-3- (propylsu 2-yl)-3-azaspiro[5.5]undecane-3-carbonyl)piperidin-1- yl)-N-(2,6-dioxopiperidin-3-yl)picolinamide, N-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-((S)-1- (5-((S)-2,6-dioxopiperidin-3-yl)pyridin-2-y zaspiro[5.5]undecan-9- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-s -aminopyrimidin-4-yl)- 2-(1-(1-(2-(1-(4-(2,6-dioxopiperidin-3-yl)p )azetidin-3- yl)piperidin-4-yl)thiazol-4-yl)-2-fluorophen , (S)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-(1-(5-(2,6-dioxol)piperidine-4- carbonyl)-3-azaspiro[5.5]undecan-9- l)thiazol-4- l)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-y piperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperidin- -fluorophenyl)propane-1- sulfonamide, (S)-N-(3-(2 eridin-3-yl)phenyl)piperidine-4- carbonyl)piperidine-4-carbonyl)pip l)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamid(1-((1-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidin-4-yl)methyl)pip in-4-yl)-5-(2- (methylamino)pyrimidin-4-yl)thiazol-4-y -1-sulfonamide, (R)-N-(3- (5-(2-aminopyrimidin-4-yl)-2-(2-(2-(1'-( -1,3-dioxoisoindolin-5- yl)-[1,4'-bipiperidin]-4-yl)acetyl)-2-azas -4-yl)-2- fluorophenyl)propane-1-sulfonamide, -(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperd ne- -carbony )p per din-4-yl)-5-(pyridin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, N-(3-(5-(2-aminopyrimidin-4-yl)-2- (1-((1-(((1S,4r)-4-(4-((S)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexyl)methyl)piperidin-4-yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluoropheny (2-aminopyrimidin-4-yl)-2-(2-(1-(2-(2,6-dioxopiperi yl)piperidine-4-carbonyl)-2-azaspiro[3.5]nonan-7-yl sulfonamide, (S)-N-(3-(2-(1-(1-(2-(1-(4-((2,6-dioxo yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(p fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(1-(1-(1-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbon iperidin- 4-yl)ethyl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfona -(3-(5-(2- aminopyrimidin-4-yl)-2-(2-(2-(4-(2-(2,6-dioxopiperidin-3 yl)piperazin-1-yl)acetyl)-2-azaspiro[3.5]nonan-7-yl)thiazo pane-1- sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)- eridin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperazin-1-yl)phenyl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(1-(1-( yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperi yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N- yl)-2-(1-(1-(1-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-car carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-suaminopyrimidin-4-yl)-2-(4-(4-((1-(4 henyl)piperidin-4- yl)methyl)piperazin-1-yl)phenyl)thi ropane-1-sulfonamide, (S)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(1 in-3-yl)pyridin-2- yl)piperidine-4-carbonyl)piperidin- hiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamid rimidin-4-yl)-2-(4-(4-(2-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)acetyl)piperazin-1-yl)phenyl)thiazol-4- -(1'- ( -(5- ( f, , n-3- yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(2- (isopropylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)piperazin-1-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, -4-yl)-2-(1-((1-((1R,4r)-4-(4-((R)-2,6- dioxopiperidin-3-yl)phenoxy iperidin-4-yl)methyl)piperidin-4- yl)thiazol-4-yl)-2-fluorophen (R)-N-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-(6-(2-(2,6-dioxopip -5-yl)hexanoyl)-2- azaspiro[3.5]nonan-7-yl)thia opane-1-sulfonamide, N-(3-(2-(1-(1- (1-(5-((S)-2,6-dioxopiperidin ne-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(2-(((R)-1-hydroxypropan-2-yl)amino)pyrimidin-4-yl)thiazol-4- (4-(4-((1- l)thiazol- yrimidin- dine-1- c-(3S)-3-{-[-(-{-[-(-{[ety(mety)su amoy]amno}-- uoropeny)--{-[(propan-2- yl)amino]pyrimidin-4-yl}-1,3-thiazol-2-yl]piperidine-1-carbonyl}piperidine-1- azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5- (2-aminopyrimidin-4-yl)-2-(1-(1-(2-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)prop (S)-N-(3-(2-(1-(1-(1-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)pi e-4-carbonyl)piperidin-4-yl)-5-(2- (methylamino)py uorophenyl)propane-1-sulfonamide, (R)-N-(3- (5-(2-aminopyrim 6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin- 4-yl)acetyl)piperi l)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(2-(1-(1-(1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)piperidine-4-carbony ylamino)pyrimidin-4-yl)thiazol- 4-yl)-2-fluorophenyl)propane- -(cyclopropylamino)pyrimidin-4- yl)-2-(1-(1-(1-(5-(2,6-dioxopip idine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol e-1-sulfonamide, (S)-N-(3-(2-(1- (1-(1-(4-(2,6-dioxopiperidin-3-yl)-4-methylpiperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, N-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-((R)-1-(4-((S)-2,6-dioxopiperidin-3- yl)phenyl)pyrrolidin-3-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(2-(2-(2- (2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-2- azaspiro[3.5]nonan 7 l thi l 4 l 2 fl henyl)propane-1-sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4- opiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)piperidin azol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R -yl)-2-(1-(2-(2-(2-(2,6-dioxopiperidin-3-yl)- 1,3-dioxoisoindoli n-7-yl)acetyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propa -(5-(2-aminopyrimidin-4-yl)-2-(3-(1-(1-(2,6- dioxopiperidin-3-y, -1H-benzo[d]imidazol-4-yl)piperidine-4- carbonyl)-3-a de, (R)-N-(3-(2-( -4- carbonyl)pip fluorophenyl -(2- (2,6-dioxopip carbonyl)pip -(2- aminopyrimidin-4-yl)-2-(2-(1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5- yl)piperidin-4-yl)azetidine-3-carbonyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2- fluorophenyl)propane-1-sulfonamide, (S)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1-(1-((1-(1- (2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)piperidin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1- sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(2-(2-(2,6-dioxopiperidin-3-yl)- 1,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-3-azaspiro[5.5]undecan-9- yl)thiazol-4-yl)-2-fluorophenyl)propane-1-sulfonamide, (R)-N-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-(1-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2,7- diazaspiro[3.5]nonan-7-yl)acetyl)piperidin-4-yl)propan-2-yl)thiazol-4-yl) fluorophenyl)propane-1-sulfonamide, and (R)-4-((4-(5-(2-aminopyrimid 3-(propylsulfonamido)phenyl)thiazol-2-yl)piperidin-1-yl)methyl)-N-(2,6- yl)benzamide. 73. The compound of claim 1, wherein X1is carbon; X2is nitrogen, carbon; and X5is hydrogen.74. The compound of claim 73, wherein R1is alkyl, dialkylamino, cycloalkyl, or heterocycloalkyl each unsubstituted or substituted with one or more halogen; R1ais halogen; R1bis hydrogen, haloalkyl or halogen; R2is -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM; Ar1is arylene or heteroarylene, each unsubstituted or substituted with one or more halogen; Z1is a bond; n is one; Z2is absent; Cy1isr heterocycloalkylene, unsubstituted or substituted with one or more alkyl or one or more halogen; Z3is absent or C1-10alkylene; L is a linker according to –L1-L2-L3-L4– or –L4-L3-L2-L1–, wherein –L1– is -Q1- or -Q2-; each –L2–, –L3–, and –L4– is independently, absent, -C1-8alkylene-, or -Q1-; each -Q1- is a three- to seven-membered heterocycloalkylene comprising at least one nitrogen and is unsubstituted or substituted with one or more methyl or halogen;each -Q2- is a five- to thirteen-membered bicyclic heterocycloalkylene comprising at least one nitrogen, wherein the five- to thirteen-membered bicyclic heterocycloalkylene is optionally a spiro bicyclic heterocycloalkylene ring; and UBM is a ubiquitin ligase binding moiety; or a stereoisomer and / or pharmaceutical salt thereof. 75. The compound of claim 73 or 74, wherein R1is selected from the group consisting of propyl, ethylmethylamino, sec-butyl, , , , , , , , , , , ,, , , , and . 76. The compound of any one of claims 73-75, wherein R1ais chloro or fluoro; and R1bis 8. p , g formulaX7absent or -C(O)-; and X8is arylene or heteroarylene.82. The compound of claim 81, wherein UBM binds CRBN and is selected from theconsi of , , , ,, , ,X9is absent or h l d m is one, two, 83. The coy one of claims 1 or, compound is selected from the group consisting of (R)-N-(5-chloro-3-(1-(4-(4-((1-(5-(2,4-dioxotetrahydropyrimidin- 1(2H)-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)-3-(pyridin-4-yl)-1H- pyrazol-4-yl)-2-fluorophenyl)-3-fluoropyrrolidine-1-sulfonamide; (R)-N-(5-chloro-3-(1-(4-(4- ((1-(5-((R)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1- yl)phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)-3-fluoropyrrolidine-1- sulfonamide; rac-(R)-N-(5-chloro-3-(1-(4-( -((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2- fluorophenyl)pyrrolidine-1-sulfonamide; rac-(R)-N-(5-chloro-3-(1-(4-(4-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)-2-fluorophenyl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)pyrrolidine-1-sulfonamide; rac-(R)-N-(3-(1- (4-(4-((1-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1- yl)phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2,5-difluorophenyl)pyrrolidine-1-sulfonamide; N-(5-chloro-3-(1-(4-((R)-4-((1-(5-((RS)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- f r r f ( f ( f ( ( [ [yl]phenyl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl]propane-1-sulfonamide; N-[5-N-{5-chloro-3-[1-(5-{4-[(1-{4-[(3R)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4- yl)methyl]piperazin-1-yl}pyridin-2-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-1-sulfonamide; N-[5-chloro-3-(1-{5-[4-({1-[4-(2,4-dioxo-1,3- diazinan-1-yl)phe -4-yl)- 1H-pyrazol-4-yl)- -(5-{4-[(1- {5-[(3R)-2,6-diox }pyridin-2-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-1-sulfonamide; N-(3-(1- (4-((R)-4-((1-(5-((RS)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)-3- methylpiperazin-1-yl)-2-fluorophenyl)-3-(pyridin-4-yl)- difluorophenyl)pyrrolidine-1-sulfonamide; N-{ dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl] (pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}pyrrolid chloro-3-[1-(4-{4-[(1-{4-[(3R)-2,6-dioxopiperidin-3-yl] yl)methyl]piperazin-1-yl}phenyl)-3-(pyridin-4-yl)-1H-pfluoropyrrolidine-1-sulfonamide; (3R)-N-[5-chloro-3-(1-{4-[4-({1-[4-(2,4-dioxo-1,3- diazinan-1-yl)phenyl]piperidin-4-yl}methyl)piperazin-1-yl]phenyl}-3-(pyridin-4-yl)-1H- pyrazol-4-yl)-2-fluorophenyl]-3-fluoropyrrolidine-1-sulfonamide; (3R)-N-{5-chloro-3-[1-(4-{4-[(1-{5-[(3R)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-1- yl}phenyl)- yrrolidine-1- sulfonamid 2,6-dioxopiperidin-3- yl]phenyl}p-4-yl)-1H-pyrazol-4- yl]-2-fluorophenyl}-3-fluoropyrrolidine-1-sulfonamide; (3R)-N-[5-chloro-3-(1-{5-[4-({1-[4- (2,4-dioxo-1,3-diazinan-1-yl)phenyl]pipe yl)piperazin-1-yl]pyridin-2-yl}-3- (pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluoro pyrrolidine-1-sulfonamide; (3R)-N- {5-chloro-3-[1-(5-{4-[(1-{5-[(3RS)-2,6-d -yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin-1-yl}pyridin-2-yl)-3 H-pyrazol-4-yl]-2-fluorophenyl}-3- fluoropyrrolidine-1-sulfonamide; -chloro-3- -(5-{4-[(1-{5-[(3R)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-1-yl}pyridin-2-yl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}-3-fluoropyrrolidine-1-sulfonamide; (3R)-N- {5-chloro-3-[1-(5-{4-[(7-{4-[(3RS)-2,6-dioxopiperidin-3-yl]phenyl}-7-azaspiro[3.5]nonan-2- n-1-yl}pyridin-2-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}-3- f -sulfonamide; N-{3-[1-(4-{4-[(1-{4-[(3R)-2,6-dioxopiperidin-3- n-4-yl)methyl]piperazin-1-yl}phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]- }pyrrolidine-1-sulfonamide; N-[3-(1-{4-[4-({1-[4-(2,4-dioxo-1,3-diazinan- in-4-yl}methyl)piperazin-1-yl]phenyl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)- ]pyrrolidine-1-sulfonamide; N-{3-[1-(4-{4-[(1-{5-[(3R)-2,6- dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-1-yl}phenyl)-3-(pyridin-4- yl)-1H-pyrazol-4-yl]-2,5-difluorophenyl}pyrrolidi -(5-{4-[(1- {4-[(3R)-2,6-dioxopiperidin-3-yl]phenyl}piperidin din-2-yl)- 3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2,5-difluorophen amide; (3R)-N-[3-(1-{5-[4-({1-[4-(2,4-dioxo-1,3-diazinan yl}methyl)piperazin-1-yl]pyridin-2-yl}-3-(pyridin- difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide (3RS)-2,6- dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-1-yl}pyridin-2-yl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl]-2,5-difluorophenyl}-3-fluoropyrrolidine-1-sulfonamide; (3R)-N-{3-[1-(5-{4-[(1-{5-[(3R)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- perazin-1-yl}pyridin-2-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2,5- yl}-3-fluoropyrrolidine-1-sulfonamide; (3R)-3-(4-{4-[(4-{4-[4-(5-chloro-3- yl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyrdin-4-yl)-1H-pyrazol-1-yl]phenyl}piperazin-1-yl)methyl]piperidin-1-yl}phenyl)piperidine-2,6-dione; 1-(4-{4-[(4-{4-[4-(5-chloro-3-{[ethyl(methyl)su }-2-fluorophenyl)-3-(pyridin-4-yl)-1H- pyrazol-1-yl]phenyl}piperazin-1 eridin-1-yl}phenyl)-1,3-diazinane-2,4-dione; rac-(3R)-3-(6-{4-[(4-{4-[4-(5-ch methyl)sulfamoyl]amino}-2-fluorophenyl)-3- (pyridin-4-yl)-1H-pyrazol-1-yl]p n-1-yl)methyl]piperidin-1-yl}pyridin-3- yl)piperidine-2,6-dione; R)-3-(6-{4-[(4-{4-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-1- yl]henl}ierazin-1-l)methl]ieridin-1-l} ridin-3-l)ieridine-26-dione (3R)-3-(4- { 1 d(pyridin-4-yl)-1H-pyrazol-1-yl]pyridin-3-yl}piperazin-1-yl)methyl]piperidin-1-yl}phenyl)- 1,3-diazinane-2,4-dione; rac-(3R)-3-(6-{4-[(4-{6-[4-(5-chloro-3- {[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-1-yl]pyridin- 3-yl}piperazin-1-yl)methyl]piperidin-1-yl}pyridin-3-yl)piperidine-2,6-dione; 1-(6-{4-[(4-{6- [4-(5-c hyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-1H- pyrazo n-3-yl}piperazin-1-yl)methyl]piperidin-1-yl}pyridin-3-yl)-1,3-diazinane- 2,4-di (3R)-3-(6-{4-[(4-{6-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2- fluoro ridin-4-yl)-1H-pyrazol-1-yl]pyridin-3-yl}pipen-1- yl)met-1-yl}pyridin-3-yl)piperidine-2,6-dione; (3)-N-[5-chloro-3-(1-{4-[(3R)- 4-({1-[4-(2,4-dioxo-1,3-diazinan-1-yl eridin-4-yl}methyl)-3-methylpiperazin-1- yl]phenyl}-3-(pyridin-4-yl)-1H-pyraz uorophenyl]-3-fluoropyrrolidine-1- sulfonamide; N-[5-c -[(3R)-4-[(1-{4-[(3R)-2,6-dioxopiperidin-3- yl]phenyl}piperidin-4-yl)methyl]-3-m in-1-yl]phenyl}-3-(pyridin-4-yl)-1H- pyrazol-4-yl)-2-fluorophenyl]pyrroli amide; ( )-N-[5-chloro-3-(1-{4-[(3R)-4- [(1-{4-[(3R)-2,6-dioxopiperidin-3-yl]pey}pperidin-4-yl)methyl]-3-methylpiperazin-1- yl]phenyl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl]-3-fluo sulfonamide; (3R)-N-[5-chloro-3-(1-{4-[(3R)-4-[(1-{5-[(3 eridin-3- yl]pyridin-2-yl}piperidin-4-yl)methyl]-3-methylpiperazin-1-yl]phen -yl)-1H- pyrazol-4-yl)-2-fluorophenyl]-3-fluoropyrrolidine-1-sulfonamide; N {4-[(3R)- 4-({1-[4-(2,4-dioxo-1,3-diazinan-1-yl)phenyl]piperidin-4-yl}methyl)-- ypp azin-1- y -yl)-2-fluorophenyl]pyrrolidine-1-sulfonamide; (- - -c oo-- -{- -- -{-[(3R)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4- yl)methyl]-3-methylpiperazin-1-yl]pyridin-2-yl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluoropheny olidine-1-sulfonamide; (3R)-N-[5-chloro-3-(1-{5-[(3R)-4-[(1-{5- [(3RS)-2,6- 3-yl]pyridin-2-yl}piperidin-4-yl)methyl]-3-methylpiperazin-1- yl]pyridin-2 -4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl]-3-fluoropyrrolidine-1- sulfonamid 3R)-N-[5-chloro-3-(1-{5-[(3R)-4-({1-[4-(2,4-dioxo-1,3-diazinan-1- yl)phenyl]p ethyl)-3-methylpiperazin-1-yl]pyridin-2-yl}-3-(pyridin-4-yl)-1H- pyrazol-4-y yl]-3-fluoropyrrolidine-1-sulfonamide; N-[5-chloro-3-(1-{5-[(3R)- 4-[(1-{5-[(3 iperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]-3- methylpiperazin-1-yl]pyridin-2-yl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2- fluorophenyl]pyrrolidine-1-sulfonamide; N-[5-chloro-3 dioxo-1,3- diazinan-1-yl)phenyl]piperidin-4-yl}methyl)-3-methylp 3- (pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl]pyrrolid loro-3-(1- {5-[(3R)-4-[(1-{5-[(3R)-2,6-dioxopiperidin-3-yl]pyridin ]-3-methylpiperazin-1-yl]pyridin-2-yl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2- fluorophenyl]pyrrolidine-1-sulfonamide; N-[5-chloro-3-(1-{5-[(3R)-4-[(1-{4-[(3R)-2,6- dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]-3-methylpiperazin-1-yl]pyridin-2-yl}-3- zol-4-yl)-2-fluorophenyl]pyrrolidine-1-sulfonamide; (RS)-N-(5-chloro- 2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin- n-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl)butane-2-sulfonamide; rac- -{4-[4-({1-[4-(2,4-dioxo-1,3-diazinan-1-yl)phenyl]piperidin-4- -yl]phenyl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl]butane- )-N-(5-chloro-3-(1-(4-(4-((1-(5-((S)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-1-yl)phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2- fluorophenyl)butane-2-sulfo - dioxopiperidin-3-yl]phenyl} 1H-pyrazol-4-yl]-2-fluoroph - [(3R)-2,6-dioxopiperidin-3- (pyridin-4-yl)-1H-pyrazol-4 - chloro-3-[1-(4-{4-[(1-{5-[(3yl)methyl]piperazin-1-yl}phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}-3- fluoroazetidine-1-sulfonamide; N-{5-chloro-3-[1-(4-{4-[(1-{4-[(3R)-2,6-dioxopiperidin-3- yl]phenyl}piperidin-4-yl)methyl]piperazin-1-yl}phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2- fluorophenyl}-3-fluoroazetidine-1-sulfonamide; (3R)-N-{5-chloro-3-[1-(4-{4-[(1-{5-[(3R)- 2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-1-yl}-2-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}-3-fluoropyrroli amide; (3R)- N-{5-chloro-3-[1-(4-{4-[(1-{5-[(3RS)-2,6-dioxopiperidin-3-yl]pyri ridin-4- yl)methyl]piperazin-1-yl}-2-fluorophenyl)-3-(pyridin-4-yl)-1H-py fluorophenyl}-3-fluoropyrrolidine-1-sulfonamide; (3R)-N-{5-chlo [(1-{4-[(3R)- 2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-1- henyl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}-3-fluoropyrrolidiide; rac-- {5-chloro-3-[1-(4-{4-[(1-{5-[(3R)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin-1-yl}-2-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2- fluoroph l fl idine-1-sulfonamide; N-{5-chloro-3-[1-(4-{4-[(1-{4-[(3R)-2,6- dioxop }piperidin-4-yl)methyl]piperazin-1-yl}-2-fluorophenyl)-3- (pyridi -yl]-2-fluorophenyl}-3-fluoroazetidine-1-sulfonamide; N-[5- chloro- ,4-dioxo-1,3-diazinan-1-yl)phenyl]piperidin-4- yl}met -fluorophenyl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2- fluorop dine-1-sulfonamide; N-{3-[1-(4-{4-[(1-{4-[(3R)-2,6- dioxopip - -y p y}piperidin-4-yl)methyl]piperazin-1-yl}-2-fluorophenyl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl]-2,5-difluorophenyl}pyrr (4-{4-[(1-{5-[(3R)-2,6-dioxopiperidin-3-yl]pyridin-2-yl yl}-2-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2 sulfonamide; N-{3-[1-(5-{4-[(1-{4-[(3R)-2,6-dio yl)methyl]piperazin-1-yl}pyrimidin-2-yl)-3-(pyridin-4-y difluorophenyl}pyrrolidine-1-sulfonamide; dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]py y y (pyridin-4-yl)-1H-pyrazol-4-yl]-2,5-difluorophenyl}pyrrolidine-1-sulfonamide; N-{5-chloro- 3-[1-(4-{4-[(1-{4-[(3R)-2,6-dioxopiperidin-3-yl]-3-fluorophenyl}piperidin-4- yl)met yl}phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2- fluoro ne-1-sulfonamide; rac-N-{5-chloro-3-[1-(4-{4-[(1-{5-[(3R)-2,6- dioxop ridin-2-yl}piperidin-4-yl)methyl]-1,4-diazepan-1-yl}-2-fluorophenyl)- 3-(pyr razol-4-yl]-2-fluorophenyl}pyrrolidine-1-sulfonamide; N-{5-chloro-3- [1-(4- 2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]-1,4-diazepan-1- yl}-2-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-1- sulfonamide; rac-N-{5-chloro-3-[1-(4-{4-[(1-{4-[(3R)-2,6-dioxopiperidin-3-yl]-2- fluorophenyl}piperidin-4-yl)methyl]piperazin-1-yl}phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4- yl]-2-fluorophenyl}pyrrolidine-1-sulfonamide; rac-N-{5-chloro-3-[1-(4-{4-[(1-{4-[(3R)-2,6-dioxopiperidin-3-yl]-3-fluorophenyl}pi zin-1-yl}phenyl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluor onamide; N-[5- (difluoromethyl)-3-[1-(4-{4-[(1-{4-[(3R phenyl}piperidin-4- yl)methyl]piperazin-1-yl}phenyl)-3-(py l]-2- fluorophenyl]pyrrolidine-1-sulfonamideyl)-3-[1-(4-{4-[(1-{5-[(3R)- 2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-1-yl}ph (pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl]pyrrolidine-1-sulfonamide; N- - (6-{4-[(1-{4-[(3R)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]pipe yl}pyridin-3-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine sulfonamide; rac-N-{5-chloro-3-[1-(6-{4-[(1-{5-[(3R)-2,6-dioxopiperidin- yl}piperidin-4-yl)methyl]piperazin-1-yl}pyridin-3-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-1-sulfonamide; N-{5-chloro-3-[1-(4-{4-[(1-{4-[(3R)-2,6- dioxopiperidin-3-yl]phe l i i i 4 l)methyl]piperazin-1-yl}-2,5-difluorophenyl)-3- (pyridin-4-yl)-1H-pyraz enyl}pyrrolidine-1-sulfonamide; rac-N-{5-chloro- 3-[1-(4-{4-[(1-{5-[(3R)- -3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin-1-y yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine- -su onam de; N-[5-chloro-3-(1-{4-[4-({1-[5-(2,4-dioxo-1,3- diazinan-1-yl)pyridin-2-yl]piperidin-4-yl}methyl)piperazin-1-yl]p din-4-yl)- 1H-pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-1-sulfonamide; N-[ hyl)-3-(1-{4- [4-({1-[4-(2,4-dioxo-1,3-diazinan-1-yl)phenyl]piperidin-4-yl}met -yl]-2- fluorophenyl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl] ulfonamide; rac-N-[5-(difluoromethyl)-3-[1-(4-{4-[(1-{5-[(3R)-2,6-dioxopipern- -y ]pyr din-2- yl}piperidin-4-yl)methyl]piperazin-1-yl}-2-fluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]- 2-fluorophenyl]pyrrolidine-1-sulfonamide; N-[5-chloro-3-(1-{5-[4-({1-[4-(2,4-dioxo-1,3- diazin yl]piperidin-4-yl}methyl)piperazin-1-yl]pyrimidin-2-yl}-3-(pyridin-4-yl)- 1H-py -fluorophenyl]pyrrolidine-1-sulfonamide; rac-N-{5-chloro-3-[1-(5-{4-[(1- {5-[(3 piperidin-3-yl]pyridin-2-yl}piperidin-4-yl)mhyl]piperazin-1-yl}pyrimidin-2-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-1- sulfonamide; N-{5-chloro-3-[1-(5-{4 )-2,6-dioxopiperidin-3-yl]phenyl}piperidin- 4-yl)methyl]piperazin-1-yl}pyrimidi ridin-4-yl)-1H-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-1-sulfonam -[5-chloro-3-(1-{4-[4-({1-[4-(2,4-dioxo-1,3- diazinan-1-yl)phenyl]piperidin-4-yl} azin-1-yl]- fluorophenyl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-1-sulfonamide; N-[5-(difluoromethyl)-3-[1-( -1-yl}-2- namide; idin-4- fuorop eny }pyrro d ne- -su onam de; N-{5-c oro-3-[ -( -{ -[( -{ -[(3R)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-1-yl}-3-fluorophenyl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-1-sulfonamide; (3R)-N-[5- chloro-3-(1-{4-[4-({1-[4-(2,4-dioxo-1,3-diazinan-1-yl)phenyl]piperidin-4- yl}methyl)piperazin-1-yl]-3-fluorophenyl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2- fluorophenyl]-3-fl {4-[(1-{5- [(3RS)-2,6-dioxop 3- fluorophenyl)-3-(p ne-1-sulfonamide; (3R)-N-{5-chloro-3-[1-(4-{4-[(1-{4-[(3R)-2,6-dioxopiperidin-3- yl]phenyl}piperidin-4-yl)methyl]piperazin-1-yl}-3-fluorophenyl)-3-(pyridin-4-yl)-1H- pyrazol-4-yl]-2-fluorophenyl}-3-fluoropyrrolidine-1-sul -(1-{4-[4- ({1-[5-(2,4-dioxo-1,3-diazinan-1-yl)pyridin-2-yl]piperid - yl]phenyl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorop sulfonamide; N-[5-chloro-3-(1-{4-[4-({1-[5-(2 pyridin-2-yl]piperidin-4-yl}methyl)piperazin-1-yl]-2-fluorophenyl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)- 2-fluorophenyl]-3-fluoroazetidine-1-sulfonamide; N-[5-chloro-3-(1-{4-[4-({1-[5-(2,4-dioxo- 1,3-diazinan-1-yl)pyridin-2-yl]piperidin-4-yl}methyl)piperazin-1-yl]-2-fluorophenyl}-3- ( razol-4-yl)-2-fluorophenyl]pyrrolidine-1-sulfonamide; (3R)-N-[5-chloro- 4-dioxo-1,3-diazinan-1-yl)pyridin-2-yl]piperidin-4-yl}methyl)piperazin- }-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-fluorophenyl]-3- f ulfonamide; N-{5-chloro-3-[1-(4-{4-[(1-{5-[(3R)-2,6-dioxopiperidin-3- idin-4-yl)methyl]piperazin-1-yl}phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4- yyclopentanesulfonamide; rac-N-{5-chloro-3-[1-(4-{4-[(1-{5-[(3R)-2,6- dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-1-yl}phenyl)-3-(pyridin-4- yl)-1H-pyrazol-4-yl]-2-fluorophenyl}cyclopentanesulfonamide; N-{5-chloro-3-[1-(4-{4-[(1- {4-[(3R)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-1-yl}phenyl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}cyclopentanesulfonamide; (3R)-3-(6-{4-[(4- {4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2,5-difluorophenyl)-3-(pyridin-4-yl)-1H-pyrazol- 1-yl]phenyl}piperazin-1-yl)methyl]piperidin-1-yl}pyridin-3-yl)piperidine-2,6-dione; rac-(3R)-3-(6-{4-[(4-{4-[4-(3-{[ oyl]amino}-2,5-difluorophenyl)-3-(pyridin- 4-yl)-1H-pyrazol-1-yl]pheny hyl]piperidin-1-yl}pyridin-3-yl)piperidine- 2,6-dione; (3R)-3-(4-{4-[(4 thyl)sulfamoyl]amino}-2,5-difluorophenyl)- 3-(pyridin-4-yl)-1H-pyrazol- in-1-yl)methyl]piperidin-1- yl}phenyl)piperidine-2,6-dio 4-[(3R)-4-[(1-{4-[(3R)-2,6-dioxopiperidin-3- yl]phenyl}piperidin-4-yl)me zin-1-yl]p nyl}-3-(pyridin-4-yl)-1H- pyrazol-4-yl)-2-fluorophenymide;(3R)-3-(6-{4-[(4-{4-[4-(3- { fl ( p 2 y 1 2-y)pper n--y)me y)-,- me ypperazn--y)-- uoropeny)--(pyr n--y)- 1H-pyrazol-4-yl)-2-fluorophenyl)pyrrolidine-1-sulfonamide; N-{5-chloro-3-[1-(5-{4-[(1-{5- [(3S)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-1-yl}pyridin-2- yl)-3-(pyrid N-{5- chloro-3-[1 - yl)methyl]p fluoropheny -[(3R)-2,6- dioxopiperi yl)-3- (pyridin-4-y {5-chloro- 3-[1-(4-{4-[ yl)methyl]piperazin-1-yl}phenyl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-1-sulfonamide; ra 4-{4-[(1-{4-[(3R)-2,6- dioxopiperidin-3-yl]-3,5-difluorophenyl}piperidin- n-1-yl}phenyl)-3- (pyridin-4-yl)-1H-pyrazol-4-yl]-2-fluorophenyl}py ide; and N-[5-chloro- 3-(1-{4-[4-({1-[5-(2,4-dioxo-1,3-diazinan-1-yl)pyr -yl}methyl)piperazin- 1-yl]phenyl}-3-(pyridin-4-yl)-1H-pyrazol-4-yl)-2-f ntanesulfonamide. 84. A pharmaceutical composition comprisinge compoun o any one of the previous claims and a pharmaceutically acceptable carrier, excipient, and / or diluent.85. A method of treating a disease or disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound or composition of any one of the previous claims. r is cancer. us claims for use in therapy. s claims for use in the treatmentembodiment, the linkerwherein 'n ca es a ac men o , an indicates attachment to UBM.[000105] In certain embodiments, the compound of Formula (I) is selected from the group consisting of (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2- aminopyrimidin-4-yl)-2-(l -(l-(l-(5-(2,6-di oxopiperi din-3 -yl)pyri din-2 -yl)piperidine-4- carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(4- (2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l- (l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, and (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5- (pyridin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide. In certain embodiments, the compond of Formula (I) is selected from the group consisting of (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(4-(3-(2-(2,6-di oxopiperi din-3-yl)- 1,3- dioxoisoindolin-4-yl)propyl)piperazin-l-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)- 2-fluorophenyl)propane- 1 -sulfonamide, N-(3 -(5 -(2-aminopyrimidin-4-yl)-2-( 1 -(( 15,4r)-4-((6- ((5)-2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(lJ7)-yl)methyl)cyclohexane-l- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l- (l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (7?)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-5-yl)piperazin-l-yl)acetyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(r-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-[l,4'-bipiperidin]-4-yl)acetyl)-4- methylpiperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2- aminopyrimidin-4-yl)-2-(l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidine-4-carbonyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-(2-(6- (2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(U7)-yl)acetyl)piperidin-4- yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N-(3-(2- (l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyridin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(r-(2-(2,6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-5-yl)-[l,4'-bipiperidin]-4-yl)acetyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(4-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperazin-l-yl)acetyl)piperidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-( 1 -( 1 -(1 -(2-(2,6-dioxopiperi din-3 -yl)- 1 ,3-dioxoisoindolin-5-yl)piperidin-4- yl)azetidine-3-carbonyl)piperidin-4-yl)propan-2-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-((17?,4r)-4-(3-((7?)-2,6- dioxopiperi din-3 -yl)phenoxy)cy cl ohexane-l-carbonyl)piperidin-4-yl)methyl)piperi din-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(3-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5- (2-aminopyrimidin-4-yl)-2-(l-(l-(2-(l-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)- 4-hydroxypiperidin-4-yl)acetyl)azetidin-3-yl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-(2-(l-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)acetyl)piperidin-4-yl)phenyl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-((l- (4-(2, 6-dioxopiperi din-3 -yl)phenyl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)thi azol -4- yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-(2- (l-(4-((2,6-dioxopiperi din-3 -yl)amino)phenyl)piperidin-4-yl)acetyl)piperi din-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2- aminopyrimidin-4-yl)-2-(4-(l-(l-(5-(2,6-dioxopiperi din-3-yl)pyri din-2 -yl)piperidine-4- carbonyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, N-(3- (5-(2-aminopyrimidin-4-yl)-2-(3-(((15,4r)-4-((5-((S)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)oxy)cyclohexyl)methyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(l-(4- (2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperazin-l-yl)phenyl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-5-(4-(9-(5-(2-aminopyrimidin-4-yl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-2-yl)-3-azaspiro[5.5]undecane-3-carbonyl)piperidin-l- yl)-N-(2,6-dioxopiperidin-3-yl)picolinamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-((5)- l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)-3-azaspiro[5.5]undecan- 9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(l-(l-(2-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)acetyl)azetidin-3- yl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-(l -(5-(2,6-di oxopiperidin-3-yl)pyri din-2 -yl)piperidine-4- carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4- carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyridin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-((l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2- (methylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N-(3 - (5-(2-aminopyrimidin-4-yl)-2-(2-(2-(l'-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)-[l,4'-bipiperidin]-4-yl)acetyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyridin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2- (l-((l-(((15,4r)-4-(4-((5)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexyl)methyl)piperidin-4- yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5- (2-aminopyrimidin-4-yl)-2-(2-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperidine-4-carbonyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(2-(l-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4- yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(l-(l-(l-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin- 4-yl)ethyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(2-(2-(4-(2-(2, 6-dioxopiperi din-3-yl)- 1,3 -di oxoisoindolin-5- yl)piperazin-l-yl)acetyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (7?)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperazin-l-yl)phenyl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(l-(l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(4-(4-((l-(4-(2, 6-dioxopiperi din-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-(l-(5-(2,6-dioxopiperidin-3-yl)pyri din-2- yl)piperidine-4-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(2-(l-(5- (2, 6-dioxopiperi din-3 -yl)pyri din-2 -yl)piperi din-4-yl)acetyl)piperazin- l-yl)phenyl)thi azol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(r- (2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-[l,4'-bipiperidin]-4-yl)acetyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5- (2-aminopyrimidin-4-yl)-2-(l-(l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidine-4-carbonyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(2- (isopropylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(4-(2-(2, 6-dioxopiperi din-3-yl)-l,3-dioxoisoindolin-5- yl)piperazin-l-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-((17?,4r)-4-(4-((7?)-2,6- dioxopiperi din-3 -yl)phenoxy)cy cl ohexane-l-carbonyl)piperidin-4-yl)methyl)piperi din-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-(6-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-2- azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, 7V-(3-(2-(l-(l- (l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(2-(((7?)-l-hydroxypropan-2-yl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-((l- (5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)thiazol- 4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, rac-(37?)-3 - { 6-[4-(4-{4-[5-(2-aminopyrimidin- 4-yl)-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-2-yl]piperidine-l- carbonyl}piperidine-l-carbonyl)piperidin-l-yl]pyridin-3-yl}piperidine-2, 6-dione, ,rac-(37?)-3- {6-[4-(4-{4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-5-{2-[(propan-2- yl)amino]pyrimidin-4-yl } - 1 ,3 -thiazol-2-yl]piperidine- 1 -carbonyl } piperi dine- 1 - carbonyl)piperidin-l-yl]pyridin-3-yl}piperidine-2, 6-dione (5)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(l-(l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2- aminopyrimidin-4-yl)-2-(l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-((l-(2-(2,6-dioxopiperidin-3-yl)-l- oxoisoindolin-5-yl)piperidin-4-yl)methyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(2-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-4- methylpiperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidine-4-carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (7?)-7V-(3-(2-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)- 2,7 -di azaspiro [3.5 ]nonan-7 -yl)acetyl)piperidin-4-yl)-5-(2-(methylamino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(3-(6-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5- (2-aminopyrimidin-4-yl)-2-(l-(l-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2-(methylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N-(3 - (5-(2-aminopyrimidin-4-yl)-2-(l-(l-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin- 4-yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2-(isopropylamino)pyrimidin-4-yl)thiazol- 4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-(cyclopropylamino)pyrimidin-4- yl)-2-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l- (l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-( (R)-l-(4-((,S)-2,6-dioxopiperidin-3- yl)phenyl)pyrrolidin-3-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(2-(2-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-2- azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(l-((l-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)piperidin-4-yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (7?)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)- l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(l-(l-(2,6- dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[d]imidazol-4-yl)piperidine-4- carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-7V-(3-(2-(l-(l-((l-(4-(2,6-dioxopiperi din-3 -yl)phenyl)piperi din-4-yl)methyl)piperi dine-4- carbonyl)piperidin-4-yl)-5-(2-(methylamino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperidin-4-yl)azetidine-3- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(2-(l-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidin-4-yl)azetidine-3-carbonyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2- fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -(5-(2-aminopyrimidin-4-yl)-2-(l -( 1 -(( 1 -( 1 - (2, 6-dioxopiperi din-3 -yl)-3-methyl-2-oxo-2, 3 -dihydro- l / 7-benzo[J]imidazol-4-yl)piperi din- 4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-3-azaspiro[5.5]undecan-9- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7- diazaspiro[3.5]nonan-7-yl)acetyl)piperidin-4-yl)propan-2-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, and (R)-4-((4-(5-(2-aminopyrimidin-4-yl)-4-(2-fluoro- 3-(propylsulfonamido)phenyl)thiazol-2-yl)piperidin-l-yl)methyl)-7V-(2,6-dioxopiperidin-3- yl)benzamide. In certain embodiments, the compound of Formula (I) is selected from the group consisting of (R)-4-(4-((6-((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5- yl)pyrimidin-2-yl)amino)-2-azaspiro[3.3]heptan-2-yl)methyl)piperidin-l-yl)-7V-(2,6- di oxopiperi din-3 -yl)benzamide, 7V-(3-(2-(tert-butyl)-5-(2-((2-(2-((5)-l-(5-((5)-2,6- dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)-2-azaspiro[3.3]heptan-6- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3-(2- (tert-butyl)-5-(2-((2-(2-(l'-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-[l,4'- bipiperidin]-4-yl)acetyl)-2-azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((2-(l-(l-(2,6- dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[d]imidazol-4-yl)piperidine-4- carbonyl)-2-azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((2-(l-(l-(2-(2,6- dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperidin-4-yl)azetidine-3-carbonyl)-2- azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((2-(2-(2-(2-(2,6-di oxopiperi din-3 -yl)- 1,3- dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-2-azaspiro[3.3]heptan-6- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3-(2- (tert-butyl)-5-(2-((2-(6-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-2- azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((2-((l-((l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)-2-azaspiro[3.3]heptan-6- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3-(2- (tert-butyl)-5-(2-((2-(2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4- yl)propyl)piperazin-l-yl)acetyl)-2-azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((2-(l-((l-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-4-fluoropiperidine-4-carbonyl)-2-azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((2-((l-(l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidine-4-carbonyl)piperidin-4-yl)methyl)-2-azaspiro[3.3]heptan-6- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, S)-N-(3-(2- (tert-butyl)-5-(2-((r-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)- [ 1 ,4'-bipiperidin]-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 - sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((7-(2-(4-(4-((2,6-dioxopiperidin-3- yl)amino)phenyl)piperidin-l-yl)acetyl)-7-azaspiro[3.5]nonan-2-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(Zert-butyl)-5-(2-((7- (((15,4r)-4-(4-((5)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexyl)methyl)-7- azaspiro[3.5]nonan-2-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, ( ?)-7V-(3-(2-(tert-butyl)-5-(2-((7-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2- dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-7-azaspiro[3.5]nonan-2-yl)amino)pyrimidin- 4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((7- ((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-7-azaspiro[3.5]nonan-2- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, and (R)-N-(3- (2-(tert-butyl)-5-(2-((7-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperazin- l-yl)acetyl)-7-azaspiro[3.5]nonan-2-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide. In certain embodiments, the compound of Formula (I) is selected from the group consisting of(5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-3-yl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3- dioxoisoindolin-5-yl)oxy)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(2-((2-(2,6- dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)oxy)acetyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N- (3-(2-(tert-butyl)-5-(2-((4-(l-(2-(4-(4-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperazin-l- yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(2-((5)-l-(5-((, )-2,6-dioxopiperidin-3- yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-4-(4-((4-(4-((4-(2-(tert-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)phenyl)piperidin-l-yl)methyl)piperi din- l-yl)-7V-(2,6-dioxopiperi din-3 -yl)benzamide, (R)-5-(4-((4-(4-((4-(2-(7ert- butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2- yl)amino)phenyl)piperidin-l-yl)methyl)piperidin-l-yl)-7V-(2,6-dioxopiperidin-3- yl)picolinamide, 7V-(3-(2-(terZ-butyl)-5-(2-((4-(l-(((15,4r)-4-((5-((5)-2,6-dioxopiperidin-3- yl)pyridin-2-yl)oxy)cyclohexyl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol- 4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-((l-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(2-((5)-l-(4-((5)-2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)acetyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3- (2-(tert-butyl)-5-(2-((4-(l-(2-( (R)-l-(4-((5)-2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3- yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, 7V-(3-(2-( ert-butyl)-5-(2-((4-(l-( (R)-l-(5-((, )-2,6-dioxopiperidin-3- yl)pyridin-2-yl)pyrrolidine-3-carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(l-(l-(4-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N- (3-(2-(terZ-butyl)-5-(2-((4-(l-(2-(l'-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)- [l,4'-bipiperidin]-4-yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(l-(5-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, N-(3- (2-(tert-butyl)-5-(2-((4-(l-(2-((5)-l-(l-( (R)-2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3- dihydro-l / Z-benzo[ ]imidazol-5-yl)pyrrolidin-3-yl)acetyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N- (3-(2-(terZ-butyl)-5-(2-((4-(l-(l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro- l / Z-benzo[ ]imidazol-4-yl)piperidine-4-carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(l- (l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)azetidine-3-carbonyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N- (3-(2-(terZ-butyl)-5-(2-((4-(l-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidine-4-carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7- yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1 -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(6-(2-(2,6-dioxopiperidin-3-yl)-3- oxoisoindolin-5-yl)hexanoyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(l-(2-(4-(2-(2,6- dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperazin-l-yl)acetyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-5- (4-((4-(((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2- yl)amino)methyl)piperidin- 1 -yl)methyl)piperidin- 1 -yl)-7V-(2,6-dioxopiperi din-3 - yl)picolinamide, (5)-5-(4-((4-(l-((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-2-methylpropan-2- yl)piperi din- l-yl)methyl)piperi din- l-yl)-7V-(2,6-dioxopiperi din-3 -yl)picolinamide, (R)-N-(3- (2-(tert-butyl)-5-(2-(((l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidin-4-yl)methyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((2-(l-((l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)-2-methylpropyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 5-(4-(( (R)-3-(((4-(2-(tert-butyl)-4-(2- fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)methyl)pyrrolidin-l- yl)methyl)piperi din- l-yl)-7V-((5)-2,6-dioxopiperi din-3 -yl)picolinamide, 7V-(3-(2-(tert-butyl)- 5-(2-(((lr,4r)-4-((4-((l-(4-((5)-2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)methyl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(Zert-butyl)-5-(2-(((15,45)-4-(4-(l-(5-((5)-2,6- dioxopiperi din-3 -yl)pyri din-2-yl)piperi dine-4-carbonyl)piperazin- 1- yl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, N- (3-(2-(terZ-butyl)-5-(2-(((lr,4r)-4-(4-(l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidine-4-carbonyl)piperazin-l-yl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(terZ-butyl)-5-(2-(((lr,4r)-4-(4-((l-(5-((5)-2,6- dioxopiperi din-3 -yl)pyri din-2-yl)piperi din-4-yl)methyl)piperazin- 1- yl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, N- (3-(2-(terZ-butyl)-5-(2-(((15,45)-4-(4-((l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperazin-l-yl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (37?)-3-{4-[4-({4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2-yl } amino)pyri din-3 -yl]piperazin- 1 -yl }methyl)piperidin- 1 -yl]phenyl }piperidine-2, 6-dione, (35)-3-{4-[4-({4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazin-l- yl}methyl)piperidin-l-yl]phenyl}piperidine-2, 6-dione, rac-(35)-3-{6-[4-({4-[6-({4-[2-tert- butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl } amino)pyri din-3 -yl]piperazin- 1 -yl }methyl)piperidin- 1 -yl]pyri din-3 -yl }piperidine-2,6- dione, rac-(3 S)-3 -(2- { [( 1 r,4r)-4- {4-[6-({4-[2-tert-butyl-4-(3 -{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl }amino)pyri din-3 -yl]piperazine-l -carbonyl }cy cl ohexyl]methyl}- 1,2, 3,4- tetrahydroisoquinolin-6-yl)piperidine-2, 6-dione, rac-(3S)-3-(2-{[(lr,4r)-4-{4-[6-({4-[2-tert- butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl }amino)pyri din-3 -yl]piperazine-l -carbonyl }cy cl ohexyl]methyl}- 1,2, 3,4- tetrahydroisoquinolin-7-yl)piperidine-2, 6-dione, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((2-(2-(4-(4- ((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-l-yl)acetyl)-l,2,3,4-tetrahydroisoquinolin- 6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, ( ?)-5-(4-(6- ((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2- yl)amino)-l,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidin-l-yl)-7V-(2,6-dioxopiperidin-3- yl)picolinamide, V-(3-(2-(ferZ-butyl)-5-(2-((2-( (R)-l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin- 2-yl)pyrrolidine-3-carbonyl)-l,2,3,4-tetrahydroisoquinolin-6-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((2-(2- (4-(4-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperazin-l-yl)acetyl)-l, 2,3,4- tetrahydroisoquinolin-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((l-((l-(2-(6-(2,6-dioxopiperidin-3-yl)-3,4- dihydroisoquinolin-2(lJ7)-yl)acetyl)piperidin-4-yl)methyl)-lJH-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, N-(3-(2-(tert- butyl)-5-(2-((l-((l-((15,4r)-4-(4-((5)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexane-l- carbonyl)piperidin-4-yl)methyl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(ter -butyl)-5-(2-((l-((l-((15',4r)-4-((5-((, )-2, 6- dioxopiperi din-3 -yl)pyridin-2-yl)oxy)cy cl ohexane-l-carbonyl)piperidin-4-yl)methyl)- 1H- pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)- 7V-(3-(2-(terZ-butyl)-5-(2-((l-((l-(2-(4-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin- l-yl)acetyl)piperidin-4-yl)methyl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-5-(4-(4-((4-((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-l / / -pyrazol-l- yl)methyl)piperi dine- l-carbonyl)piperidin-l-yl)-7V-(2,6-dioxopiperi din-3 -yl)picolinamide, N- (3-(2-(terZ-butyl)-5-(2-((l -((1 -(( / ?)- 1 -(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine- 3-carbonyl)piperidin-4-yl)methyl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((l-((l-(2-(4-(4-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)piperazin-l-yl)acetyl)piperidin-4-yl)methyl)-lJH-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, N-(3-(2-(tert- butyl)-5-(2-((l-((l-(2-((5)-l-(4-((5)-2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3- yl)acetyl)piperidin-4-yl)methyl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(Zert-butyl)-5-(2-((l-((l-(2-( (R)-l-(4-((5)-2,6- dioxopiperi din-3 -yl)phenyl)pyrrolidin-3-yl)acetyl)piperidin-4-yl)m ethyl)- l / f-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, N-(3-(2-(tert- butyl)-5 -(2-(( 1 -( 1 -(( 15,4r)-4-(4-((5)-2, 6-dioxopiperi din-3 -yl)phenoxy)cy clohexane- 1 - carbonyl)piperidin-4-yl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((l-(l-((15',4r)-4-((5-((5)-2,6- dioxopiperidin-3-yl)pyridin-2-yl)oxy)cyclohexane-l-carbonyl)piperidin-4-yl)-lJH-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (7?)-7V-(3-(2- (tert-butyl)-5-(2-((l-(l-(2-(4-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-l- yl)acetyl)piperidin-4-yl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-5-(4-(4-(4-((4-(2-(tert-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-l / Z-pyrazol-l-yl)piperidine- l-carbonyl)piperidin-l-yl)-N-(2,6-dioxopiperidin-3-yl)picolinamide, 7V-(3-(2-(tert-butyl)-5- (2-((l-(l-( (R)-l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine-3- carbonyl)piperidin-4-yl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((l-(l-(2-((5)-l-(4-((5)-2,6- dioxopiperi din-3 -yl)phenyl)pyrrolidin-3 -yl)acetyl)piperi din-4-yl)- l / f-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(2- (tert-butyl)-5-(2-((3-(l-(2-(6-(2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(lJ7)- yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((3-(l-(2-(4-(4-((2,6-dioxopiperidin-3- yl)amino)phenyl)piperidin-l-yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane- 1 -sulfonamide, N-(3 -(2-(tert-butyl)-5 -(2-((3 -( 1 -((R)- 1 -(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine-3-carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N- (3-(2-(7er -butyl)-5-(2-((3-((l-(2-(6-(2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(lJ7)- yl)acetyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -(2-(ter -butyl)-5 -(2-((3 -(( 1 -( 1 -(4-(2, 6- dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (S)-N-(3 -(2-(tert-butyl)-5 -(2-((3 -(( 1 -( 1 -(3 -(2, 6-dioxopiperi din-3 -yl)phenyl)piperidine-4- carbonyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, jV-(3-(2-(tert-butyl)-5-(2-((3-((l-((15,4r)-4-(4-((5)-2,6- dioxopiperi din-3 -yl)phenoxy)cy cl ohexane-1 -carbonyl)piperi din-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, N- (3-(2-(ter -butyl)-5-(2-((3-((l-((15,4r)-4-((5-((, )-2,6-dioxopiperidin-3-yl)pyridin-2- yl)oxy)cy cl ohexane-1 -carbonyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thi azol -4- yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((3-((l-(2-(4-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-l-yl)acetyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-5-(4-(4-(3-((4-(2-(terZ-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5- yl)pyrimidin-2-yl)amino)phenoxy)piperidine-l-carbonyl)piperidin-l-yl)-7V-(2,6- dioxopiperidin-3-yl)picolinamide, 7V-(3-(2-(tert-butyl)-5-(2-((3-((l-( (R)-l-(5-((5)-2,6- dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine-3-carbonyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((3-((l-(2-(4-(4-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperazin- l-yl)acetyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(terZ-butyl)-5-(2-((3-((l-(2-((5)-l-(4-((5)-2,6- dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)acetyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, 7V- (3-(2-(terZ-butyl)-5-(2-((3-((l-(2-( (R)-l-(4-((5)-2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3- yl)acetyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(l-((l-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(l- ((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3-(2-(terZ-butyl)-5-(2-((4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(4-((l-(4-(2,6- dioxopiperi din-3 -yl)phenyl)piperi din-4-yl)m ethyl)piperazin- 1 -yl)-3- fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (25,47?)-l-((5)-2-(5-(4-(4-((4-(2-(terZ-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)phenyl)piperidin-l-yl)-5- oxopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-7V-((5)-l-(4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2-carboxamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((2-((l-(2-(2,6- dioxopiperi din-3-yl)- 1 -oxo-1, 2-dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-l, 2,3,4- tetrahydroisoquinolin-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, 7V-(3-(2-(terZ-butyl)-5-(2-((l-((l-(((15,4r)-4-(4-((5)-2,6-dioxopiperidin-3- yl)phenoxy)cyclohexyl)methyl)piperidin-4-yl)methyl)-lJH-pyrazol-4-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N-(3 -(2-(7ert-butyl)-5 -(2-(( 1 -(( 1 - ((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4- yl)methyl)piperidin-4-yl)methyl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-5-(4-((4-((4-((4-(2-(terZ-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-l / Z-pyrazol-l- yl)methyl)piperi din- l-yl)methyl)piperi din- l-yl)-7V-(2,6-dioxopiperi din-3 -yl)picolinamide, N- (3 -(2-(ter -butyl)-5 -(2-(( 1 -(( 1 -(2-((R)~ 1 -(5 -((5)-2, 6-dioxopiperi din-3 -yl)pyridin-2- yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)methyl)-lJ7-pyrazol-4-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((l-(l- ((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4- yl)methyl)piperidin-4-yl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-5-(4-((4-(4-((4-(2-(tert-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-l / Z-pyrazol-l-yl)piperidin-l- yl)methyl)piperi din- l-yl)-7V-(2, 6-dioxopiperi din-3 -yl)picolinamide, TV-(3-(2-(te / 7-butyl)-5-(2- ((l-(l-(2-( (R)-l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin- 4-yl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((l-(l-(2-((5)-l-(5-(())-2,6-dioxopiperidin-3- yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)-lJH-pyrazol-4-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((3-(l- ((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, N-(3 -(2-(ter -butyl)-5 -(2-((3 -(1 -(2-((R)~ 1 -(5 -((5 -2,6-dioxopiperi din-3 - yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane- 1 -sulfonamide, N-(3 -(2-(ter -butyl)-5 -(2-((3 -( 1 -(2-((5)- 1 -(5 -((5)- 2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N- (3-(2-(terZ-butyl)-5-(2-((3-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidin- 4-yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(terZ-butyl)-5-(2-((3-((l-(((15,4r)-4-(4-((5)-2, 6- dioxopiperidin-3-yl)phenoxy)cyclohexyl)methyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((3-((l-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2- dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(terZ-butyl)-5-(2-((3-((l-(2- ( (R)-l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, N- (3-(2-(terZ-butyl)-5-(2-((3-((l-(2-((5)-l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -(2-(tert-butyl)-5 -(2-((3 - (( 1 - (( 1 - (5 - (2 , 6- dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)methyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-5-(4-((4-(4-((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5- yl)pyrimidin-2-yl)amino)-l / Z-pyrazol-l-yl)piperidin-l-yl)methyl)piperidin-l-yl)-N-(2,6- dioxopiperidin-3-yl)picolinamide, (R)-5-(4-((4-((4-((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-l / Z-pyrazol-l- yl)methyl)piperi din- l-yl)methyl)piperi din- l-yl)-7V-(2,6-dioxopiperi din-3 -yl)picolinamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(4-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4- carbonyl)piperazin-l-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-((4-(l-((l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)-2- methylthiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-((4-(l-((l-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4- yl)-2-methylthiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(5-(2-((5-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l-yl)pyridin-2- yl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- 7V-(3-(5-(2-((5-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazin-l- yl)pyridin-2-yl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, ( ?)-7V-(3-(5-(2-((5-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)pyri din-2 -yl)amino)pyrimi din-4-yl)-2-methylthi azol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(4-((l-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(4- ((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazin-l- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N- (3-(2-(terZ-butyl)-5-(2-((4-(4-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)piperazin-l-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, rac-(37?)-3-[6-(4-{4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl}amino)pyridin-3-yl]piperazine-l-carbonyl}piperidin-l-yl)pyridin-3-yl]piperidine-2,6- dione, (5)-7V-(3-(5-(2-((4-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((4-(4-( (R)-l-(5-( (R)-2,6- dioxopiperi din-3 -yl)pyridin-2-yl)pyrrolidine-3 -carbonyl)piperazin- 1 -y l)-3 - fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)- 7V-(3-(5-(2-((4-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(terZ-butyl)-5-(2-((4-(4-((R)-l -(5-(( ?)-2,6- dioxopiperi din-3 -yl)pyridin-2-yl)pyrrolidine-3 -carbonyl)piperazin- 1 -y l)-3 - fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, rac- (35)-3-[6-(3-{4-[6-({4-[2-tert-butyl-4-(3-{ [ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)- l,3-thiazol-5-yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazine-l-carbonyl}azetidin-l- yl)pyri din-3 -yl]piperidine-2, 6-dione, (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(4-(2-(l-(4-((2,6- dioxopiperidin-3-yl)amino)-2-fluorophenyl)-4-hydroxypiperidin-4-yl)acetyl)piperazin-l-yl)- 3 -fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (T?)-7V-(3-(2-(te / 7-butyl)-5-(2-((4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin- 2(lH)-yl)acetyl)piperazin-l-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((4-(4-((15',4r)-4-((5-((5)-2,6- dioxopiperi din-3 -yl)pyridin-2-yl)oxy)cy cl ohexane-1 -carbonyl)piperazin- l-yl)-3- fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)- 7V-(3-(2-(tert-butyl)-5-(2-((4-(4-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)piperazin-l-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(4-((l-(5-(2,6- di oxopiperi din-3 -yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin- 1- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N- (3-(2-(terZ-butyl)-5-(2-((4-(4-(2-(l-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4- yl)acetyl)piperazin-l-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(4-((l-(5-(2,6- di oxopiperi din-3 -yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin- l-yl)-3- fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (5)- 7V-(3-(5-(2-((4-(l-(2-(l-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4- yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, rac-(35)-3-{6-[4-({4-[6-({4-[4-(3-{ [ethyl (methyl)sulfamoyl]amino}-2-fluorophenyl)-2-methyl-l, 3-thi azol-5-yl]pyrimidin-2- yl } amino)pyri din-3 -yl]piperazin- 1 -yl }methyl)piperidin- 1 -yl]pyri din-3 -yl }piperidine-2,6- dione, rac-(35)-3-[6-(4-{4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-l, 3-thi azol-5-yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazine-l -carbonyl }-4- methylpiperi din- l-yl)pyri din-3 -yl]piperidine-2, 6-dione, (37?)-3-{4-[4-({4-[6-({4-[4-(3- { [ethyl (methyl)sulfamoyl]amino}-2-fluorophenyl)-2-methyl-l, 3-thi azol-5-yl]pyrimidin-2- yl } amino)pyri din-3 -yl]piperazin- 1 -yl }methyl)piperidin- 1 -yl]phenyl }piperidine-2, 6-dione, rac-(35)-3-[6-(4-{4-[6-({4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fhrorophenyl)-2- methyl-1, 3-thi azol-5-yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazine-l -carbonyl Jpiperi din- l-yl)pyri din-3 -yl]piperidine-2, 6-dione, rac-(37?)-3-{6-[4-(2-{4-[6-({4-[4-(3-{ [ethyl (methyl)sulfamoyl]amino}-2-fluorophenyl)-2-methyl-l, 3-thi azol-5-yl]pyrimidin-2- yl}amino)pyridin-3-yl]piperazin-l-yl}-2-oxoethyl)piperidin-l-yl]pyridin-3-yl}piperidine-2,6- dione, (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(4-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine- 4-carbonyl)piperazin-l-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(l-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, rac-(35)-3-[4-(4-{4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl}amino)pyridin-3-yl]piperazine-l-carbonyl}piperidin-l-yl)phenyl]piperidine-2, 6-dione, (R)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1 -sulfonamide, rac-(35)-3-{6-[4-({4-[6-({4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-2 -methyl- 1 ,3 -thiazol-5-yl]pyrimidin-2-yl } amino)pyri din-3 -yl]piperazin- 1 - yl}methyl)-4-methylpiperidin-l-yl]pyridin-3-yl}piperidine-2, 6-dione, rac-(35)-3-{4-[4-({4- [6-({4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-2-methyl-l,3-thiazol-5- yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazin-l-yl}methyl)-4-fluoropiperidin-l- yl]phenyl}piperidine-2, 6-dione, (5 -7V-(3-(5-(2-((4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)methyl)piperazin-l-yl)phenyl)amino)pyrimidin-4-yl)-2- methylthiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-((4-(4-((l-(4-(2,6- dioxopiperi din-3 -yl)phenyl)-4-fluoropiperidin-4-yl)m ethyl)piperazin-l - yl)phenyl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, rac-(37?)-3-{6-[6-({4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl}amino)pyridin-3-yl]piperazin-l-yl}methyl)-2-azaspiro[3.3]heptan-2-yl]pyridin-3- yl}piperidine-2, 6-dione, (37?)-3-{6-[4-({4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl } amino)pyri din-3 -yl]piperazin- 1 -yl }methyl)piperidin- 1 -yl]pyri din-3 -yl }piperidine-2,6- dione, rac-(37?)-3-[2-(2-{4-[4-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2-yl}amino)-2-fluorophenyl]piperazin-l-yl}-2- oxoethyl)-l,2,3,4-tetrahydroisoquinolin-6-yl]piperidine-2,6-dione, and (37?)-3-{6-[4-({4-[6- ({4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-2-methyl-l,3-thiazol-5- yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridin-3- yl}piperidine-2, 6-dione. In certain embodiments, the compound of Formula (I) is selected from the group consisting of (5)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, ( ?)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, and (5)-7V-(3-(l-(4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin- 4-yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide. In certain embodiments, the compound of Formula (I) isselected from the group consisting of (R)-7V-(3-(l-(4-(4-(l-(4-(2,6-dioxopiperidin-3- yl )phenyl)pi peri di ne-4-carbonyl)piperazine-l -carbonyl )phenyl)-3-(pyri di n-4-yl)-U7-pyrazol - 4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidin-4-yl)methyl)piperazine-l-carbonyl)phenyl)-3-(pyridin-4-yl)-l / 7-pyrazol- 4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(l-(4-(4-(l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidine-4-carbonyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(l-(4-((l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4-yl)oxy)phenyl)-3-(pyridin-4-yl)-U7- pyrazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(l-(4-(4-((l-(5-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)methyl)piperazin-l-yl)phenyl)-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (7?)-7V-(3-(l-(4-(4- ((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazine-l-carbonyl)phenyl)-3 -(pyridin-4-yl)- lZ7-pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -( 1 -(1 -( 1 - (l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)-3-fluorophenyl)piperidin-4-yl)methyl)piperazin-l- yl)phenyl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N- (3-(l-(4-(l-((l-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)methyl)piperidin- 4-yl)phenyl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- 7V-(3-(l-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperi din-3 -yl)-2-fluorophenyl)piperi din-4- yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (5)-7V-(3-(l-(6-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)pyri din-3 -yl)-3-(pyri din-4-yl)- 1 / 7-pyrazol -4-yl)-2- fluorophenyl)propane-l -sulfonamide, (7?)-7V-(3-(l-(4-(4-(2-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidin-4-yl)acetyl)piperazine-l-carbonyl)phenyl)-3-(pyridin-4-yl)-l / 7- pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -( 1 - ( 1 - ( 1 -(( 1 - ( 5 -(2 , 6 - dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)- 3 -(pyridi n-4-yl)- l / / -pyrazol -4-yl )-2-fluorophenyl)propane- l -sulfonamide, (5)-7V-(3-(l-(4-(4- ((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(l-(6-(4- ((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l-yl)pyridin-3-yl)-3-(pyridin-4-yl)-l / / -pyrazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(l-(4- (l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)-3- (pyridin-4-yl)- 1 / / -pyrazol -4-yl )-2-fl uorophenyl Jpropane- 1 -sulfonamide, (S)-N-(3 -(1 -(4-( 1 -((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)-3- (pyridin-4-yl)- 1 / / -pyrazol -4-yl )-2-fl uorophenyl Jpropane- 1 -sulfonamide, (S)-N-(3 -(1 -(4-( 1 -((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)-3- (pyridin-4-yl)-l / / -pyrazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(l-(4-(4- ((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)-3- (pyridin-4-yl)- I / / -py razol -4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -( 1 -( 1 -( 1 -( 1 - (5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)-4-methylpiperidine-4- carbonyl)piperidin-4-yl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(l-(4-(l-((l-(4-(2,6-dioxopiperidin-3-yl)-3-fluorophenyl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, and (7?)-7V-(3-(l-(4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin- 4-yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2- fluoropheny l)prop ane- 1 - sulfonami de .[000106] In certain embodiments, the compound of Formula (II) is selected from the group consisting of (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2- aminopyrimidin-4-yl)-2-(l -(l-(l-(5-(2,6-di oxopiperi din-3 -yl)pyri din-2 -yl)piperidine-4- carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(4- (2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l- (l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, and (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(pyridin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide. In certain embodiments, the compound of Formula (II) is selected from the group consisting of (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(3 -(2-(4-(3 -(2-(2,6-dioxopiperi din-3 -yl)- 1 ,3 -dioxoi soindolin-4- yl)propyl)piperazin-l-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((15',4r)-4-((6- ((5)-2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(lJ7)-yl)methyl)cyclohexane-l- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l- (l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-5-yl)piperazin-l-yl)acetyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(r-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-[l,4'-bipiperidin]-4-yl)acetyl)-4- methylpiperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2- aminopyrimidin-4-yl)-2-(l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidine-4-carbonyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-(2-(6- (2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(lJ7)-yl)acetyl)piperidin-4- yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N-(3-(2- (l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyridin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(r-(2-(2,6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-5-yl)-[l,4'-bipiperidin]-4-yl)acetyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(4-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperazin-l-yl)acetyl)piperidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-( 1 -( 1 -(1 -(2-(2,6-dioxopiperi din-3 -yl)- 1 ,3-dioxoisoindolin-5-yl)piperidin-4- yl)azetidine-3-carbonyl)piperidin-4-yl)propan-2-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-((17?,4r)-4-(3-( (R)-2,6- dioxopiperi din-3 -yl)phenoxy)cy cl ohexane-l-carbonyl)piperidin-4-yl)methyl)piperi din-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5- (2-aminopyrimidin-4-yl)-2-(l-(l-(2-(l-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)- 4-hydroxypiperidin-4-yl)acetyl)azetidin-3-yl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-(2-(l-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)acetyl)piperidin-4-yl)phenyl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-((l- (4-(2, 6-dioxopiperi din-3 -yl)phenyl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)thi azol -4- yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-(2- (l-(4-((2,6-dioxopiperi din-3 -yl)amino)phenyl)piperi din-4-yl)acetyl)piperi din-4- yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(4-(l-(l-(5-(2,6-dioxopiperi din-3-yl)pyri din-2 -yl)piperidine-4- carbonyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, N-(3- (5-(2-aminopyrimidin-4-yl)-2-(3-(((15,4r)-4-((5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)oxy)cyclohexyl)methyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(l-(4- (2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperazin-l-yl)phenyl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-5-(4-(9-(5-(2-aminopyrimidin-4-yl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-2-yl)-3-azaspiro[5.5]undecane-3-carbonyl)piperidin-l- yl)-7V-(2,6-dioxopiperidin-3-yl)picolinamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-((5)-l- (5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)-3-azaspiro[5.5]undecan-9- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)- 2-(l-(l-(2-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)acetyl)azetidin-3- yl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-(l -(5-(2,6-di oxopiperidin-3-yl)pyri din-2 -yl)piperidine-4- carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4- carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyridin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2- (methylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N-(3 - (5-(2-aminopyrimidin-4-yl)-2-(2-(2-(l'-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)-[l,4'-bipiperidin]-4-yl)acetyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyridin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2- (l-((l-(((15,4r)-4-(4-((5)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexyl)methyl)piperidin-4- yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3- 5- (2-aminopyrimidin-4-yl)-2-(2-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidine-4-carbonyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(2-(l-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4- yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(l-(l-(l-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin- 4-yl)ethyl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3- 5-(2- aminopyrimidin-4-yl)-2-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperazin-l-yl)acetyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, ( ?)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperazin-l-yl)phenyl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(l-(l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-(l-(5-(2,6-dioxopiperidin-3-yl)pyri din-2- yl)piperidine-4-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(2-(l-(5- (2, 6-dioxopiperi din-3 -yl)pyri din-2 -yl)piperi din-4-yl)acetyl)piperazin- l-yl)phenyl)thi azol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(r- (2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-[l,4'-bipiperidin]-4-yl)acetyl)-3-azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5- (2-aminopyrimidin-4-yl)-2-(l-(l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidine-4-carbonyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(2- (isopropylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperazin-l-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-((17?,4r)-4-(4-(( ?)-2,6- dioxopiperi din-3 -yl)phenoxy)cy cl ohexane-l-carbonyl)piperidin-4-yl)methyl)piperi din-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-(6-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-2- azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, 7V-(3-(2-(l-(l- (l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(2-((( ?)-l-hydroxypropan-2-yl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-((l- (5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)thiazol- 4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, rac-(35)-3 - { 6- [4 - (4 - {4-[5-(2-aminopyrimidin- 4-yl)-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-2-yl]piperidine-l- carbonyl}piperidine-l-carbonyl)piperidin-l-yl]pyridin-3-yl}piperidine-2, 6-dione, rac-(35)-3- {6-[4-(4-{4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-5-{2-[(propan-2- yl)amino]pyrimidin-4-yl } - 1 ,3 -thiazol-2-yl]piperidine- 1 -carbonyl } piperi dine- 1 - carbonyl)piperidin-l-yl]pyridin-3-yl}piperidine-2, 6-dione, (5)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(l-(l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-((l-(2-(2,6-dioxopiperidin-3-yl)-l- oxoisoindolin-5-yl)piperidin-4-yl)methyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(2-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-4- methylpiperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3- 5-(2- aminopyrimidin-4-yl)-2-(3-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperidine-4-carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, ( ?)-7V-(3-(2-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)- 2,7 -di azaspiro [3.5 ]nonan-7 -yl)acetyl)piperidin-4-yl)-5-(2-(methylamino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(3-(6-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5- (2-aminopyrimidin-4-yl)-2-(l-(l-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2- (methylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N-(3 - (5-(2-aminopyrimidin-4-yl)-2-(l-(l-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin- 4-yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2-(isopropylamino)pyrimidin-4-yl)thiazol- 4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-(cyclopropylamino)pyrimidin-4- yl)-2-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l- (l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-( (R)-l-(4-(())-2,6-dioxopiperidin-3- yl)phenyl)pyrrolidin-3-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(2-(2-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-2- azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(l-((l-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)piperidin-4-yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)- l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(l-(l-(2,6- dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[d]imidazol-4-yl)piperidine-4- carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, ( ?)-7V-(3-(2-(l-(l-((l-(4-(2,6-dioxopiperi din-3 -yl)phenyl)piperidin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2-(methylamino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperidin-4-yl)azetidine-3- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(2-(l-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidin-4-yl)azetidine-3-carbonyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2- fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -(5-(2-aminopyrimidin-4-yl)-2-(l -( 1 -(( 1 -( 1 - (2, 6-dioxopiperi din-3 -yl)-3-methyl-2-oxo-2, 3 -dihydro- l / Z-benzo[d]imidazol-4-yl)piperi din- 4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, ( ?)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(2-(2-(2,6-dioxopiperidin-3-yl)- l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-3-azaspiro[5.5]undecan-9- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7- diazaspiro[3.5]nonan-7-yl)acetyl)piperidin-4-yl)propan-2-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, and ( / ?)-4-((4-(5-(2-aminopyrimidin-4-yl)-4-(2-fluoro- 3-(propylsulfonamido)phenyl)thiazol-2-yl)piperidin-l-yl)methyl)-N-(2,6-dioxopiperidin-3- yl)benzamide.[000107] In certain embodiments of Formula (I), X1is carbon; X2is nitrogen, X3is nitrogen; X4is carbon; and X5is hydrogen. In certain embodiments of Formula (I), R1is alkyl, dialkylamino, cycloalkyl, or heterocycloalkyl each unsubstituted or substituted with one or more halogen; Rlais halogen; Rlbis hydrogen, haloalkyl or halogen; R2is -[Ar1-Z1]n-Z2-Cy1- Z3-L-UBM; Ar1is arylene or heteroarylene, each unsubstituted or substituted with one or more halogen; Z1is a bond; n is one; Z2is absent; Cy1is absent or heterocycloalkylene, unsubstituted or substituted with one or more alkyl or one or more halogen; Z3is absent or Ci-io alkylene; L is a linker according to -L4-L2-L3-L4- or -L4-L3-L2-L4-, wherein -L1- is -Q1- or -Q2-; each -L2-, -L3-, and -L4- is independently, absent, -Ci-8 alkylene-, or -Q1-; each -Q1- is a three- to seven-membered heterocycloalkylene comprising at least one nitrogen and is unsubstituted or substituted with one or more methyl or halogen; each -Q2- is a five- to thirteen-membered bicyclic heterocycloalkylene comprising at least one nitrogen, wherein the five- to thirteen-membered bicyclic heterocycloalkylene is optionally a spiro bicyclic heterocycloalkylene ring; and UBM is a ubiquitin ligase binding moiety; or a stereoisomer and / or pharmaceutical salt thereof.[000108] In certain embodiments of Formula (I), R1is selected from the group consistingpropyl. In one embodiment, R1is ethylmethylamino. In one embodiment, R1is ec-butyl. In one embodiment, R1is. In one embodiment, R1isone embodiment, R1is. In one embodiment, R1isembodiment,R1is . In one embodiment, R1is. In one embodiment,[000109] In certain embodiments of Formula (I), Rlais chloro or fluoro; and Rlbis hydrogen, chloro, fluoro, or haloalkyl. In certain embodiments of Formula (I), Ar1is arylene or heteroarylene unsubstituted or substituted with one or two halogen. In certain embodiments of Formula (I), UBM binds an E3 ubiquitin ligase. In certain embodiments of Formula (I), UBM binds SCFP-TRCP, VHL, MDM2, IAP, or CRBN. In certain embodiments of Formula (I), UBM binds CRBN. In certain embodiments of Formula (I), UBM binds CRBN and has the following chemical formulawherein X6absent or NR3; X7absent or -C(O)-; and X8is arylene or heteroarylene. In certain embodiments of Formula (I), UBM binds CRBN and is selected from the group consistingabsent or halogen; and m is one, two, three, or four. In one embodiment, UBM binds CRBNwherein X9is absent or halogen; and m is one, two, three, or four. In one embodiment, UBM binds CRBN and iswherein X9is absent. In one embodiment, UBM bindswherein X9is halogen; and m is one. In one embodiment, UBM bindswherein X9is halogen; and m is two.In one embodiment, UBM bindswherein X9is halogen; and m isthree. In one embodiment, UBM bindswherein X9is halogen; and m is four. In one embodiment, UBM bindsone embodiment, UBMbinds CRBN and is . In one embodiment, UBM binds CRBN and is . In one embodiment, UBM bindsone embodiment, UBM binds,embodiment, UBM bindswherein X9is absent or halogen; and m is one, two, three, or four. In one embodiment, UBM bindswherein X9is absent. In one embodiment, UBM bindswhereinX9is halogen; and m is one. In one embodiment, UBM bindswherein X9is halogen; and m is two. In one embodiment, UBM binds CRBN and iswherein X9is halogen; and m is three. In one embodiment, UBM binds,, embodiment, UBM bindsone embodiment, UBM binds CRBN,[0001 10] In certain embodiments of Formula (I), the compound is selected from the group consisting of (R)-7V-(5-chloro-3-(l-(4-(4-((l-(5-(2,4-dioxotetrahydropyrimidin-l(2J7)-yl)pyridin-2-yl)piperidin-4-yl )methyl)piperazin-l -yl)phenyl )-3-(pyridin-4-yl)-l / / -pyrazol-4- yl)-2-fluorophenyl)-3 -fluoropyrrolidine- 1 -sulfonamide; (R)-N-(5 -chi oro-3 -( 1 -(4-(4-((l -(5-((7?)-2, 6-dioxopiperi din-3 -yl)pyri din-2-yl)piperi din-4-yl)m ethyl)piperazin- l-yl)phenyl)-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl)-2-fluorophenyl)-3-fluoropyrrolidine-l -sulfonamide; rac-(7?)- 7V-(5-chloro-3-(l-(4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperazin- 1 -yl)phenyl)-3 -(pyridin-4-yl)- l / 7-pyrazol-4-yl)-2- fluorophenyl)pyrrolidine-l -sulfonamide; rac- (R)-7V-(5-chloro-3-(l-(4-(4-((l-(5-(2,6- dioxopiperi din-3 -yl)pyri din-2-yl)piperi din-4-yl)methyl)piperazin- 1 -yl)-2-fluorophenyl)-3 - (pyridin-4-yl)-lJ7-pyrazol-4-yl)-2-fluorophenyl)pyrrolidine-l-sulfonamide; rac-(7?)-7V-(3-(l- (4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l- yl)phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2,5-difluorophenyl)pyrrolidine-l-sulfonamide; 7V-(5-chloro-3-(l-(4-( (R)-4-((l-(5-((7?5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)-3-methylpiperazin-l-yl)phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2- fluorophenyl)pyrrolidine-l -sulfonamide; (7?)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)- 2-fluorophenyl)piperidin-4-yl)methyl)piperazin-l-yl)-2-fluorophenyl)-3-(pyridin-4-yl)-lJH- pyrazol-4-yl)-2,5-difluorophenyl)cyclopentanesulfonamide; rac-(7?)-7V-(3-(l-(4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperazin-l-yl)-3-fluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2,5- difluorophenyl)cyclopentanesulfonamide; rac-(7?)-7V-(5-chloro-3-(l-(4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperazin-l-yl)-3-fluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2- fluorophenyl)cyclopentanesulfonamide;(R)-N-(5 -chi oro-3 -( 1 -(4-(4-(( 1 -(4-(2, 6-dioxopiperi din-3 -yl)-2-fluorophenyl)piperidin-4- yl)methyl)piperazin-l-yl)-3-fluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2- fluorophenyl)cyclopentanesulfonamide;(R)-N-(5 -chi oro-3 -( 1 -(4-(4-(( 1 -(4-(2, 6-dioxopiperi din-3 -yl)-2-fluorophenyl)piperidin-4- yl)methyl)-l,4-diazepan-l-yl)-2-fluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2- fluorophenyl)pyrrolidine-l -sulfonamide; (7?)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)- 2-fluorophenyl)piperidin-4-yl)methyl)-l,4-diazepan-l-yl)-2-fluorophenyl)-3-(pyridin-4-yl)- lZZ-pyrazol-4-yl)-2,5-difluorophenyl)pyrrolidine-l-sulfonamide; 7V-[5-chloro-3-(l-{4-[(37?)- 4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]-3-methylpiperazin-l- yl]phenyl} -3 -(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl]propane-l -sulfonamide; 7V-[5- chloro-3-(l-{4-[(37?)-4-[(l-{5-[(37?5)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl )methyl ]-3 -methyl pi perazi n- 1 -yl ]phenyl } -3 -(pyri di n-4-yl )- l / / -pyrazol -4-yl )-2- fluorophenyl] prop aned -sulfonamide; 7V-[5-chloro-3-(l-{4-[(37?)-4-({ l-[4-(2,4-dioxo-l,3- diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)-3 -methylpiperazin- 1 -yl]phenyl } -3 -(pyridin-4- yl)-lJ7-pyrazol-4-yl)-2-fluorophenyl]propane-l -sulfonamide; 7V-[5-chloro-3-(l-{4-[(35)-4- [(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]-3-methylpiperazin-l- yl]phenyl} -3 -(pyridin-4-yl)-lJ7-pyrazol-4-yl)-2-fluorophenyl]propane-l -sulfonamide; 7V-[5- chloro-3-(l-{4-[(35)-4-[(l-{5-[(37?5')-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]-3-methylpiperazin-l-yl]phenyl}-3-(pyridin-4-yl)-lJ7-pyrazol-4-yl)-2- fluorophenyl]propane-l -sulfonamide; 7V-[5-chloro-3-(l-{4-[(35)-4-({l-[4-(2,4-dioxo-l,3- diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)-3 -methylpiperazin- 1 -yl]phenyl } -3 -(pyridin-4- yl)-l / / -pyrazol-4-yl)-2-fluorophenyl]propane-l -sulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l-{4- [(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}-2-fluorophenyl)- 3-(pyridin-4-yl)-lJ7-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l -sulfonamide; 7V-{5-chloro-3- [l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l- yl }phenyl)-3 -(pyridin-4-yl)- U7-pyrazol-4-yl]-2-fluorophenyl } pyrrol i dine- 1 -sulfonamide; N- [5-chloro-3-(l-{4-[4-({l-[4-(2,4-dioxo-l,3-diazinan-l-yl)phenyl]piperidin-4- yl}methyl)piperazin-l-yl]phenyl}-3-(pyridin-4-yl)-U7-pyrazol-4-yl)-2- fluorophenyl]pyrrolidine-l -sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl}-4-fluoropiperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)-l / / -pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l -sulfonamide; 7V-{5-chloro-3- [l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-1-yl}phenyl)-3-(pyridin-4-yl)-lJ7-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l-sulfonamide; 7V-{5-chloro-3-[l-(5-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4- yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyridin-4-yl)-U7-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; 7V-[5-chloro-3-(l-{5-[4-({l-[4-(2,4-dioxo-l,3- diazinan- 1 -yl)phenyl]piperidin-4-yl } methylpiperazin- 1 -yl]pyri din-2 -yl } -3 -(pyridin-4-yl)- l / Z-pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; rac-7V-{5-chloro-3-[l-(5-{4-[(l- {5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l-sulfonamide; 7V-(3-(l-(4-( (R)-4-((l-(5-((7?5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)-3- methylpiperazin- 1 -yl)-2-fluorophenyl)-3 -(pyridin-4-yl)- 1 H-py razol-4-yl)-2, 5 - difluorophenyl)pyrrolidine- 1 -sulfonamide; N- { 5 -chi oro-3 - [l-(5-{4-[(l-{ 5 - [ (37?) -2 , 6 - dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyridin-4-yl )-l / / -pyrazol-4-yl]-2-fluorophenyl } pyrrolidine-1 -sulfonamide; (3R)-N-{5- chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4- yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2-fluorophenyl}-3- fluoropyrrolidine-1 -sulfonamide; (37?)-7V-[5-chloro-3-(l-{4-[4-({l-[4-(2,4-dioxo-l,3- diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)piperazin- 1 -yl]phenyl } -3 -(pyridin-4-yl)- 1H- pyrazol-4-yl)-2-fluorophenyl]-3 -fluoropyrrolidine- 1 -sulfonamide; (3R)-N- { 5-chl oro-3 -[ 1 -(4- {4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l- yl }phenyl)-3 -(pyridin-4-yl)- lZ7-pyrazol-4-yl]-2-fluorophenyl } -3 -fluoropyrrolidine- 1 - sulfonamide; (37?)-7V-{5-chloro-3-[l-(5-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3- yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyridin-4-yl)-lJH-pyrazol-4- yl]-2-fluorophenyl}-3-fluoropyrrolidine-l-sulfonamide; (37?)-zV-[5-chloro-3-(l-{5-[4-({ l-[4- (2,4-dioxo-l,3-diazinan-l-yl)phenyl]piperidin-4-yl}methyl)piperazin-l-yl]pyridin-2-yl}-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl)-2-fluorophenyl]-3-fluoropyrrolidine-l -sulfonamide; (3R)-N- {5-chloro-3-[l-(5-{4-[(l-{5-[(37?5)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyridin-4-yl)-U7-pyrazol-4-yl]-2-fluorophenyl}-3- fluoropyrrolidine- 1 -sulfonamide; (37?)-7V-{5-chloro-3-[l-(5-{4-[(l-{5-[(37?)-2,6- dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2-yl)-3- (pyridin-4-yl)-17 / -pyrazol-4-yl]-2-fluorophenyl J-3-fluoropyrrolidine-l -sulfonamide; (3R)-N- {5-chloro-3-[l-(5-{4-[(7-{4-[(37?5)-2,6-dioxopiperidin-3-yl]phenyl}-7-azaspiro[3.5]nonan-2- yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyridin-4-yl)-177-pyrazol-4-yl]-2-fluorophenyl}-3- fluoropyrrolidine- 1 -sulfonamide; 7V-{3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3- yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2.5-difluorophenyl}pyrrolidine-l-sulfonamide; 7V-[3-(l-{4-[4-({l-[4-(2,4-dioxo-l,3-diazinan- l-yl)phenyl]piperidin-4-yl}methyl)piperazin-l-yl]phenyl}-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2.5-difluorophenyl]pyrrolidine-l-sulfonamide; 7V-{3-[l-(4-{4-[(l-{5-[(37?)-2,6- dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4- yl)- IT / -pyrazol-4-yl]-2,5-difluorophenyl Jpyrrolidine- I -sulfonamide; (37?)-7V-{3-[l-(5-{4-[(l - {4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2-yl)- 3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2,5-difluorophenyl}-3-fluoropyrrolidine-l-sulfonamide; (37?)-7V-[3-(l-{5-[4-({l-[4-(2,4-dioxo-l,3-diazinan-l-yl)phenyl]piperidin-4- yl}methyl)piperazin-l-yl]pyridin-2-yl}-3-(pyridin-4-yl)-177-pyrazol-4-yl)-2,5- difluorophenyl]-3-fluoropyrrolidine-l-sulfonamide; (37?)-7V-{3-[l-(5-{4-[(l-{5-[(3R5)-2,6- dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyri di n-4-yl )-l / / -pyrazol -4-yl ]-2,5-difl uoropheny 1 } -3 -fl uoropyrrol i di ne-1 -sulfonamide; (3 / ?)-7V-{3-[l-(5-{4-[(l-{5-[(3 / ?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl )methyl ]pi perazin- 1 -yl } pyri di n-2-yl )-3 -fpyri di n-4-yl )- l / / -pyrazol -4-yl ]-2,5- difluorophenyl } -3 -fluoropyrrolidine- 1 -sulfonamide; (3R)-3 -(4- { 4- [(4- { 4- [4 - (5 -chi oro-3 -[ [ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-l / 7-pyrazol-l- yl]phenyl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidine-2, 6-dione; l-(4-{4-[(4-{4- [4-(5-chloro-3-{ [ethyl(methyl)sulfamoyl]amino[-2-fluorophenyl)-3-(pyridin-4-yl)-l / 7- pyrazol-l-yl]phenyl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)-l,3-diazinane-2, 4-dione; rac-(37?)-3-(6-{4-[(4-{4-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3- (pyridin-4-yl)- I / 7-pyrazol - 1 -yl]phenyl } piperazin- 1 -yl)methyl]piperidin- 1 -yl }pyri din-3 - yl)piperidine-2, 6-dione; (37?)-3-(6-{4-[(4-{4-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-177-pyrazol-l- yl]phenyl}piperazin-l-yl)methyl]piperidin-l-yl}pyridin-3-yl)piperidine-2, 6-dione; (37?)-3-(4- {4-[(4-{6-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)- I / 7-pyrazol - 1 -yl]pyri din-3 -yl } piperazin- 1 -yl)methyl]piperidin- 1 -yl } phenyl )pi peri di ne-2, 6- dione; l-(4-{4-[(4-{6-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2-fhrorophenyl)-3- (pyridin-4-yl)-177-pyrazol-l-yl]pyridin-3-yl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)-1.3-diazinane-2, 4-dione; rac-(37?)-3-(6-{4-[(4-{6-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-177-pyrazol-l-yl]pyridin-3-yl}piperazin-l-yl)methyl]piperidin-l-yl}pyridin-3-yl)piperidine-2, 6-dione; l-(6-{4-[(4-{6- [4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-177- pyrazol-l-yl]pyridin-3-yl}piperazin-l-yl)methyl]piperidin-l-yl}pyridin-3-yl)-l,3-diazinane-2.4-dione; (37?)-3-(6-{4-[(4-{6-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-3 -(pyridin-4-yl)- I / 7-pyrazol - 1 -yl]pyri din-3 -yl } piperazin- 1 - yl)methyl]piperidin-l-yl}pyridin-3-yl)piperidine-2, 6-dione; (37?)-7V-[5-chloro-3-(l-{4-[(37?)-4-({ 1 -[4-(2,4-dioxo- 1 ,3 -diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)-3 -methylpiperazin- 1 - yl]phenyl} -3 -(pyridin-4-yl)-177-pyrazol-4-yl)-2-fluorophenyl]-3 -fluoropyrrolidine- 1- sulfonamide; 7V-[5-chloro-3-(l-{4-[(37?)-4-[(l-{4-[(37?)-2,6-dioxopiperidin-3- yl]phenyl}piperidin-4-yl)methyl]-3-methylpiperazin-l-yl]phenyl}-3-(pyridin-4-yl)-177- pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; (37?)-7V-[5-chloro-3-(l-{4-[(37?)-4- [(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]-3-methylpiperazin-l- yl]phenyl} -3 -(pyridin-4-yl)-177-pyrazol-4-yl)-2-fluorophenyl]-3 -fluoropyrrolidine- 1- sulfonamide; (37?)-7V-[5-chloro-3-(l-{4-[(37?)-4-[(l-{5-[(37?5)-2,6-dioxopiperidin-3-y 1 ] py ri din-2-y 1 } piperi din-4-y l)methy 1 ] -3 -methylpiperazin- 1 -yl]phenyl } -3 -(pyridin-4-yl)- 1H- pyrazol-4-yl)-2-fluorophenyl]-3-fluoropyrrolidine-l-sulfonamide; / V-[5-chloro-3-(l-{4-[(37?)- 4-({ 1 -[4-(2,4-dioxo- 1 ,3 -diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)-3 -methylpiperazin- 1 - yl]phenyl } -3 -(pyri di n-4-yl)-l / / -pyrazol -4-yl )-2-fluorophenyl]pyrroli di ne-1 -sulfonamide; (37?)-7V-[5-chloro-3-(l-{5-[(37?)-4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4- yl)methyl]-3 -methylpiperazin- 1 -yl]pyri din-2 -yl } -3 -(pyridin-4-yl)- l / 7-pyrazol-4-yl)-2- fluorophenyl]-3-fluoropyrrohdine-l-sulfonamide; (37?)-7V-[5-chloro-3-(l-{5-[(37?)-4-[(l-{5- [(37?5)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]-3-methylpiperazin-l- yl]pyridin-2-yl } -3 -(pyridin-4-yl)- l / 7-pyrazol-4-yl)-2-fluorophenyl]-3 -fluoropyrrolidine- 1 - sulfonamide; (37?)-7V-[5-chl oro-3 -(1 - { 5-[(37?)-4-({ 1 -[4-(2,4-dioxo- 1 ,3 -diazinan- 1 - yl)phenyl]piperidin-4-yl}methyl)-3 -methylpiperazin- 1 -yl]pyridin-2-yl } -3 -(pyri din-4-yl)- 1 / 7- pyrazol-4-yl)-2-fluorophenyl]-3-fluoropyrrolidine-l-sulfonamide; 7V-[5-chloro-3-(l-{5-[(37?)- 4-[(l-{5-[(37?5)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]-3- methylpiperazin-l-yl]pyri din-2 -yl} -3 -(pyri din-4-yl)-l / 7-pyrazol-4-yl)-2- fluorophenyl]pyrrolidine- 1 -sulfonamide; 7V-[5-chloro-3 -( 1 -{ 5 - [(37?)-4-( { 1 -[4-(2,4-dioxo- 1,3- diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)-3 -methylpiperazin- 1 -yl]pyridin-2-yl }-3- (pyridin-4-yl)-l / / -pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; 7V-[5-chloro-3-(l- {5-[(37?)-4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]-3- methylpiperazin-l-yl]pyri din-2 -yl} -3 -(pyri din-4-yl)-l / 7-pyrazol-4-yl)-2- fluorophenyl]pyrrolidine-l -sulfonamide; 7V-[5-chloro-3-(l-{5-[(37?)-4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]-3-methylpiperazin-l-yl]pyridin-2-yl}-3- (pyridin-4-yl)-l / / -pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; ( / 7S')-A-(5-chloro- 3-(l-(4-(4-((l-(5-((7?)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin- 1 -yl)phenyl)-3 -(pyridin-4-yl)- I / / -py razol -4-yl )-2-fl uorophenyl )butane-2-sulfonami de; rac-(27?)-7V-[5-chl oro-3 -(1 - { 4- [4-({ 1 -[4-(2,4-dioxo- 1 ,3 -diazinan- 1 -yl)phenyl]piperidin-4- yl}methyl)piperazin-l-yl]phenyl}-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2-fluorophenyl]butane- 2-sulfonamide; rac- (R)-7V-(5-chloro-3-(l-(4-(4-((l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl)-2- fluorophenyl)butane-2-sulfonamide; (2 / 7S')-A-{5-chloro-3-[l-(4-{4-[(l-{4-[(3 / ?)-2,6- dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)- l / / -pyrazol-4-yl]-2-fluorophenyl}butane-2-sulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l-{5- [(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)-l / 7-pyrazol-4-yl]-2-fluorophenyl}-3-fluoroazetidine-l-sulfonamide; rac- / V-{5-chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin- l-yl Jphenyl)-3-(pyridin-4-yl)- l / / -pyrazol-4-yl]-2-fliiorophenyl J-3- fluoroazetidine- 1 -sulfonamide; V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3- yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-177-pyrazol-4-yl]-2- fluorophenyl } -3 -fluoroazetidine- 1 -sulfonamide; (3R)-N- { 5 -chi oro-3 -[ 1 -(4- { 4- [( 1 - { 5 -[(37?)-2.6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}-2-fluorophenyl)- 3-(pyridin-4-yl)-177-pyrazol-4-yl]-2-fluorophenyl}-3-fluoropyrrolidine-l-sulfonamide; (37?)-V-{5-chloro-3-[l-(4-{4-[(l-{5-[(37?S)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin-l-yl}-2-fluorophenyl)-3-(pyridin-4-yl)-177-pyrazol-4-yl]-2- fluorophenyl} -3 -fluoropyrrolidine- 1 -sulfonamide; (37?)- V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2.6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}-2-fluorophenyl)-3- (pyridin-4-yl)-17f-pyrazol-4-yl]-2-fluorophenyl}-3-fluoropyrrolidine-l-sulfonamide; rac- V- {5-chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin-l-yl}-2-fluorophenyl)-3-(pyridin-4-yl)-177-pyrazol-4-yl]-2- fluorophenyl} -3 -fluoroazetidine- 1 -sulfonamide; V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}-2-fluorophenyl)-3- (pyridin-4-yl)-177-pyrazol-4-yl]-2-fluorophenyl}-3-fluoroazetidine-l-sulfonamide; 7V-[5- chl oro-3-(l-{4-[4-({l-[4-(2,4-di oxo-1, 3-diazinan-l -yl)phenyl]piperidin-4- yl }methyl)piperazin- 1 -yl]-2-fluorophenyl } -3 -(pyridin-4-yl)- 177-pyrazol-4-yl)-2- fluorophenyl]-3 -fluoroazetidine- 1 -sulfonamide; V-{3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}-2-fluorophenyl)-3- (pyridin-4-yl)-177-pyrazol-4-yl]-2,5-difluorophenyl}pyrrolidine-l-sulfonamide; rac-7V-{3-[l- (4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l- yl } -2-fluorophenyl)-3 -(pyridin-4-yl)- 177-pyrazol-4-yl]-2, 5 -difluorophenyl (pyrrolidine- 1 - sulfonamide; V-{3-[l-(5-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4- yl)methyl]piperazin-l-yl}pyrimidin-2-yl)-3-(pyridin-4-yl)-177-pyrazol-4-yl]-2,5- difluorophenyl } pyrrolidine- 1 -sulfonamide; rac- V- {3-[l-(5-{4-[(l-{5 -[(37?)-2,6- dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}pyrimidin-2-yl)-3- (pyridin-4-yl)-177-pyrazol-4-yl]-2,5-difluorophenyl}pyrrolidine-l-sulfonamide; V-{5-chloro- 3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]-3-fluorophenyl}piperidin-4- yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-177-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; rac- V-{5-chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6- dioxopiperi din-3 -yl]pyridin-2-yl }piperidin-4-yl)methyl]- 1 ,4-diazepan- 1 -yl } -2-fluorophenyl)-3-(pyridin-4-yl)-l / / -pyrazol-4-yl]-2-fluorophenyl Jpyrrolidine- I -sulfonamide; 7V-{5-chloro-3- [l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]-l,4-diazepan-l- yl } -2-fluorophenyl)-3 -(pyridin-4-yl)- lZ7-pyrazol-4-yl]-2-fluorophenyl J pyrrol i di ne- 1 - sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]-2- fluorophenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4- yl]-2-fluorophenyl}pyrrolidine-l-sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]-3-fluorophenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l-sulfonamide; 7V-[5-(difluoromethyl)-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4- yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2- fluorophenyl]pyrrolidine-l -sulfonamide; rac-7V-[5-(difluoromethyl)-3-[l-(4-{4-[(l-{5-[(37?)- 2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)- l / / -pyrazol-4-yl]-2-fluorophenyl]pyrrolidine- l -sulfonamide; 7V-{5-chloro-3-[l- (6-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l- yl}pyridin-3-yl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l- sulfonamide; rac-7V-{5-chloro-3-[l-(6-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2- yl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-3-yl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}-2,5-difluorophenyl)-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l-sulfonamide; rac-7V-{5-chloro- 3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin-l-yl}-2,5-difluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; 7V-[5-chloro-3-(l-{4-[4-({l-[5-(2,4-dioxo-l,3- diazinan- 1 -yl)pyri din-2 -y 1 ] piperi din-4-yl }methyl)piperazin- 1 -yl]phenyl } -3 -(pyridin-4-yl)- l / Z-pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; 7V-[5-(difluoromethyl)-3-(l-{4- [4-({l-[4-(2,4-dioxo-l,3-diazinan-l-yl)phenyl]piperidin-4-yl}methyl)piperazin-l-yl]-2- fluorophenyl} -3 -(pyridin-d-y^-l / f-pyrazoM-y^-Z-fluorophenylJpyrrolidine-l -sulfonamide; rac-7V-[5-(difluoromethyl)-3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2- yl}piperidin-4-yl)methyl]piperazin-l-yl}-2-fluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]- 2-fluorophenyl]pyrrolidine-l -sulfonamide; 7V-[5-chloro-3-(l-{5-[4-({l-[4-(2,4-dioxo-l,3- diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)piperazin- 1 -yl]pyrimidin-2-yl } -3 -(pyridin-4-yl)- l / Z-pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; rac-7V-{5-chloro-3-[l-(5-{4-[(l- {5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl Jpyrimidin-2-yl)-3-(pyridin-4-yl)- l / / -pyrazol-4-yl]-2-fluorophenyl Jpyrrolidine- I- sulfonamide; 7V-{5-chloro-3-[l-(5-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin- 4-yl)methyl]piperazin-l-yl}pyrimidin-2-yl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l -sulfonamide; 7V-[5-chloro-3-(l-{4-[4-({l-[4-(2,4-dioxo-l,3- diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)piperazin- 1 -y 1 ] -3 -fluorophenyl } -3 -(pyridin-4- yl)-l / / -pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; 7V-[5-(difluoromethyl)-3-[l- (4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}-2- fluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2-fluorophenyl]pyrrolidine-l -sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin- 1 -yl } -3 -fluorophenyl)-3 -(pyridin-4-yl)- l / 7-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}-3-fluorophenyl)-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l-sulfonamide; (3R)-N-[5- chloro-3-(l-{4-[4-({l-[4-(2,4-di oxo-1, 3-diazinan-l -yl)phenyl]piperidin-4- yl } methyl)piperazin- 1 -yl] -3 -fluorophenyl } -3 -(py ridin-4-yl)- l / 7-pyrazol-4-yl)-2- fhiorophenyl]-3-fhroropyrrohdine-l-sulfonamide; (37?)-7V-{5-chloro-3-[l-(4-{4-[(l-{5- [(37?5)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}-3- fluorophenyl)-3 -(pyridin-4-yl)- lZ7-pyrazol-4-yl]-2-fluorophenyl } -3 -fluoropyrrolidine- 1 - sulfonamide; (37?)-N-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3- yl]phenyl }piperidin-4-yl)methyl]piperazin- 1 -yl } -3 -fluorophenyl)-3 -(pyridin-4-yl)- 1H- pyrazol-4-yl]-2-fhiorophenyl}-3-fhroropyrrolidine-l-sulfonamide; 7V-[5-chloro-3-(l-{4-[4- ({1 -[5-(2,4-dioxo- 1 ,3 -diazinan- 1 -yl)pyri din-2 -y 1 ]piperi din-4-yl }methyl)piperazin- 1 - yl]phenyl} -3 -(pyridin-4-yl)- lZ7-pyrazol-4-yl)-2-fluorophenyl]-3 -fluoroazetidine- 1- sulfonamide; 7V-[5-chloro-3-(l-{4-[4-({l-[5-(2,4-dioxo-l,3-diazinan-l-yl)pyridin-2- yl]piperidin-4-yl}methyl)piperazin-l-yl]-2-fluorophenyl}-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl] -3 -fluoroazetidine- 1 -sulfonamide; 7V-[5-chloro-3-(l-{4-[4-({l-[5-(2,4-dioxo- l,3-diazinan-l-yl)pyridin-2-yl]piperidin-4-yl}methyl)piperazin-l-yl]-2-fluorophenyl}-3- (pyridin-4-yl)-l / / -pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; (37?)-7V-[5-chloro-3-(l-{4-[4-({l-[5-(2,4-dioxo-l,3-diazinan-l-yl)pyridin-2-yl]piperidin-4-yl}methyl)piperazin- l-yl]-2-fluorophenyl}-3-(pyridin-4-yl)-lJ7-pyrazol-4-yl)-2-fluorophenyl]-3- fluoropyrrolidine-1 -sulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3- yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4- yl]-2-fhrorophenyl}cyclopentanesulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4- yl)-l / / -pyrazol-4-yl]-2-fluorophenyl } cyclopentanesulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l- {4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)-U7-pyrazol-4-yl]-2-fluorophenyl}cyclopentanesulfonamide; (37?)-3-(6-{4-[(4- {4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2,5-difluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol- 1 -yl]phenyl } piperazin- 1 -yl)methyl]piperidin- 1 -yl }pyri din-3 -yl)piperidine-2, 6-dione; rac-(37?)-3-(6-{4-[(4-{4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2,5-difluorophenyl)-3-(pyridin- 4-yl)- I / / -py razol - 1 -yl]phenyl } piperazin- 1 -yl)methyl]piperidin- 1 -yl }pyri din-3 -yl)piperidine- 2, 6-dione; (37?)-3-(4-{4-[(4-{4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2,5-difluorophenyl)- 3 -(pyridin-4-yl)- 1 / / -pyrazol - 1 -yl]phenyl } piperazin- 1 -yl)methyl]piperidin- 1 - yl}phenyl)piperidine-2, 6-dione; 7V-[3-(l-{4-[(37?)-4-[(l-{4-[(37?)-2,6-dioxopiperidin-3- yl]phenyl }piperidin-4-yl)methyl]-3-methylpiperazin-l -yl]phenyl }-3-(pyridin-4-yl)-lJ7- pyrazol-4-yl)-2-fluorophenyl]propane-l -sulfonamide; (37?)-3-(6-{4-[(4-{4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-lJ7-pyrazol-l-yl]-3- fluorophenyl } piperazin- 1 -yl)methyl]piperidin- 1 -yl }pyri din-3 -yl)piperidine-2, 6-dione; (3S)-3 - (6-{4-[(4-{4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-lJH- pyrazol-l-yl]-2-fluorophenyl}piperazin-l-yl)methyl]piperidin-l-yl}pyridin-3-yl)piperidine- 2,6-dione; rac-(7?)-N-(3-(l-(4-(4-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-l- yl)methyl)piperidin-l-yl)phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl)propane-1 -sulfonamide; 7V-(5-chloro-3-(l-(4-((37?,57?)-4-((l-(5-((7?5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)-3,5-dimethylpiperazin-l-yl)-2-fluorophenyl)-3-(pyridin-4-yl)- l / Z-pyrazol-4-yl)-2-fluorophenyl)pyrrolidine-l -sulfonamide; 7V-{5-chloro-3-[l-(5-{4-[(l-{5- [(35)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2- yl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l-sulfonamide; N-{5- chloro-3-[l-(4-{4-[(l-{4-[(35)-2,6-dioxopiperidin-3-yl]-3-fluorophenyl}piperidin-4- yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]-2,3-difluorophenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l-sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]-2,5-difluorophenyl}piperidin-4- yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]-3,5-difluorophenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)4J7-pyrazol-4-yl]-2-fluorophenyl (pyrrolidine- 1 -sulfonamide; and 7V-[5-chloro- 3-(l-{4-[4-({ l-[5-(2,4-dioxo-l,3-diazinan-l-yl)pyridin-2-yl]piperidin-4-yl}methyl)piperazin- l-yl]phenyl}-3-(pyridin-4-yl)-lJ / -pyrazol-4-yl)-2-fluorophenyl]cyclopentanesulfonamide.Linkers[0001 1 1 ] In Formula (I) or (II), L is a linker. The linker can be any linker suitable for linking the right and left portions of a molecule or Formula herein. In certain embodiments, the linker does not interfere with the harness or hook functions of a molecule or Formula herein. In certain embodiments, the linker provides useful solubility, flexibility, and / or distance between the portions of a molecule or Formula herein. In certain embodiments, L is a linker according to -L1L2L3L4L5L6-!?- orIn certain embodiments, L is a linker according to -L1L2L3-L4 -L5-L;6- or -L6L5L4L3-!?-!?-. In certain embodiments, L is a linker according toIn certain embodiments, L is a linker according to-L1-L2-L3-L,4- or -L4-L3-L2-L1-. In certain embodiments, L is a linker according to -L1-L2- L3- or -L3-L2-L1-. In certain embodiments, L is a linker according to -L1-L2- or -L2-L1-. In certain embodiments, L is a linker according to -L1-, -L2-, -L3-, -L4-, -L5-, -L6-, -L7-, or other combinations as would be appreciated by a person of skill in the art. For example, in certain embodiments, L is a linker according to -L1-L3-L6-, -L7-L5-L1-, or -L1-L3-L6-L2-. Each group Lxis described in detail below. In certain embodiments, the linker L comprises at least one heterocyclic group. In certain embodiments, the linker L comprises one heterocyclic group. In certain embodiments, the linker L comprises two heterocyclic groups. In certain embodiments, the linker L comprises three heterocyclic groups. In certain embodiments, the linker L comprises at least one spiro bicyclic heterocycloalkylene group. In certain embodiments, the linker L comprises one spiro bicyclic heterocycloalkylene group. In certain embodiments, the linker L comprises two spiro bicyclic heterocycloalkylene groups. In certain embodiments, the linker L comprises three spiro bicyclic heterocycloalkylene groups. In certain embodiments, the linker L comprises at least one heterocycloalkylene group and at least one spiro bicyclic heterocycloalkylene. The remaining groups of or within the linker are selected for chemical compatibility with adjacent groups, as will be recognized by those of skill in the art.[0001 12] In certain embodiments, L is a linker according to -L^L^L^lAlAlAL7-. In certain embodiments, L is a linker according to -L7-L6-L5-L4-L3-L2-L1-. In certain embodiments, -L1- is absent, -N(R10)-, -C(R11)2-, -C(O)-, -Ci-8 alkylene-, -C2-8 alkynylene-, -Ce-Cio aryl-, -heteroaryl-, -C4-C10 heteroaryl-, -Q1-, or -Q2-; each -L2-, -L3-, -L4-, and -L5- is independently, absent, -N(R10)-, -C(Rn)2-, -C(O)-, -O-, -(CH2-CH2-O)I-8-, C1-8 alkylene-, -C2-8 alkynylene-, -Ce-Cio aryl-, substituted -Ce-Cio aryl-, -heteroaryl-, -C4-C10 heteroaryl-, -Q1-, -Q2-, or -Q3-; each -L6- and -L7- is independently, absent, -N(R10)-, -C(R10)2-, -C(O)-, -C(O)-N(R10)-, -N(R10)-C(O)-, -heteroaryl-, -C4-C10 heteroaryl-, or -C(R11)2-C(O)-N(R10)-. In certain embodiments, L comprises at least one -Q1-. In certain embodiments, L comprises one -Q1-. In certain embodiments, L comprises two -Q1-. In certain embodiments, L comprises three -Q1-. In certain embodiments, L comprises at least one -Q2-. In certain embodiments, L comprises one -Q2-. In certain embodiments, L comprises two -Q2-. In certain embodiments, L comprises three -Q2-. In certain embodiments, L comprises at least one -Q1- and at least one -Q2-. In certain embodiments, L comprises one -Q1- and one -Q2-.[0001 13] In certain embodiments, each -Q1- is an unsubstituted or substituted three- to seven-membered heterocycloalkylene comprising at least one nitrogen; each -Q2- is a five- to thirteen-membered bicyclic heterocycloalkylene comprising at least one nitrogen, wherein the five- to thirteen-membered bicyclic heterocycloalkylene is optionally a spiro bicyclic heterocycloalkylene ring; each -Q3- is a three- to six-membered cycloalkylene; each R10is hydrogen or methyl; and each R11is independently, hydrogen, methyl, aryl, substituted aryl, or heteroaryl. In certain embodiments, R10is hydrogen. In certain embodiments, R10is methyl. In certain embodiments, one R11is hydrogen. In certain embodiments, both R11are hydrogen. In certain embodiments, one R11is methyl. In certain embodiments, one R11is hydrogen and the other is methyl. In certain embodiments, both R11are methyl. In certain embodiments, one R11is aryl. In certain embodiments, one R11is hydrogen or methyl and the other is aryl. In certain embodiments, both R11are aryl. In certain embodiments, R11is a substituted aryl. In certain embodiments, one R11is heteroaryl. In certain embodiments, one R11is hydrogen or methyl and the other is heteroaryl. In certain embodiments, both R11are heteroaryl.[0001 14] In certain embodiments of Formula (I) or (II), L comprises at least one -Q1- according t, wherein n1is one or two, and n2is one or two.[0001 15] In certain embodiments of Formula (I) or (II), L comprises at least one -Q1-.[000116] In certain embodiments of Formula (I) or (II), L is selected from-Q^N^-Cfb-Q^QO)-;-NtMe^Q^Clb-Q^CXO)-;-Q2-CH2-Q1-C(O)-;-Q1-CH2-Q1-C(O)-;-Qi-Qi-C(O)-;-Q^CFh-N^e^Q^QO)-;-Q1-CH2-Q1-CH2-C(O)-N(Me)-;-Q^CHi-Q2-;-Q1-CH2-CH2-Q1-;-(^-CFh-CFh-Q2-;Q>-C(())-Q'-Qi-QC^-Q2-;-Q1-CH2-Q1-N(Me)-C(O)-;-CH2-CH2-CH2-CH2-Q1-C(O)-;-Qi-C(O)-;-Q1-C(O)-Q1-CH(C6H5)-;-C=CCH2-Q1-C(O)-;-Q^Cfb-Q^NH-QO)-;-CFh-CFh-CFh-Q^QO)-;-Q1-CH2-Q1-C(Me)-C(O)-N(Me)-;-CH2-Q1-;-Q^QCO-Q^CIb-;-N(H)-(CH2)s-C(O)-Q1-CH(C6H5)-;-N(H)-(CH2)2-O-(CH2)2-C(O)-Q1-CH(C6H5)-;-Q1-(CH2)3-C(O)-Q1-CH(C6H5)-;-Q2-C(O)-Q1-CH(C6H5)-;-Q2-CH2-C(O)-Q1-CH(C6H5)-;-Q2-(CH2)3-C(O)-Q1-CH(C6H5)-;-Q2-(CH2)2-C(O)-Q1-CH(C6H5)-;-(CH2)6-Q1-CH(C6H5)-;-Q1-Q1-C(O)-Q1-CH(C6H5)-;-Q1-CH2-C(O)-Q1-CH(C6H5)-;-Q1-(CH2)2-C(O)-Q1-CH(C6H5)-;-(CH2)3-C(O)-Q1-CH(C6H5)-;-(CH2)4-C(O)-Q1-CH(C6H5)-;-(CH2)5-C(O)-Q1-CH(C6H5)-;-(CH2)6-C(O)-Q1-CH(C6H5)-;-(CH2)3-Q1-CH2-C(O)-Q1-CH(C6H5)-;-(CH2)3-O-Q3-C(O)-Q1-CH(C6H5)-;-(CH2)3-O-(CH2)2-C(O)-Q1-CH(C6H5)-;-(CH2)3-O-(CH2)2-C(O)-Q1-CH(pyrid-2-yl)-;-(CH2)4-Q1-CH(C6H5)-;-(CH2)5-Q1-CH(C6H5)-;-(CH2)6-Q1-CH(pyrid-2-yl)-;-(CH2)7-Q1-CH(C6H5)-;-(CH2)7-Q1-CH(Me)-C(O)-N(Me)-;-N(H)-(CH2)2-O-(CH2)2-Q1-CH(Me)-C(O)-N(Me)-;-(CH2)3-O-(CH2)2-C(O)-Q1- CH(Me)-C(O)-N(Me)-;-N(H)-(CH2)2-O-(CH2)2-Q1-CH(C6H5)-;-N(H)-(CH2)2-[O-(CH2)2]2-C(O)-Q1-CH(C6H5)-;-N(H)-(CH2)2-[O-(CH2)2]3-C(O)-Q1-CH(C6H5)-;-N(H)-(CH2)2-[O-(CH2)2]4-C(O)-Q1-CH(C6H5)-;-N(H)-(CH2)2-[O-(CH2)2]5-C(O)-Q1-CH(C6H5)-;-N(H)-(CH2)2-[O-(CH2)2]6-C(O)-Q1-CH(C6H5)-;-N(H)-(CH2)2-[O-(CH2)2]7-C(O)-Q1-CH(C6H5)-;-N(H)-(CH2)2-[O-(CH2)2]8-C(O)-Q1-CH(C6H5)-;-N(H)-Q3-O-(CH2)2-CH2-;-N(H)-(CH2)3-Q1-(CH2)2-;-C(O)-N(H)-[(CH2)3-O]3-(CH2)2-NH-;-C(O)-N(H)-[(CH2)3-O]3-(CH2)2-;-Q1-C(O)-[(CH2)2-O]3-(CH2)2-NH-;-Q1-(CH2)3-O-CH2-;-Qi-CCOXCeHeHDHs-;-Q1-(2-pyridyl)--N(H)-Q3-X-(2-pyridyl)--N(H)-Q3-X-(4-pyridyl)-CH=C-(CH2)2-Q1-;-Q1-;-C(O)-(CH2-CH2-O)-(CH2)2-C(O)-Q1-CH(C6H5)-;-N(H)-C(O)-(CH2-CH2-O)4-(CH2)2-C(O)-Q1-CH(C6H5)-;-N(H)-C(O)-(CH2-CH2-O)5-(CH2)2-C(O)-Q1-CH(C6H5)-;-(CH2-CH2-O)5-(CH2)2-C(O)-Q1-CH(C6H5)-;-(CH2-CH2-O)-(CH2)2-C(O)-Q1-CH(C6H5)-;-(CH2-CH2-O)4-(CH2)2-C(O)-Q1-CH(C6H5)-;-(CH2)4-Q1-CH(C6H5)-;-(CH2)3-Q1-CH(C6H5)-;-(CH2)6-Q1-CH(C6H5)-;-(CH2)5-Q1-CH(C6H5)-;-(CH2-CH2-O)-(CH2)2-Q1-CH(C6H5)-;-C(O)-(CH2-CH2-O)4-(CH2)2-Q1-CH(C6H5)-;-C(O)-(CH2-CH2-O)5-(CH2)2-C(O)-Q1-CH(C6H5)-;-C(O)-(CH2-CH2-O)6-(CH2)2-C(O)-Q1-CH(C6H5)-;-C(O)-(CH2-CH2-O)3-(CH2)2-C(O)-Q1-CH(C6H5)-;-(CH2)5-C(O)-Q1-CH(C6H5)-;-(CH2-CH2-O)3-(CH2)2-C(O)-Q1-CH(C6H5)-;-(CH2)7-C(O)-Q1-CH(C6H5)-;-C(O)-(CH2)-Q1-CH2-C(O)-Q1-CH(C6H5)-;-(CH2)2-C(O)-Q1-CH(C6H5)-;-C(O)-(CH2)2-Q1-(CH2)2-C(O)-Q1-CH(C6H5)-;-C(O)-(CH2)9-C(O)-Q1-CH(C6H5)-;-C(O)-(CH2)7-C(O)-Q1-CH(C6H5)-;-C(O)-(CH2)5-C(O)-Q1-CH(C6H5)-;-C(O)-(CH2-CH2-O)2-(CH2)2-C(O)-Q1-CH(C6H5)-;-CH2-C(O)-Q1-CH(C6H5)-;-(CH2)3-C(O)-Q1-CH(C6H5)-;-(CH2)4-C(O)-Q1-CH(C6H5)-; and-QM-pyridyl-. In some embodiments, X is oxygen or sulfur.[0001 17] In certain embodiments of Formula (I) or Formula (II), L comprises at least one(I) or Formula (II), L comprises at least one -certain embodiments ofFormula (I) or Formula (II), L comprises at least oneembodiments of Formula (I) or Formula (II), L comprises at least oneIn certain embodiments of Formula (I) or Formula (II), L comprises at least one -Q1- as embodiments of Formula (I) or Formula (II), L comprises at least onecertain embodiments of Formula (I) or Formula (II), L comprises at least one -Q1- asIn certain embodiments of Formula (I) or Formula (II), L comprises at least one[0001 18] In certain embodiments of Formula (I) or Formula (II), L comprises at least one-Q2- according twherein n3is one or two.[0001 19] In certain embodiments of Formula (I) or Formula (II), L comprises at least one-Q2- according t[000120] In certain embodiments of Formula (I) or Formula (II), L comprises at least one-Q2- according t, wherein n4is one or two, n5is one or two, and n6is one or two.[000121] In certain embodiments of Formula (I) or Formula (II), L comprises at least one-Q2- according t[000122] In certain embodiments of Formula (I) or Formula (II), L comprises at least one-Q2- according towherein n8is one or two.[000123] In certain embodiments of Formula (I) or Formula (II), L comprises at least one-Q2- according t[000124] In certain embodiments of Formula (I) or Formula (II), L comprises at least one-Q2- according twherein n18and n19is two, or n18is two and n19is three, or n18is three and n19is two.[000125] In certain embodiments of Formula (I) or Formula (II), L comprises at least one-Q2- according t[000126] In certain embodiments of Formula (I) or Formula (II), L comprises at least one n22 / \ / \n23|_N N-|-Q2- according ton24, wherein n22is zero to two; n23is zero to two, and n24is one or two, or wherein n22is two and each n23and n24is one; or n22is two and each n23and n24is two.[000127] In certain embodiments of Formula (I) or Formula (II), L comprises at least one-Q2- according t[000128] In certain embodiments of Formula (I) or Formula (II), L comprises at least one-Q2- according t[000129] In certain embodiments of Formula (I) or Formula (II), L comprises at least one-Q3- according t, wherein n1is one or two, and n2is one or two.[000130] In certain embodiments of Formula (I) or Formula (II), L comprises at least one-Q3- selected from the group consistingbodiments of Formula (I) or Formula (II), L comprises at least onecertain embodiments of Formula (I) or Formula (II), L comprises at least onecomprises at least onePharmaceutical Compositions[000131] The compounds described herein can be formulated into pharmaceutical compositions that further comprise a pharmaceutically acceptable carrier, diluent, adjuvant, or vehicle. In one embodiment, this disclosure provides a pharmaceutical composition comprising one or more compounds described herein, and a pharmaceutically acceptable carrier, diluent, adjuvant, or vehicle. In one embodiment, this disclosure provides a pharmaceutical composition comprising an effective amount of one or more compounds of this disclosure, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, adjuvant, or vehicle. Pharmaceutically acceptable carriers include, for example, pharmaceutical diluents, excipients, or carriers suitably selected with respect to the intended form of administration, and consistent with conventional pharmaceutical practices.[000132] According to another embodiment, this description provides a composition comprising one or more compounds herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. Pharmaceutical compositions of this description comprise a therapeutically effective amount of one or more compounds of Formula (I) or (II), wherein a “therapeutically effective amount” is an amount that is (a) effective to measurably degrade BRAF (or reduce the amount of BRAF) in a biological sample or in a patient; or (b) effective in treating and / or ameliorating a disease or disorder that is mediated by BRAF.[000133] It will also be appreciated that certain compounds of this disclosure can exist in free form (e.g., a neutral compound) for treatment, or where appropriate, as a pharmaceutically acceptable derivative (e.g., a salt) thereof. According to this disclosure, a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable prodrugs, salts, esters, salts of such esters, or any other adduct / educt or derivative that uponadministration to a patient in need is capable of providing, directly or indirectly, one or more compounds as otherwise described herein, or a metabolite, or residue thereof.[000134] As used herein, the term “pharmaceutically acceptable salt” refers to those salts that are, within the scope of sound medical practice or judgment, suitable for use in contact with cells, tissues, and / or the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like.[000135] Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this description include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts include salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid; or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid; or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3 -phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, -toluenesulfonate, undecanoate, and valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium (NH4+), and N+(CI-4alkyl)4salts. This description also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersable products may be obtained by such quaternization. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.[000136] A pharmaceutically acceptable carrier may contain inert ingredients that do not unduly inhibit the biological activity of the compounds described herein. The pharmaceutically acceptable carriers should be biocompatible, for example, non-toxic, non-inflammatory, non- immunogenic, and / or devoid of other undesired reactions or side-effects upon administration to a subject. Standard pharmaceutical formulation techniques can be employed.[000137] The pharmaceutically acceptable carrier, adjuvant, or vehicle, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion, or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, and the like, as suited to the particular dosage form desired. Remington’s Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions, and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds described herein, such as by producing any undesirable biological effect, or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, the use of such conventional carrier medium is contemplated to be within the scope of this description. As used herein, the phrase “side effects” encompasses unwanted and adverse effects of a therapy (e.g., a prophylactic or therapeutic agent). Side effects are usually unwanted, but unwanted effects are not necessarily adverse or unbeneficial. An adverse effect from a therapy (e.g., prophylactic or therapeutic agent) might be harmful, uncomfortable, or risky. Side effects include, but are not limited to, fever, chills, lethargy, gastrointestinal toxicities (including gastric and intestinal ulcerations and erosions), nausea, vomiting, neurotoxicities, nephrotoxicities or renal toxicities (including such conditions as papillary necrosis and chronic interstitial nephritis), hepatic toxicities (including elevated serum liver enzyme levels), myelotoxicities (including leukopenia, myelosuppression, thrombocytopenia, and anemia), dry mouth, metallic taste, prolongation of gestation, weakness, somnolence, pain (including muscle pain, bone pain, and headache), hair loss, asthenia, dizziness, extra-pyramidal symptoms, akathisia, cardiovascular disturbances, and sexual dysfunction.[000138] Some examples of materials that can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as Tween 80, phosphates, glycine, sorbic acid, or potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate, disodium hydrogenphosphate, potassium hydrogen phosphate, sodium chloride, or zinc salts), colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, methylcellulose, hydroxypropyl methylcellulose, wool fat, sugars such as lactose, glucose, and sucrose; starches such as com starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen -free water; isotonic saline; Ringer’s solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring, and perfuming agents. Preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.[000139] As used herein, the term “measurably degrade” means a measurable reduction in (a) BRAF activity, between a sample comprising one or more compounds of this description and BRAF versus an equivalent sample comprising BRAF in the absence of said compound(s); or (b) the concentration of BRAF in a sample over time.Administration[000140] The compositions of this disclosure may be administered orally, parenterally, via inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir. As used herein, the term “parenteral” includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrastemal, intrathecal, intraocular, intrahepatic, intralesional, and intracranial injection or infusion techniques. Compositions can be administered orally, intraperitoneally, or intravenously. Sterile injectable forms of the compositions of this disclosure may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3 -butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.[000141] For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives, are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans, and other emulsifying agents or bioavailability enhancers that are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.[000142] The pharmaceutically acceptable compositions of this disclosure may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions, or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring, or coloring agents may also be added.[000143] Alternatively, the pharmaceutically acceptable compositions of this disclosure may be administered in the form of suppositories for rectal or vaginal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal or vaginal temperature and therefore will melt in the rectum or vaginal cavity to release the drug. Such materials include cocoa butter, polyethylene glycol, or a suppository wax that is solid at ambient temperature but liquid at body temperature and therefore melts in the rectum or vaginal cavity and releases the active compound.[000144] The pharmaceutically acceptable compositions of this disclosure may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, skin, or lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.- I l l -[000145] Topical application for the lower intestinal tract can be via a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.[000146] For topical applications, the pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this disclosure include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax, and water. Alternatively, the pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water.[000147] For ophthalmic use, the pharmaceutically acceptable compositions may be formulated, for example, as micronized suspensions in isotonic, pH adjusted sterile saline or other aqueous solution, or as solutions in isotonic, pH adjusted sterile saline or other aqueous solution, either with or without a preservative such as benzyl alkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum. The pharmaceutically acceptable compositions of this disclosure may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.[000148] In certain embodiments, the compositions of this disclosure are administered orally. The pharmaceutically acceptable compositions of this description may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions, or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient iscombined with emulsifying and suspending agents. If desired, certain sweetening, flavoring, or coloring agents may also be added.[000149] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the biologically active compounds herein, the liquid dosage forms may contain inert diluents commonly used in the art, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3 -butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.[000150] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the biologically active compound(s) described herein are mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate, and / or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents, for example, cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay; and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also comprise buffering agents.[000151] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. Solid dosage forms optionally may contain opacifying agents. These solid dosage forms can also be of acomposition such that they release the active ingredient(s) only, for example, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.[000152] The active compounds herein can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings, and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose, or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, for example, tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition such that they release the active ingredient(s) only, for example, in a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.[000153] The compounds of the description are formulated in dosage unit form for ease of administration and uniformity of dosage. As used herein, the phrase “dosage unit form” refers to a physically discrete unit of agent appropriate for the subject, cell, tissue, or patient to be treated. It will be understood, however, that the total daily usage of the compounds, and compositions of this disclosure will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular subject, cell, tissue, patient, or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound(s) employed; the specific composition(s) employed; the age, body weight, general health, sex, and diet of the subject, cell, tissue, and / or patient; the time of administration, route of administration, and rate of excretion of the specific compound(s) employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound(s) employed, and like factors well known in the medical arts.[000154] The amount of the compounds of this disclosure that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the subject, cell, tissue, and / or host treated, the particular mode of administration, and other factors. The compositions should be formulated so that a dosage of between 0.01 - 100 mg / kg body weight / day of the compound(s) or inhibitor(s) can be administered to a subject, cell, tissue, and / or patient receiving these compositions.[000155] Depending upon the particular condition or disease to be treated or prevented, additional therapeutic agents, which are normally administered to treat or prevent that condition, may also be present in the compositions of this disclosure. As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated.”[000156] The compound or composition can be administered concurrently with, prior to, or subsequent to, one or more additional therapeutically active agents. In general, each agent will be administered at a dose and / or on a time schedule determined for that agent. It will further be appreciated that the additional therapeutically active agent utilized in this combination can be administered together in a single composition or administered separately in different composition. The particular combination to employ in a regimen will take into account compatibility of the compounds described herein with the additional therapeutically active agent and / or the desired therapeutic effect to be achieved. In general, it is expected that additional therapeutically active agents utilized in combination will be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually. Additional therapeutically active agents include, but are not limited to, small organic molecules such as drug compounds (e.g., compounds approved by the Food and Drug Administration as provided in the Code of Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides or proteins, small molecules linked to proteins, glycoproteins, steroids, nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells. In certain embodiments, the additional therapeutically active agent is a cancer agent (e.g., a biotherapeutic or chemo therapeutic cancer agent). In other embodiments, the additional therapeutically active agent is an anti-inflammatory agent.[000157] The amount of additional therapeutic agent present in the compositions of this disclosure will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. The amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.Methods of Use[000158] The bifunctional compounds described herein are useful for degrading BRAF in biological samples, or in patients via a ubiquitin proteolytic pathway. Thus, an embodiment of this disclosure provides a method of treating a BRAF-mediated disease or disorder. As used herein, the term “BRAF-mediated disease or disorder” means any disease, disorder, or other deleterious condition in which BRAF is known to play a role. In some instances, an BRAF- mediated disease or disorder is a proliferative disorder or an autoimmune disorder. Examples of proliferative disorders include cancer.[000159] In one aspect, provided herein are methods of treating or preventing cancer in a subject in need thereof. In certain embodiments, the methods comprise the step of orally administering to the subject an amount of a bifunctional compounds(s) described herein capable of inducing proteolytic degradation of BRAF. In certain embodiments, the amount is effective to treat or prevent the cancer.[000160] In certain embodiments, the cancer is any cancer described below. In particular embodiments, the cancer comprises a solid tumor. In certain embodiments, the cancer is a B cell malignancy. In certain embodiments, the cancer is selected from the group consisting of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), transformed CLL or Richter’s transformation, small cell lymphoma, follicular lymphoma (FL), diffuse large B- cell lymphoma (DLBCL), non-Hodgkin lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Waldenstrom macroglobulinemia (WM), and central nervous system (CNS) lymphoma. In certain embodiments, the cancer is chronic lymphocytic leukemia. In certain embodiments, the cancer is small cell lymphoma. In certain embodiments, the cancer is follicular lymphoma. In certain embodiments, the cancer is diffuse large B-cell lymphoma. In certain embodiments, the cancer is non-Hodgkin lymphoma. In certain embodiments, the cancer is mantle cell lymphoma. In certain embodiments, the cancer is marginal zone lymphoma. In certain embodiments, the cancer is Waldenstrom macroglobulinemia. In certainembodiments, the cancer is small lymphocytic lymphoma (SLL). In certain embodiments, the cancer is CNS lymphoma. In certain embodiments, the cancer is transformed CLL or Richter’s transformation. In certain embodiments, the cancer is chronic lymphocytic leukemia (CLL).[000161] In another aspect, provided herein are methods of degrading BRAF in a subj ect in need thereof. The methods comprise the step of orally administering to the subject an amount of a bifunctional compound(s) described herein and capable of inducing proteolytic degradation of BRAF. In certain embodiments, the amount is effective to degrade BRAF in the subject. The BRAF can be expressed in any cells or tissues of the subject.[000162] In another aspect, provided herein are methods of preventing B cell activation in a subject in need thereof. The methods comprise the step of orally administering to the subject an amount of a bifunctional compound(s) described herein and capable of inducing proteolytic degradation of BRAF. In certain embodiments, the amount is effective to prevent B cell activation. In certain embodiments, the B cell expresses CD69. In certain embodiments, the B cell expresses CD86. In certain embodiments, the B cell expresses CD69 and CD86.[000163] In the methods, the bifunctional compound(s) described herein comprise a moiety capable of specifically binding BRAF and further comprise a moiety capable of recruiting a ubiquitin ligase to degrade the BRAF. Particular compounds with each capability are described herein. The compounds can be administered in any form, including pharmaceutically acceptable salts and pharmaceutical compositions.[000164] The bifunctional compound(s) described herein can be administered in any dose deemed suitable by the practitioner of skill. In certain embodiments, the dose is 0.1-1000 mg / kg. In certain embodiments, the dose is 0.1-900 mg / kg. In certain embodiments, the dose is 0.1-800 mg / kg. In certain embodiments, the dose is 0.1-700 mg / kg. In certain embodiments, the dose is 0.1-600 mg / kg. In certain embodiments, the dose is 0.1-500 mg / kg. In certain embodiments, the dose is 0.1-400 mg / kg. In certain embodiments, the dose is 0.1-300 mg / kg. In certain embodiments, the dose is 0.1-200 mg / kg. In certain embodiments, the dose is 0.1- 100 mg / kg. In certain embodiments, the dose is selected from the group consisting of 100 mg / kg, 200 mg / kg, 300 mg / kg, 450 mg / kg, 600 mg / kg, 800 mg / kg, and 1000 mg / kg. In certain embodiments, the dose is about 25 mg / kg. In certain embodiments, the dose is about 50 mg / kg. In certain embodiments, the dose is about 75 mg / kg. In certain embodiments, the dose is about 100 mg / kg. In certain embodiments, the dose is about 150 mg / kg. In certain embodiments, the dose is about 200 mg / kg. In certain embodiments, the dose is about 250 mg / kg. In certainembodiments, the dose is about 300 mg / kg. In certain embodiments, the dose is about 400 mg / kg. In certain embodiments, the dose is about 450 mg / kg. In certain embodiments, the dose is about 500 mg / kg. In certain embodiments, the dose is about 600 mg / kg. In certain embodiments, the dose is about 700 mg / kg. In certain embodiments, the dose is about 750 mg / kg. In certain embodiments, the dose is about 800 mg / kg. In certain embodiments, the dose is about 900 mg / kg. In certain embodiments, the dose is about 1000 mg / kg.[000165] The dose can be administered on a schedule deemed suitable by the person of skill in the art. In certain embodiments, the dose is administered once per day. In certain embodiments, the dose is administered twice per day. In certain embodiments, the dose is administered three times per day. In certain embodiments, the dose is administered four times per day. In certain embodiments, the dose is administered in divided doses. In certain embodiments, the dose is administered in two divided doses per day. In certain embodiments, the dose is administered in three divided doses per day. In certain embodiments, the dose is administered in four divided doses per day.[000166] Dosing can continue for any length of time deemed suitable by the person of skill in the art. In certain embodiments, the dose is administered daily for fourteen days. In certain embodiments, the dose is administered daily for thirteen days. In certain embodiments, the dose is administered daily for twelve days. In certain embodiments, the dose is administered daily for eleven days. In certain embodiments, the dose is administered daily for ten days. In certain embodiments, the dose is administered daily for nine days. In certain embodiments, the dose is administered daily for eight days. In certain embodiments, the dose is administered daily for seven days. In certain embodiments, the dose is administered daily for six days. In certain embodiments, the dose is administered daily for five days. In certain embodiments, the dose is administered daily for four days. In certain embodiments, the dose is administered daily for three days. In certain embodiments, the dose is administered daily for two days. In certain embodiments, the dose is administered for one day.[000167] In the dosing schedule, the doses can be administered on consecutive days or cyclicly, according to the judgment of the practitioner of skill. In certain embodiments, the doses are administered on consecutive days. In certain embodiments, the doses are administered with an interval between doses. In certain embodiments, the interval is one day. In certain embodiments, the interval is two days. In certain embodiments, the interval is threedays. In certain embodiments, the interval is four days. In certain embodiments, the interval is five days. In certain embodiments, the interval is six days.[000168] In certain embodiments, the dose is administered weekly. In certain embodiments, the dose is administered twice per week. In certain embodiments, the dose is administered three times per week.[000169] In certain embodiments, the dose(s) are administered for a period of time with a first interval between dose(s), and then the dose(s) are re-administered for a period of time following the first interval between dose(s), wherein this dosing regimen can be repeated (i.e., cyclicly or cyclically, for example, after a second, third, etc. interval between subsequent administrations of dose(s)) according to the judgment of the practitioner of skill. For example, in one embodiment, a first dose is administered for one week, followed by a first interval of one week without the first dose administration; then, a second dose is re-administered for another week, followed by a second interval of one week without the first or second dose administration, and so on cyclically. Other perturbations for first, second, third, etc. dose(s) followed by perturbations for first, second, third, etc. interval(s), and combinations thereof, are contemplated herein as would be appreciated by the practitioner of skill and the need of the subject, cell, tissue, and / or patient. For example, in one embodiment, a first dose is administered daily for one week, followed by a first interval of three weeks without the first daily dose administration; then, a second dose is re-administered biweekly for another week, followed by a second interval of four weeks without the first daily or second biweekly dose administration, and so on cyclically.[000170] The compound can be administered by any route of administration deemed suitable by the practioner of skill. In certain embodiments, the dose is administered orally. Formulations and techniques for administration are described elsewhere herein.[000171 ] In certain embodiments, term “cancer” includes, but is not limited to, the following cancers: epidermoid Oral: buccal cavity, lip, tongue, mouth, pharynx, squamous cell carcinoma of the head and neck (HNSCC); Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma, non-small cell lung cancer (NSCLC); Gastrointestinal: gastric cancer, esophagus (squamous cell carcinoma,larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestines (adenocarcinoma, lymphoma, carcinoid tumors, Karposi’s sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestines (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal, microsatellite stable colorectal cancer (MSS CRC), rectum; Genitourinary tract: kidney (adenocarcinoma, Wilm’s tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma), metastatic castrate-resistant prostate cancer (mCRPC), muscle-invasive urothelial cancer; Liver: hepatoma (hepatocellular carcinoma), cholangiocar cinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma, biliary passages; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing’s sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma (MM), malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical cancer, cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast, triple-negative breast cancer (TNBC), platinum-resistant epithelial ovarian cancer (EOC); Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin’s disease, non-Hodgkin’s lymphoma (malignantlymphoma) hairy cell; lymphoid disorders (e.g., mantle cell lymphoma, Waldenstrom’s macroglobulinemia, Marginal zone lymphoma, and Follicular lymphoma); Skin: malilymphgnant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi’s sarcoma, keratoacanthoma, moles or dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; Thyroid gland: papillary thyroid carcinoma, follicular thyroid carcinoma; medullary thyroid carcinoma, undifferentiated thyroid cancer, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, familial medullary thyroid cancer, pheochromocytoma, paraganglioma; Adrenal glands: neuroblastoma; and metatstaic melanoma.[000172] In certain embodiments, the term “autoimmune disease” includes, but is not limited to, the following autoimmune diseases: uticaria, graft-versus-host disease (GVHD), acute graft-versus-host disease, pemphigus vulgaris, achalasia, Addison’s disease, Adult Still’s disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti- GBM / anti-TBM nephritis, antiphospholipid syndrome, autoimmune angioedema, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, axonal and neuronal neuropathy (AMAN), Balo disease, Behcet’s disease, benign mucosal pemphigoid, bullous pemphigoid, Castleman disease (CD), Celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss Syndrome (CSS) or Eosinophilic Granulomatosis (EGPA), cicatricial pemphigoid, Cogan’s syndrome, cold agglutinin disease, congenital heart block, coxsackie myocarditis, CREST syndrome, Crohn’s disease, dermatitis herpetiformis, dermatomyositis, Devic’s disease (neuromyelitis optica), discoid lupus, Dressier’s syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, Evans syndrome, fibromyalgia, fibrosing alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture’s syndrome, granulomatosis with polyangiitis, Graves’ disease, Guillain-Barre syndrome, Hashimoto’s thyroiditis, hemolytic anemia, Henoch-Schonlein purpura (HSP), herpes gestationis or pemphigoid gestationis (PG), hidradenitis suppurativa (HS) (Acne Inversa), hypogammalglobulinemia, IgA nephropathy, IgG4-related sclerosing disease, immune thrombocytopenic purpura (ITP), inclusion body myositis (IBM), interstitial cystitis (IC), juvenile arthritis, juvenile diabetes (Type 1 diabetes), juvenile myositis (JM), Kawasakidisease, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), lupus, lyme disease (chronic), Meniere’s disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD), Mooren’s ulcer, Mucha-Habermann disease, Multifocal Motor Neuropathy (MMN) or MMNCB, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neonatal lupus, neuromyelitis optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism (PR), PANDAS, paraneoplastic cerebellar degeneration (PCD), paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, pars planitis (peripheral uveitis), Parsonnage-Tumer syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia (PA), POEMS syndrome, polyarteritis nodosa, polyglandular syndromes type I, II, or III, polymyalgia rheumatica, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia (PRC A), pyoderma gangrenosum, Raynaud’s phenomenon, reactive arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome (RLS), retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjogren’s syndrome, sperm and testicular autoimmunity, stiff person syndrome (SPS), subacute bacterial endocarditis (SBE), Susac’s syndrome, sympathetic ophthalmia (SO), Takayasu’s arteritis, temporal arteritis (giant cell arteritis), thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome (THS), transverse myelitis, Type 1 diabetes, ulcerative colitis (UC), undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vitiligo, Vogt-Koyanagi-Harada Disease, and Wegener’s granulomatosis (or Granulomatosis with Poly angiitis (GPA)).[000173] In certain embodiments, the term “inflammatory disease” includes, but is not limited to, the following inflammatory diseases: encephalitis, myelitis, meningitis, arachnoiditis, neuritis, dacryoadenitis, scleritis, episcleritis, keratitis, retinitis, chorioretinitis, blepharitis, conjunctivitis, uveitis, otitisexterna, otitismedia, labyrinthitis, mastoiditis, endocarditis, myocarditis, pericarditis, vasculitis, arteritis, phlebitis, capillaritis, sinusitis, rhinitis, pharyngitis, laryngitis, tracheitis, bronchitis, bronchiolitis, pneumonitis, pleuritis, mediastinitis, stomatitis, gingivitis, gingivostomatitis, glossitis, tonsillitis, sialadenitis / parotitis, cheilitis, pulpitis, gnathitis, esophagitis, gastritis, gastroenteritis, enteritis, colitis, enterocolitis, duodenitis, ileitis, caecitis, appendicitis, proctitis, hepatitis, ascendingcholangitis, cholecystitis, pancreatitis, peritonitis, dermatitis, folliculitis, cellulitis,hidradenitis, arthritis, dermatomyositis, myositis, synovitis / tenosynovitis, bursitis, enthesitis, fasciitis, capsulitis, epicondylitis, tendinitis, panniculitis, osteochondritis / osteitis / osteomyelitis, spondylitis, periostitis, chondritis, nephritis, glomerulonephritis, pyelonephritis, ureteritis, cystitis, urethritis, oophoritis, salpingitis, endometritis, parametritis, cervicitis, vaginitis, vulvitis, mastitis, orchitis, epididymitis, prostatitis, seminalvesiculitis, balanitis, posthitis, balanoposthitis, chori oamnionitis, funisitis, omphalitis, insulitis, hypophysitis, thyroiditis, parathyroiditis, adrenalitis, lymphangitis, and lymphadenitis.Articles of Manufacture and Kits[000174] Also provided are articles of manufacture comprising any of the compounds or pharmaceutical compositions described herein. The articles of manufacture include suitable containers or packaging materials for the compounds or pharmaceutical compositions. Examples of a suitable container include, but are not limited to, a bottle, a vial, a syringe, an intravenous bag, or a tube.[000175] Also provided are kits comprising any of the compounds or pharmaceutical compositions described herein. The kits can contain the compounds or pharmaceutiucal compositions in suitable containers or packaging materials, including, but not limited to, a bottle, a vial, a syringe, an intravenous bag, or a tube. The kits can comprise the compounds or pharmaceutiucal compositions for administration to a subject, cell, tissue, and / or individual in single-dose form or in multiple-dose form. The kits can further comprise instructions or a label for administering the compounds or pharmaceutiucal compositions to a subject, cell, tissue, and / or individual according to any of the methods disclosed herein. The kits can further comprise equipment for administering the compounds or pharmaceutiucal compositions to a subject, cell, tissue, and / or individual, including, but not limited to, needles, syringes, tubing, or intravenous bags. The kits can further comprise instructions for producing any of the compounds or pharmaceutiucal compositions disclosed herein.[000176] Also provided are articles of manufacture comprising any of the compounds or pharmaceutical compositions described herein. The articles of manufacture include suitable containers or packaging materials for the compounds or pharmaceutical compositions. The articles of manufacture include suitable containers or packaging materials for the compounds or pharmaceutical compositions. Examples of a suitable container include, but are not limited to, a bottle, a vial, a syringe, an intravenous bag, or a tube.[000177] This disclosure will be more fully understood by reference to the following Examples. They should not, however, be construed as limiting the scope of this disclosure. It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.EXAMPLES[000178] Additional embodiments are disclosed in further detail in the following examples, which are not in any way intended to limit the scope of the claims.Analytical Methods and Instrumentation[000179] Proton nuclear magnetic resonance (NMR) spectra were obtained on Bruker Ascend™ 500 MHz spectrometer. NMR spectra are reported as follows: chemical shift 5 (ppm), multiplicity, coupling constant J (Hz), and (relative) integration. The abbreviations s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and br = broad are used throughout. Mass spectral data were measured using the following systems: Waters Acquity i-class ultraperformance liquid chromatography (UPLC) system with Acquity Photo Diode Array Detector, Acquity Evaporative Light Scattering Detector (ELSD), and Waters ZQ Mass Spectrometer. Data was acquired using Waters MassLynx 4.1 software and purity was characterized by UV wavelength 220 nm, evaporative light scattering detection (ELSD), and electrospray positive ion (ESI) (column: Acquity UPLC BEH Cl 8 1.7 p i 2.1 x 50 mm). Solvents used: acetonitrile / water, containing 0.1% formic acid; flow rate 0.7 mL / min. Preparatory HPLC purifications were conducted with a flow rate of 15 mL / min and detection by UV wavelength at 214 nm and 254 nm (Column: Jupiter© 10 pM Proteo 90 A, 250 x 21.2 mm A, solvent: acetonitrile / water, containing a modifier such as 0.1% trifluoroacetic acid).[000180] Abbreviations used in the examples include:Table 1. CompoundsAttorney Docket No. : 121843.00271NU-3200 PCT-207-1100573566\5\AMERICAS[000181 ] Synthesis of \- !2- (2-:iiiiiiiopyriiiiidin-4-yl)-4-|2-nuoro-3-(propane-l - sulfonamido)phenyl]-l.,3-thiazol-2-yl]-2-niethylpropynoxane-4-carboxaniide[000182] Step-1: Synthesis of tert-butyl 7V-(2-carbamoyl-2.,2- dimethylethyl)carbamate (2)To a mixture of 3-[(tert-butoxycarbonyl)amino]-2,2-dimethylpropanoic acid (5 g, 23.01 mmol, 1 equiv) and NEUCl (6.15g, 115.06 mmol, 5 equiv) in DMF (50 mL) was added HATU (13.13 g, 34.52 mmol, 1.5 equiv) and DIEA (8.92 g, 69.03 mmol, 3 equiv) at room temperature. The resulting mixture was stirred for one hour at room temperature. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford tert-butyl A-(2-carbamoyl-2,2-dimethylethyl)carbamate (3.5 g, crude) as a yellow oil.[000183] Step-2: Synthesis o butyl / V-(2-carbamothioyl-2.,2-dimethylethyl)carbamate (3)To a mixture of tert-butyl A-(2-carbamoyl-2,2-dimethylethyl)carbamate (3.5 g, 16.183 mmol, 1 equiv) in THF (40 mL) was added Lawesson’s Reagent (3.27 g, 8.091 mmol, 0.5 equiv) at room temperature. The resulting mixture was stirred overnight at room temperature. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE:EtOAc(5: l) to afford tert-butyl A-(2-carbamothioyl-2,2-dimethylethyl)carbamate (1.6 g, 38.30%) as a white solid. LCMS: C10H20N2O2S requires: 232.1, found: m / z = 233.1 [M+H]+.[000184] Step-3: Synthesis of tert-butyl A-]2-[5-(2-chloropyrimidin-4-yl)-4-(2- fluoro-3-][(prop-2-en-l-yloxy)carbonyl]amino}phenyl)-l.,3-thiazol-2-yl]-2- methylpropyBcarbamate (4)To a mixture of tert-butyl A-(2-carbamothioyl-2,2-dimethylethyl)carbamate (370 mg, 1.59 mmol, 1 equiv) and NBS (283 mg, 1.59 mmol, 1 equiv) in DMA (5 mL) was added prop-2-en- 1-yl 7V-{3-[2-(2-chloropyrimidin-4-yl)acetyl]-2-fluorophenyl}carbamate (556 mg, 1.59 mmol, 1 equiv) at room temperature. The resulting mixture was stirred for 2 h at 60 °C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE:EtOAc (5: 1) to afford tert-butyl A-{2-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3-{[(prop-2-en-l- yloxy)carbonyl]amino}phenyl)-l,3-thiazol-2-yl]-2-methylpropyl}carbamate (200 mg, 20.11%) as a white solid. LCMS: C26H29CIFN5O4S requires: 561.2, found: m / z = 562.1 [M+H]+.[000185] Step-4: Synthesis of prop-2-en-l-yl 7V-]3-[2-(l-amino-2-methylpropan-2- yl)-5-(2-chloropyrimidin-4-yl)-l.,3-thiazol-4-yl]-2-fluorophenvncarbaniate (5)A solution of tert-butyl A-{2-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3-{[(prop-2-en-l- yloxy)carbonyl]amino}phenyl)-l,3-thiazol-2-yl]-2-methylpropyl}carbamate (190 mg, 0.338 mmol, 1 equiv) in HC1 / 1,4 -di oxane (5 mL, 4 M) was stirred for one hour at room temperature. The resulting mixture was concentrated under reduced pressure to afford prop-2-en-l-yl N-{3- [2-(l-amino-2-methylpropan-2-yl)-5-(2-chloropyrimidin-4-yl)-l,3-thiazol-4-yl]-2- fluorophenyl (carbamate (110 mg, crude) as a yellow oil. LCMS: C21H21CIFN5O2S requires: 461.1, found: m / z = 462.0 [M+H]+.[000186] Step-5: Synthesis of prop-Z-en-l-yl 7V-]3-[5-(2-chloroDyrimidin-4-yl)-2-[2- methyl-l- 4-ylformamido)propan-2-yl]-l.,3-thiazol-4-yl]-2-fluorophenyBcarbamate (6)To a mixture of prop-2-en-l-yl 7V-{3-[2-(l-amino-2-methylpropan-2-yl)-5-(2- chloropyrimidin-4-yl)-l,3-thiazol-4-yl]-2-fluorophenyl}carbamate (200 mg, 0.43 mmol, 1 equiv) and oxane-4-carboxylic acid (84 mg, 0.64 mmol, 1.5 equiv) in DMF (2 mL) was added HATU (246 mg, 0.64 mmol, 1.5 equiv) and DIEA (279 mg, 2.16 mmol, 5 equiv) at room temperature. The resulting mixture was stirred for one hour at room temperature. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE:EtOAc (5: 1) to afford prop-2-en-l-yl A-{3-[5-(2-chloropyrimidin-4-yl)-2-[2-methyl-l-(oxan-4- ylformamido)propan-2-yl]-l,3-thiazol-4-yl]-2-fhiorophenyl}carbamate (150 mg, 53.11%) as a yellow oil. LCMS: C27H29CIFN5O4S requires: 573.2, found: m / z = 574.1 [M+H]+.[000187] Step-6: Synthesis of A-]2-[4-(3-amino-2-fluorophenyl)-5-(2- chloropyrimidin-4-yl)-l.,3-thiazol-2-yl]-2-methylpropynoxane-4-carboxamide (7)To a mixture of prop-2-en-l-yl A-{3-[5-(2-chloropyrimidin-4-yl)-2-[2-methyl-l-(oxan-4- ylformamido)propan-2-yl]-l,3-thiazol-4-yl]-2-fluorophenyl}carbamate (140 mg, 0.244 mmol, 1 equiv) and Pd(PPh3)2C12 (3.42 mg, 0.005 mmol, 0.02 equiv) in DCM (2 mL) was added HOAc (35.15 mg, 0.586 mmol, 2.4 equiv) and w-BusSnH (106.47 mg, 0.366 mmol, 1.5 equiv) at 0 °C. The resulting mixture was stirred for 0.5 h at 0 °C. The reaction was quenched by the addition of saturated NaHCCL aqueous at 0 °C. The resulting mixture was extracted with CH2Q2. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford N-{2- [4-(3-amino-2-fluorophenyl)-5-(2-chloropyrimidin-4-yl)-l,3-thiazol-2-yl]-2- methylpropyl }oxane-4-carboxamide (120 mg, crude) as a yellow oil. LCMS: C23H25CIFN5O2S requires: 489.1, found: m / z = 490.1 [M+H]+.[000188] Step-7: Synthesis of 7V-(2-(5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3- (propylsulfon:iniido)phenyl)thi:izol-2-yl)-2-niethylpropyl)tetr:ihvdro-2 / / -pyran-4- carboxamide (8)To a mixture of A-{2-[4-(3-amino-2-fluorophenyl)-5-(2-chloropyrimidin-4-yl)-l,3-thiazol-2- yl]-2-methylpropyl}oxane-4-carboxamide (80 mg, 0.163 mmol, 1 equiv) in DCM (2 mL) wasadded TEA (49.56 mg, 0.489 mmol, 3 equiv) and propane- 1 -sulfonyl chloride (34.92 mg, 0.244 mmol, 1.5 equiv) at room temperature. The resulting mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under reduced pressure to afford 7V-(2-(5- (2-chloropyrimidin-4-yl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-2-yl)-2- methylpropyl)tetrahydro-2J / -pyran-4-carboxamide (100 mg, crude) as a brown oil. LCMS: C26H31CIFN5O4S2 requires: 595.1, found: m / z = 596.1 [M+H]+.[000189] Step-8: Synthesis of tert-butyl 7V-(4-14-[2-fluoro-3-(propane-l- sulfonamido)phenyl]-2-[2-methyl-l-(oxan-4-ylformamido)propan-2-yl]-l.,3-thiazol-5- vnpyrimidin-2-yl)carbamate (9)To a mixture of 7V-{2-[5-(2-chloropyrimidin-4-yl)-4-[2-fluoro-3-(propane-l- sulfonamido)phenyl]-l,3-thiazol-2-yl]-2-methylpropyl}oxane-4-carboxamide (70 mg, 0.117 mmol, 1 equiv) and tert-butyl carbamate (20.63 mg, 0.176 mmol, 1.5 equiv) in dioxane (2 mL) was added Pd(OAc)2 (2.64 mg, 0.012 mmol, 0.1 equiv), CS2CO3 (61.21 mg, 0.187 mmol, 1.6 equiv), and BINAP (21.94 mg, 0.035 mmol, 0.3 equiv) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 3 h at 90 °C under the nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-TLC CFEChiEtOAc (1 : 1) to afford tert-butyl 7V-(4-{4-[2-fluoro-3-(propane-l- sulfonamido)phenyl]-2-[2-methyl-l-(oxan-4-ylformamido)propan-2-yl]-l,3-thiazol-5- yl}pyrimidin-2-yl)carbamate (45 mg, 50.96%) as a white solid. LCMS: C31H41FN6O6S2 requires: 676.3, found: m / z = 677.2 [M+H]+.[000190] Step-9: Synthesis of \-!2-|5-(2-aniinopyrimidin-4-yl)-4-|2-nuoro-3- (propane-l-sulfonamido)phenyl]-l.,3-thiazol-2-yl]-2-niethylpropyl}oxane-4-carboxaniideA solution of tert-butyl A-(4-{4-[2-fluoro-3-(propane-l-sulfonamido)phenyl]-2-[2-methyl-l- (oxan-4-ylformamido)propan-2-yl]-l,3-thiazol-5-yl}pyrimidin-2-yl)carbamate (35 mg, 0.052 mmol, 1 equiv) in HCl / l,4-di oxane (5 mL, 4 M) was stirred overnight at room temperature. The resulting mixture was concentrated under reduced pressure. The crude product was purified by reverse phase flash chromatography with FEChMeCN (3: 1) to afford 7V-{2-[5-(2- aminopyrimidin-4-yl)-4-[2-fluoro-3-(propane-l-sulfonamido)phenyl]-l,3-thiazol-2-yl]-2- methylpropyl }oxane-4-carboxamide (28.8 mg, 92.71%) as an off-white solid. LCMS: C26H33FN6O4S2 requires: 576.2, found: m / z = 577.2 [M+H]+.1H NMR (400 MHz, CD3OD) 5 8.10 - 8.08 (m, 1H), 7.71 - 7.67 (m, 1H), 7.53 - 7.51 (m, 1H), 7.40 - 7.36 (m, 1H), 6.67 - 6.64 (m, 1H), 3.92 - 3.88 (m, 2H), 3.56 - 3.54 (m, 2H), 3.42 - 3.33(m, 2H), 3.18 - 3.14 (m, 2H), 2.57 - 2.42 (m, 1H), 1.90 - 1.84 (m, 2H), 1.74 - 1.62 (m, 4H), 1.52 (s, 6H), 1.06 - 1.04 (m, 3H).[000191] Synthesis of 7V-(3-(5-(2-aminoDyrimidin-4-yl)-2-(2-(DiDeridin-4-yl)DroDan- 2-yl)thiazol-4-yl)-2-fluoroDhenyl)DroDane-l-sulfonamide[000192] Step-1: Synthesis of tert-butyl 4-(2-(4-(3-(((allyloxy)carbonyl)amino)-2- fluoroDhenyl)-5-(2-chloroDyrimidin-4-yl)thiazol-2-yl)DroDan-2-yl)Diperidine-l- carboxylate (3)To a mixture of prop-2-en-l-yl A-{3-[2-(2-chloropyrimidin-4-yl)acetyl]-2- fluorophenyl} carbamate (2.4 g, 6.98 mmol, 1 equiv) in DMA (20.0 mL) was added NBS (1.24 g, 6.98 mmol, 1 equiv) for 15 min at room temperature followed by the addition of tert-butyl 4-(l-carbamothioyl-l-methylethyl)piperidine-l-carboxylate (2.0 g, 6.98 mmol, 1 equiv) at room temperature. The resulting mixture was stirred for 2 h at 60 °C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and driedover anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE:EtOAc (3: 1) to afford tert-butyl 4-{2-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3-{[(prop-2-en-l- yloxy)carbonyl]amino}phenyl)-l,3-thiazol-2-yl]propan-2-yl}piperidine-l-carboxylate (1.80 g, 41.84%) as a white solid. LCMS: C30H35CIFN5O4S requires: 615.2, found: m / z = 616.2 [M+H]+.[000193] Step-2: Synthesis of tert-butyl 4-]2-[4-(3-amino-2-fluorophenyl)-5-(2- chloropyrimidin-4-yl)-l.,3-thiazol-2-yl]propan-2-vnpiperidine-l-carboxylate (4)To a mixture of tert-butyl 4-{2-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3-{[(prop-2-en-l- yloxy)carbonyl]amino}phenyl)-l,3-thiazol-2-yl]propan-2-yl}piperidine-l-carboxylate (1.0 g, 1.623 mmol, 1 equiv) and HOAc (243.66 mg, 4.058 mmol, 2.5 equiv) in DCM (4 mL) was added Pd(PPh3)2Ch (22.78 mg, 0.032 mmol, 0.02 equiv) and w-BusSnH (755.83 mg, 2.597 mmol, 1.6 equiv) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 0.5 h at room temperature under the nitrogen atmosphere. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure to afford tert-butyl 4-{2-[4-(3-amino-2-fluorophenyl)-5-(2-chloropyrimidin-4-yl)-l,3-thiazol-2- yl]propan-2-yl (piperidine- 1 -carboxylate (700 mg, crude) as a brown oil. The crude product was used in the next step directly without further purification. LCMS: C26H31CIFN5O2S requires: 531.2, found: m / z = 532.2 [M+H]+.[000194] Step-3: Synthesis of tert-butyl 4-]2-[5-(2-chloropyrimidin-4-yl)-4-[2-fluoro- 3-(propane-l-sulfonamido)phenyl]-l.,3-thiazol-2-yl]propan-2-vnpiperidine-l- carboxylate (5)To a mixture of tert-butyl 4-{2-[4-(3-amino-2-fluorophenyl)-5-(2-chloropyrimidin-4-yl)-l,3- thiazol-2-yl]propan-2-yl( piperidine- 1 -carboxylate (1.6 g, 3.007 mmol, 1 equiv) and pyridine (0.24 g, 3.007 mmol, 1.0 equiv) in DCM (15 mL) was added propane- 1 -sulfonyl chloride (0.43 g, 3.007 mmol, 1.0 equiv) dropwise at 0 °C. The resulting mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was dissolved in THF (5 mL), ACN (5 mL), and H2O (5 mL). ISfeCCL (3.7 g, 35.190 mmol, 6 equiv) was added at room temperature. The resulting mixture was stirred at 50 °C overnight. The resulting mixture was concentrated under vacuum. The resulting mixture was extracted with DCM. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue waspurified by silica gel column chromatography eluted with PE:EtOAc (5: 1) to afford tert-butyl 4-{2-[5-(2-chloropyrimidin-4-yl)-4-[2-fluoro-3-(propane-l-sulfonamido)phenyl]-l,3-thiazol- 2-yl]propan-2-yl (piperidine- 1 -carboxylate (1.0 g, 52.11%) as a yellow solid. LCMS: C29H37CIFN5O4S2 requires: 637.2, found: m / z = 638.2 [M+H]+.[000195] Step-4: Synthesis of tert-butyl 4-|2-(5-!2-|(tert- butoxycarbonyl)amino]pyrimidin-4-vn-4-[2-fluoro-3-(propane-l-sulfonamido)phenyl]- l,3-thiazol-2-yl)propan-2-yl]piperidine-l-carboxylate (6)To a mixture of tert-butyl 4-{2-[5-(2-chloropyrimidin-4-yl)-4-[2-fluoro-3-(propane-l- sulfonamido)phenyl]-l,3-thiazol-2-yl]propan-2-yl}piperidine-l-carboxylate (1.0 g, 1.567 mmol, 1 equiv) and BocNEE (917.79 mg, 7.835 mmol, 5.0 equiv) in 1,4-dioxane (10 mL) was added BrettPhos Pd G3 (142.0 mg, 0.157 mmol, 0.1 equiv) and CS2CO3 (E02g, 3.134 mmol, 2.0 equiv) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred at 80 °C overnight under the nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE:EtOAc (1 : 1) to afford tert-butyl 4-[2-(5-{2-[(tert-butoxycarbonyl)amino]pyrimidin-4- yl}-4-[2-fluoro-3-(propane-l-sulfonamido)phenyl]-l,3-thiazol-2-yl)propan-2-yl]piperidine-l- carboxylate (800 mg, 82.51%) as a yellow solid. LCMS: C34H47FN6O6S2 requires: 718.3, found: m / z = 719.1 [M+H]+.[000196] Step-5: Synthesis of \-!3-|5-(2-aniinopyriniidin-4-yl)-2-|2-(piperidin-4- yl)propan-2-yl]-l.,3-thiazol-4-yl]-2-fluorophenvnpropane-l-sulfonaniide hydrochlorideTo a mixture of tert-butyl 4-[2-(5-{2-[(tert-butoxycarbonyl)amino]pyrimidin-4-yl}-4-[2- fluoro-3-(propane-l-sulfonamido)phenyl]-l,3-thiazol-2-yl)propan-2-yl]piperidine-l- carboxylate (800 mg, 1.113 mmol, 1 equiv) in DCM (8 mL) was added HC1 (gas) in 1,4- dioxane (2 mL, 4 M). The resulting mixture was stirred at room temperature for 2 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in Water (0.1% formic acid (FA)), 10% to 50% gradient in 10 min; detector, UV 254 nm to afford A-{3-[5-(2-aminopyrimidin-4-yl)-2-[2-(piperidin-4-yl)propan-2-yl]-l,3- thiazol-4-yl]-2-fluorophenyl}propane-l-sulfonamide hydrochloride (553 mg, 89.52%) as a yellow solid. LCMS : C24H31FN6O2S2 requires: 518.2, found: m / z = 519.2 [M+H]+.'H NMR (400 MHz, CD3OD) 5 8.10 (d, J= 6.8 Hz, 1H), 7.69 (d, J= 1.6 Hz, 1H), 7.52 - 7.49 (m, 1H), 7.40 - 7.36 (m, 1H), 6.66 - 6.64 (m, 1H), 3.51 - 3.40 (m, 2H), 3.23 - 3.13 (m, 2H),3.05 - 2.85 (m, 2H), 2.24 - 2.16 (m, 1H), 2.01 - 1.82 (m, 4H), 1.71 - 1.65 (m, 2H), 1.55 (s, 6H), 1.10 - 1.07 (m, 3H).[000197] Synthesis of 7V-(3-(5-(2-aminoDyrimidin-4-yl)-2-(DiDeridin-4-yl)thiazol-4- yl)-2-fluoroDhenyl)DroDane-l-sulfonamide hydrochloride salt[000198] Step-1: Synthesis of tert-butyl 4-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3- f[(DroD-2-en-l-yloxy)carbonyl]amino} phenyl)-l.,3-thiazol-2-yl]DiDeridine-l-carboxylateTo a mixture of prop-2-en-l-yl 7V-{3-[2-(2-chloropyrimidin-4-yl)acetyl]-2-fluorophenyl} carbamate (1.1 g, 3.145 mmol, 1.00 equiv) and NBS (559.8 mg, 3.145 mmol, 1.0 equiv) in DMA (13 mL) was added tert-butyl 4-carbamothioylpiperidine-l -carboxylate (922.2 mg, 3.774 mmol, 1.20 equiv) at room temperature. The resulting mixture was stirred for 2 h at 60 °C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography elutedwith PE:EtOAc (1 : 1) to afford tert-butyl 4-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3-{[(prop- 2-en-l-yloxy)carbonyl]amino} phenyl)- 1, 3 -thiazol-2-yl]piperi dine- 1-carboxylate (580 mg, 32.12%) as a yellow solid. LCMS: C27H29CIFN5O4S requires: 573.2, found: m / z = 574.2 [M+H]+.[000199] Step-2: Synthesis of tert-butyl 4-[4-(3-amino-2-fluorophenyl)-5-(2- chloropyrimidin-4-yl)-l.,3-thiazol-2-yl]piperidine-l-carboxylate (3)To a mixture of tert-butyl 4-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3-{[(prop-2-en-l- yloxy)carbonyl] amino}phenyl)-l,3-thiazol-2-yl]piperidine-l-carboxylate (600 mg, 1.045 mmol, 1 equiv) and HOAc (156.9 mg, 2.612 mmol, 2.5 equiv) in DCM (8 mL) was added Pd(PPh3)2Ch (14.7 mg, 0.021 mmol, 0.02 equiv) and w-BusSnH (486.7 mg, 1.672 mmol, 1.6 equiv) in portions at 0 °C. The resulting mixture was stirred for 0.5 h at room temperature under a nitrogen atmosphere. The resulting mixture was concentrated under vacuum to afford tert- butyl 4-[4-(3-amino-2-fluorophenyl)-5-(2-chloropyrimidin-4-yl)-l,3-thiazol-2-yl]piperidine- 1-carboxylate (510 mg, crude) as a red oil. The resulting mixture was used in the next step directly without further purification. LCMS: C23H25CIFN5O2S requires: 489.1, found: m / z = 490.1 [M+H]+.[000200] Step-3: Synthesis of tert-butyl 4-(5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-2-yl)piperidine-l-carboxylate (4)To a mixture of tert-butyl 4-[4-(3-amino-2-fluorophenyl)-5-(2-chloropyrimidin-4-yl)-l,3- thiazol-2-yl]piperidine- 1-carboxylate (2 g, 4.082 mmol, 1 equiv) and TEA (1.24 g, 12.246 mmol, 3 equiv) in DCM (20 mL) was added propane- 1 -sulfonyl chloride (873.08 mg, 6.123 mmol, 1.5 equiv) dropwise at 0 °C. The resulting mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. To the crude product in H2O (7 mL), MeCN (7 mL), and THF (7 mL) was added Na2CO3(1.06 g, 10.065 mmol, 2.46 equiv) at room temperature. The resulting mixture was stirred at 50 °C overnight. The resulting mixture was extracted with DCM. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with CEECh MeOH (10: 1) to afford tert-butyl 4-(5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-2-yl)piperidine-l-carboxylate (1.58 g, 64.93%) as ayellow solid. LCMS: C26H31CIFN5O4S2 requires: 595.1, found: m / z = 596.1 [M+H]+.[000201 ] Step-4: Synthesis of tert-butyl 4-(5-(2-((tert- butoxycarbonyl)amino)pyrimidin-4-yl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-2-yl)piperidine-l-carboxylate (5)To a mixture of tert-butyl 4-(5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-2-yl)piperidine-l-carboxylate (1 g, 1.677 mmol, 1 equiv) and tert-butyl carbamate (982.6 mg, 8.385 mmol, 5 equiv) in 1,4-dioxane (10 mL) was added BrettPhos Pd G3 (152 mg, 0.168 mmol, 0.1 equiv) and CS2CO3 (1.1 g, 3.354 mmol, 2 equiv) at room temperature. The resulting mixture was stirred for 2 h at 80 °C under a nitrogen atmosphere. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE:EtOAc (1 : 1) to afford tert-butyl 4-(5-(2-((te / 7- butoxycarbonyl)amino)pyrimidin-4-yl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-2- yl)piperidine-l -carboxylate (850 mg, 74.87%) as a yellow solid. LCMS: C31H41FN6O6S2 requires: 676.3, found: m / z = 677.3 [M+H]+.[000202] Step-5: Synthesis of A-13-[5-(2-aminopyrimidin-4-yl)-2-(piperidin-4-yl)- l,3-thiazol-4-yl]-2-fluorophenvnpropane-l-sulfonamide hydrochlorideTo a mixture of tert-butyl 4-(5-(2-((terZ-butoxycarbonyl)amino)pyrimidin-4-yl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-2-yl)piperidine-l-carboxylate (1.5 g, 2.217 mmol, 1 equiv) in DCM (3 mL) was added HC1 (gas) in 1,4-dioxane (12 mL, 4 M) at room temperature. The resulting mixture was stirred at room temperature overnight. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography with the following conditions: column, C18 silica gel; mobile phase, MeCN in water (0.1% formic acid (FA)), 10% to 50% gradient in 10 min; detector, UV 254 nm to afford A-{3-[5-(2-aminopyrimidin-4-yl)-2-(piperidin-4-yl)-l,3-thiazol-4-yl]-2- fluorophenyl (propane- 1 -sulfonamide hydrochloride salt (649.6 mg, 57.13%) as a yellow solid. LCMS: C21H25FN6O2S2 requires: 476.3, found: m / z = 477.3 [M+H]+. 'H NMR (400 MHz, CD3OD) 5 8.09 (d, J= 6.0 Hz, 1H), 7.68 - 7.66 (m, 1H), 7.49 - 7.28 (m, 2H), 6.65 - 6.63 (m, 1H), 3.60 - 3.48 (m, 3H), 3.28 - 3.16 (m, 2H), 3.17 - 3.05 (m, 2H), 2.49 - 2.39 (m, 2H), 2.21 - 2.09 (m, 2H), 1.94 - 1.78 (m, 2H), 1.14 - 0.98 (m, 3H).[000203] Synthesis of 7V-12-fluoro-3-[2-(piperidin-4-yl)-5-(pyrimidin-4-yl)-l.,3- thiazol-4-vHphenvnpropane-l-sulfonamide hydrochloride salt[000204] Step-1: Synthesis of tert-butyl 4-14-[2-fluoro-3-(propane-l- sulfonamido)phenyl]-5-(pyrimidin-4-yl)-l.,3-thiazol-2-vnpiperidine-l-carboxylate (2)To a mixture of tert-butyl 4-[5-(2-chloropyrimidin-4-yl)-4-[2-fluoro-3-(propane-l- sulfonamido)phenyl]-l,3-thiazol-2-yl]piperidine-l-carboxylate (700 mg, 1.174 mmol, 1 equiv) and NH4OAC (905.14 mg, 11.740 mmol, 10 equiv) in MeOH (10 mL) was added Pd / C (700 mg) at room temperature. The resulting mixture was stirred for 30 min at 40 °C. The resulting mixture was filtered. The filtrate was concentrated under reduced pressure. The residue was purified by C18 silica gel column chromatography eluted with CHjCN^O (1 : 1) to afford tert- butyl 4-{4-[2-fluoro-3-(propane-l-sulfonamido)phenyl]-5-(pyrimidin-4-yl)-l,3-thiazol-2- yl}piperidine-l-carboxylate (450 mg, 68.23%) as a yellow solid. LCMS: C26H32FN5O4S2 requires: 561.2, found: m / z = 562.2 [M+H]+.[000205 ] Step-2: Synthesis of 7V-12-fluoro-3-[2-(piperidin-4-yl)-5-(pyrimidin-4-yl)- l,3-thiazol-4-yl]phenvnpropane-l-sulfonamide hydrochlorideA mixture of tert-butyl 4-{4-[2-fluoro-3-(propane-l-sulfonamido)phenyl]-5-(pyrimidin-4-yl)-1.3-thiazol-2-yl}piperidine-l-carboxylate (450 mg, 0.801 mmol, 1 equiv) in HCl / l,4-di oxane (5 mL, 4 N) was stirred overnight at room temperature. The resulting mixture was concentrated under reduced pressure. This resulted in A-{2-fluoro-3-[2-(piperidin-4-yl)-5-(pyrimidin-4-yl)-1.3-thiazol-4-yl]phenyl}propane-l-sulfonamide hydrochloride salt (300.1 mg, crude) as a yellow solid. LCMS: C21H24FN5O2S2 requires: 461.1, found: m / z = 462.1 [M+H]+. 'H NMR (400 MHz, CD3OD) 5 9.30 - 9.28 (m, 1H), 8.76 - 8.74 (m, 1H), 7.71 - 7.67 (m, 1H), 7.50 - 7.38 (m, 3H), 3.60 - 3.55 (m, 3H), 3.27 - 3.22 (m, 2H), 3.16 - 3.12 (m, 2H), 2.48 - 2.43 (m, 2H), 2.20 - 2.14 (m, 2H), 1.89 - 1.83 (m, 2H), 1.06 - 1.03 (m, 3H).[000206] Synthesis of 7V-13-[5-(2-aminoDyrimidin-4-yl)-2-[4-(DiDeridin-4-yl)phenyl]- l,3-thiazol-4-yl]-2-fluoroDhenynDroDane-l-sulfonamide[000207] Step-1: Synthesis o butyl 4-(4-carbamoylDhenyl)Diperidine-l-carboxylate (2)To a mixture of 4-[l-(tert-butoxycarbonyl)piperidin-4-yl]benzoic acid (5 g, 16.37 mmol, 1 equiv) and NH4CI (4.37 g, 81.86 mmol, 5 equiv) in DMF (50 mL) was added HATU (9.33 g, 24.55 mmol, 1.5 equiv) and DIEA (6.34 g, 49.11 mmol, 3 equiv) at room temperature. The resulting mixture was stirred for one hour at room temperature. The resulting mixture wasextracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The product was washed with EtOAc. The precipitated solids were collected by filtration to afford tert-butyl 4-(4-carbamoylphenyl)piperidine-l -carboxylate (4.8 g, 96.31%) as a white solid. LCMS: C17H24N2O3 requires: 304.2, found: m / z = 305.2 [M+H]+.[000208] Step-2: Synthesis of tert-butyl 4-(4-carbamothioylphenyl)piperidine-l- carboxylate (3)To a mixture of tert-butyl 4-(4-carbamoylphenyl)piperidine-l -carboxylate (3 g, 9.85 mmol, 1 equiv) in THF (30 mL) was added Lawesson’s Reagent (1.99 g, 4.92 mmol, 0.5 equiv) at room temperature. The resulting mixture was stirred overnight at 50 °C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with aqueous NaHCOs and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with CEECh EtOAc (4: 1) to afford tert-butyl 4-(4-carbamothioylphenyl)piperidine-l -carboxylate (2.2 g, 69.66%) as a white solid. LCMS: C17H24N2O2S requires: 320.1, found: m / z = 321.2 [M+H]+.[000209] Step-3: Synthesis of tert-butyl 4-]4-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3-][(prop-2-en-l-yloxy)carbonyl]amino}phenyl)-l.,3-thiazol-2-yl]phenvnpiperidine-l- carboxylate (5)To a mixture of prop-2-en-l-yl A-{3-[2-(2-chloropyrimidin-4-yl)acetyl]-2- fluorophenyl} carbamate (1.8 g, 5.14 mmol, 1 equiv) in DMA (20 mL) was added tert-butyl 4- (4-carbamothioylphenyl)piperidine-l -carboxylate (1.98 g, 6.17 mmol, 1.2 equiv) and NBS (1.83 g, 10.29 mmol, 2 equiv) at room temperature. The resulting mixture was stirred for 2 h at 60 °C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE:EtOAc (5: 1) to afford tert-butyl 4-{4-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3-{[(prop-2-en-l-yloxy)carbonyl]amino}phenyl)-l,3-thiazol-2- yl]phenyl}piperidine-l-carboxylate (1.8 g, 48.95%) as a yellow solid. LCMS: C33H33CIFN5O4S requires: 649.2, found: m / z = 650.2 [M+H]+.[000210] Step-4: Synthesis of tert-butyl 4-]4-[4-(3-amino-2-fluorophenyl)-5-(2- chloropyrimidin-4-yl)- 1.,3-thiazol-2-yl] phenyl] piperidine- 1-carboxylate (6)To a mixture of tert-butyl 4-{4-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3-{[(prop-2-en-l- yloxy)carbonyl]amino}phenyl)-l,3-thiazol-2-yl]phenyl}piperidine-l-carboxylate (1.8 g, 2.76 mmol, 1 equiv) and HOAc (415 mg, 6.93 mmol, 2.5 equiv) in DCM (20 mL) was added n- BusSnH (1.29 g, 4.43 mmol, 1.6 equiv) and Pd(PPh3)2Ch (39 mg, 0.05 mmol, 0.02 equiv) at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 30 min at room temperature. The reaction was quenched with saturated aqueous NaHCCL at 0 °C. The resulting mixture was extracted with CH2Q2. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to afford tert-butyl 4-{4-[4-(3-amino-2-fluorophenyl)-5-(2-chloropyrimidin-4-yl)-1.3-thiazol-2-yl]phenyl}piperidine-l-carboxylate (1.5 g, crude) as a brown solid. LCMS: C29H29CIFN5O2S requires: 565.2, found: m / z = 566.2 [M+H]+.[000211 ] Step-5: Synthesis of tert-butyl 4-(4-(5-(2-chloropyrimidin-4-yl)-4-(2-fluoro- 3-(propylsulfonamido)phenyl)thiazol-2-yl)phenyl)piperidine-l-carboxylate (7)To a mixture of tert-butyl 4-{4-[4-(3-amino-2-fluorophenyl)-5-(2-chloropyrimidin-4-yl)-l,3- thiazol-2-yl]phenyl}piperidine-l-carboxylate (1.5 g, 2.65 mmol, 1 equiv) in DCM (15 mL) was added propane- 1 -sulfonyl chloride (755 mg, 5.30 mmol, 2 equiv) and TEA (804 mg, 7.95 mmol, 3 equiv) at 0 °C. The resulting mixture was stirred for one hour at room temperature. The resulting mixture was concentrated under reduced pressure. The crude product was dissolved in THF (5 mL), H2O (5 mL), and MeCN (5 mL). ISfeCCL (1.13 g, 10.68 mmol, 5 equiv) was added at room temperature. The resulting mixture was stirred overnight at 50 °C. The resulting mixture was concentrated under vacuum. The residue was extracted with DCM. The combined organic layers were washed with water and dried over anhydrous ISfeSC After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with DCM:MeOH (10: 1) to afford tert-butyl 4-(4-(5-(2- chloropyrimidin-4-yl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-2- yl)phenyl)piperidine-l -carboxylate (1.1 g, 73.77%) as a yellow solid. LCMS: C32H35CIFN5O4S2 requires: 671.2, found: m / z = 672.2 [M+H]+.[000212] Step-6: Synthesis of tert-butyl 4-[4-(5- [(tert-butoxycarbonyl)amino]pyrimidin-4-vn-4-[2-fluoro-3-(propane-l-sulfonamido)phenyl]-1.3-thiazol-2-yl)phenyl]piperidine-l-carboxylate (8)To a mixture of tert-butyl 4-{4-[5-(2-chloropyrimidin-4-yl)-4-[2-fluoro-3-(propane-l- sulfonamido)phenyl]-l,3-thiazol-2-yl]phenyl}piperidine-l-carboxylate (600 mg, 0.89 mmol, 1 equiv) and tert-butyl carbamate (522.80 mg, 4.465 mmol, 5 equiv) in dioxane (6 mL) wasadded BrettPhos Pd G3 (81 mg, 0.089 mmol, 0.1 equiv) and CS2CO3 (581 mg, 1.78 mmol, 2 equiv) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred for 2 h at 80 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE:EtOAc (1 : 1) to afford tert-butyl 4-[4-(5-{2-[(tert-butoxycarbonyl)amino]pyrimidin-4-yl}-4-[2-fluoro-3-(propane-l- sulfonamido)phenyl]-l,3-thiazol-2-yl)phenyl]piperidine-l-carboxylate (400 mg, 53.57%) as a yellow solid. LCMS: C37H45FN6O6S2 requires: 752.2, found: m / z = 753.3 [M+H]+.[000213] Step-7: Synthesis of 7V-13-[5-(2-aminoDyrimidin-4-yl)-2-[4-(DiDeridin-4- Yl)phenyl]-l.,3-thiazol-4-yl]-2-fluoroDhenynDroDane-l-sulfonamideA mixture of tert-butyl 4-[4-(5-{2-[(tert-butoxycarbonyl)amino]pyrimidin-4-yl}-4-[2-fluoro- 3-(propane-l-sulfonamido)phenyl]-l,3-thiazol-2-yl)phenyl]piperidine-l -carboxylate (400 mg, 0.53 mmol, 1 equiv) in HCl / l,4-di oxane (5 mL, 4 M) was stirred overnight at room temperature. The resulting mixture was concentrated under reduced pressure. The crude product was purified by Prep-HPLC with the following conditions: Column: XBridge Prep OBD C18 Column, 30*150 mm, 5 pm; Mobile Phase A: water (10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 30% B to 38% B in 8 min; Wave Length: 220 / 254 nm; Rti (min): 6.75 to afford A-{3-[5-(2-aminopyrimidin-4-yl)-2-[4-(piperidin-4-yl)phenyl]-l,3- thiazol-4-yl]-2-fhiorophenyl}propane-l-sulfonamide (223.7 mg, 70.01%) as a yellow solid. LCMS: C27H29FN6O2S2 requires: 552.2, found: m / z = 553.2 [M+H]+. 'H NMR (400 MHz, DMSO-tL) 5 8.15 - 8.06 (m, 1H), 7.98 - 7.93 (m, 2H), 7.56 - 7.52 (m, 1H), 7.40 - 7.37 (m, 2H), 7.24 - 7.16 (m, 2H), 6.79 (s, 2H), 6.18 - 6.16 (m, 1H), 3.21 - 3.12 (m, 2H), 2.97 - 2.93 (m, 2H), 2.77 - 2.69 (m, 3H), 1.80 - 1.71 (m, 2H), 1.69 - 1.57 (m, 4H), 0.94 - 0.90 (m, 3H).[000214] Synthesis of 4-[2-tert-butyl-4-(3-llethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-l.,3-thiazol-5-yl]-A-(4-13.,8-diazabicvclo[3.2.1]octan-8-vn-3- fluoroDhenyl)Dyrimidin-2-amine; trifluoroacetic acid salt[000215] Step-1: Synthesis of tert-butyl 8-(2-fluoro-4-nitrophenyl)-3.,8- diazabicyclo[3.2.1]octane-3-carboxylate (2)To a mixture of l,2-difluoro-4-nitrobenzene (1.0 g, 6.286 mmol, 1 equiv) and DIEA (2.44 g, 18.858 mmol, 3.0 equiv) in DMSO (10 mL) was added tert-butyl 3,8- diazabicyclo[3.2.1]octane-3-carboxylate (1.33 g, 6.286 mmol, 1.0 equiv) in portions at room temperature. The resulting mixture was stirred for 3 h at 100 °C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with CEECh MeOH (10: 1) to afford tert-butyl 8-(2-fluoro-4-nitrophenyl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (1.2 g, 54.33%) as a yellow solid. LCMS: C17H22FN3O4 requires: 351.2, found: m / z = 352.2 [M+H]+.[000216] Step-2: Synthesis of tert-butyl 8-(4-amino-2-fluorophenyl)-3.,8- diazabicyclo[3.2.1]octane-3-carboxylate (3)To a mixture of tert-butyl 8-(2-fluoro-4-nitrophenyl)-3,8-diazabicyclo[3.2.1]octane-3- carboxylate (600 mg, 1.708 mmol, 1 equiv) in EtOH (10 mL) was added Pd / C (299.84 mg, 2.818 mmol, 1.65 equiv) in portions at room temperature. The resulting mixture was stirred for 3 h at room temperature under a hydrogen atmosphere. The resulting mixture was filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with CFLCL MeOH (10: 1) to afford tert-butyl 8-(4-amino-2-fluorophenyl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (400 mg, 72.89%) as a yellow solid. LCMS: C17H24FN3O2 requires: 321.2, found: m / z = 322.2 [M+H]+.[000217] Step-3: Synthesis of tert-butyl 8-|4-(!4-|2-tert-butyl-4-(3- flethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l.,3-thiazol-5-yl]pyrimidin-2- vnamino)-2-fluorophenyl]-3.,8-diazabicvclo[3.2.1]octane-3-carboxylate (5)To a mixture of tert-butyl 8-(4-amino-2-fluorophenyl)-3,8-diazabicyclo[3.2.1]octane-3- carboxylate (380 mg, 1.182 mmol, 1 equiv) and ({3-[2-tert-butyl-5-(2-chloropyrimidin-4-yl)- l,3-thiazol-4-yl]-2-fluorophenyl}sulfamoyl)(ethyl)methylamine (629.49 mg, 1.300 mmol, 1.1 equiv) in 1,4-dioxane (4 mL) was added BrettPhos Pd G3 (107.18 mg, 0.118 mmol, 0.1 equiv) and CS2CO3 (770.46 mg, 2.364 mmol, 2.0 equiv) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 80 °C under the nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with CthCh MeOH (5: 1) to afford tert- butyl 8-[4-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3- thiazol-5-yl]pyrimidin-2-yl}amino)-2-fluorophenyl]-3,8-diazabicyclo[3.2.1]octane-3- carboxylate (385 mg, 42.35%) as a yellow solid. LCMS: C37H46F2N8O4S2 requires: 768.3, found: m / z = 769.3 [M+H]+.[000218] Step-4: Synthesis of 4-[2-tert-butyl-4-(3-][ethyl(methyl)sulfamoyl]amino}- 2-fluorophenyl)-l.,3-thiazol-5-yl]-7V-(4-f3.,8-diazabicvclo[3.2.1]octan-8-vn-3- fluorophenyl)pyrimidin-2-amine; trifluoroacetic acidTo a mixture of tert-butyl 8-[4-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2-yl}amino)-2-fluorophenyl]-3,8- diazabicyclo[3.2.1]octane-3-carboxylate (380 mg, 0.494 mmol, 1 equiv) in DCM (3 mL) was added TFA (3 mL) dropwise at room temperature. The resulting mixture was stirred for one hour at room temperature. The resulting mixture was concentrated under reduced pressure to afford 4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5- yl]-A-(4-{3,8-diazabicyclo[3.2.1]octan-8-yl}-3-fluorophenyl)pyrimidin-2-amine; trifluoroacetic acid salt (350 mg, crude) as a red solid. LCMS: C32H38F2N8O2S2 requires: 668.3, found: m / z = 669.3 [M+H]+. 'H NMR (300 MHz, CD3OD) 5 8.24 (d, J = 4.8 Hz, 1H), 7.72 - 7.62 (m, 2H), 7.32 (d, J= 8.4 Hz, 2H), 7.20 (d, J = 8.7 Hz, 1H), 6.95 - 7.82 (m, 1H), 6.60 - 6.50 (m, 1H), 4.28 (s, 2H), 3.49 - 3.38 (m, 2H), 3.28 - 3.17 (m, 4H), 2.82 - 2.76 (m, 3H), 2.32 -2.21 (m, 2H), 2.09 - 1.98 (m, 2H), 1.58 - 1.52 (m, 9H), 1.18 - 1.02 (m, 3H).[000219] Synthesis of A-13-[5-(2-aminoDyrimidin-4-yl)-2-(4-methylpiDeridin-4-yl)- l,3-thiazol-4-yl]-2-fluoroDhenynDroDane-l-sulfonamide[000220] Step-1: Synthesis of tert-butyl 4-carbamothioyl-4-methylDiDeridine-l- carboxylate (2)To a mixture of tert-butyl 4-carbamoyl-4-methylpiperidine-l -carboxylate (4 g, 16.5 mmol, 1 equiv) in THF (40 mL) was added Lawesson’s Reagent (3.34 g, 8.25 mmol, 0.5 equiv) at room temperature. The resulting mixture was stirred overnight at 50 °C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and dried overanhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE:EtOAc (3 : 1) to afford tert-butyl 4-carbamothioyl-4-methylpiperidine-l -carboxylate (2.1 g, 44.31%) as a yellow oil. LCMS: C12H22N2O2S requires: 258.1, found: m / z = 259.0 [M+H]+.[000221 ] Step-2: Synthesis of tert-butyl 4-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3- f[(prop-2-en-l-yloxy)carbonyl]amino}phenyl)-l.,3-thiazol-2-yl]-4-methylpiperidine-l- carboxylate (4)To a mixture of prop-2-en-l-yl A-{3-[2-(2-chloropyrimidin-4-yl)acetyl]-2- fluorophenyl} carbamate (3 g, 8.57 mmol, 1 equiv) in DMA (30 mL) was added NBS (1.53 g,8.57 mmol, 1 equiv) and tert-butyl 4-carbamothioyl-4-methylpiperidine-l -carboxylate (2.66 g, 10.29 mmol, 1.2 equiv) at room temperature. The resulting mixture was stirred for 2 h at 60 °C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE:EtOAc (3: 1) to afford tert-butyl 4-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3-{[(prop- 2-en-l-yloxy)carbonyl]amino}phenyl)-l,3-thiazol-2-yl]-4-methylpiperidine-l -carboxylate (2.1 g, 36.63%) as a yellow solid. LCMS: C28H31CIFN5O4S requires: 587.2, found: m / z = 588.1 [M+H]+.[000222] Step-3: Synthesis of tert-butyl 4-(4-(3-amino-2-fluorophenyl)-5-(2- chloropyrimidin-4-yl)thiazol-2-yl)-4-methylpiperidine-l-carboxylate (5)To a mixture of tert-butyl 4-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3-{[(prop-2-en-l- yloxy)carbonyl]amino}phenyl)-l,3-thiazol-2-yl]-4-methylpiperidine-l-carboxylate (2.1 g,3.57 mmol, 1 equiv) and Pd PPtr^Ch (50.13 mg, 0.07 mmol, 0.02 equiv) in DCM (30 mL) was added HO Ac (514.6 mg, 8.57 mmol, 2.4 equiv) and w-BusSnH (1.56 g, 5.35 mmol, 1.5 equiv) at 0 °C under a nitrogen atmosphere. The resulting mixture was stirred for 0.5 h at 0 °C under the nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE:EtOAc (1 : 1) to afford tert-butyl 4-(4-(3-amino-2-fluorophenyl)-5-(2-chloropyrimidin-4-yl)thiazol-2-yl)-4- methylpiperidine- 1 -carboxylate (1.6 g, 92.82%) as a yellow oil. LCMS: C24H27CIFN5O2S requires: 503.2, found: m / z = 504.1 [M+H]+.[000223] Step-4: Synthesis of tert-butyl 4-(5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-2-yl)-4-methylpiperidine-l-carboxylate (6)To a mixture of tert-butyl 4-[4-(3-amino-2-fluorophenyl)-5-(2-chloropyrimidin-4-yl)-l,3- thiazol-2-yl]-4-methylpiperidine-l-carboxylate (1.6 g, 3.17 mmol, 1 equiv) in DCM (20 mL) was added TEA (963.7 mg, 9.52 mmol, 3 equiv) and propane- 1 -sulfonyl chloride (679.0 mg, 4.76 mmol, 1.5 equiv) at 0 °C. The resulting mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under reduced pressure. To the crude product in THF (10 mL), MeCN (10 mL), and H2O (10 mL) was added ISfeCCL (2 g, 19.25 mmol, 10 equiv) at room temperature. The resulting mixture was stirred overnight at 50 °C. The resulting mixture was extracted with DCM. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE: EtOAc (5: 1) to afford tert-butyl 4-[5-(2-chloropyrimidin-4-yl)-4-[2-fluoro-3-(propane-l- sulfonamido)phenyl]-l,3-thiazol-2-yl]-4-methylpiperidine-l-carboxylate (1.1 g, 92.38%) as a yellow solid. LCMS: C27H33CIFN5O4S2 requires: 609.2, found: m / z = 610.1 [M+H]+.[000224] Step-5: Synthesis of tert-butyl 4-(5-!2-|(tert- butoxycarbonyl)amino]pyrimidin-4-vn-4-[2-fluoro-3-(propane-l-sulfonamido)phenyl]- l,3-thiazol-2-yl)-4-methylpiperidine-l-carboxylate (7)To a mixture of tert-butyl 4-[5-(2-chloropyrimidin-4-yl)-4-[2-fluoro-3-(propane-l- sulfonamido)phenyl]-l,3-thiazol-2-yl]-4-methylpiperidine-l-carboxylate (1 g, 1.63 mmol, 1 equiv) and Pd2(dba)3 (150 mg, 0.16 mmol, 0.1 equiv) in dioxane (10 mL) was added XPhos (156.2 mg, 0.32 mmol, 0.2 equiv), CS2CO3 (LI g, 3.27 mmol, 2 equiv) and tert-butyl carbamate (287.9 mg, 2.45 mmol, 1.5 equiv) at room temperature under a nitrogen atmosphere. The resulting mixture was stirred overnight at 80 °C. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE:EtOAc (9: 1) to afford tert-butyl 4-(5-{2-[(tert-butoxycarbonyl)amino]pyrimidin-4-yl}-4- [2-fluoro-3 -(propane- 1 -sulfonamido)phenyl]- 1 ,3 -thiazol-2-yl)-4-m ethylpiperidine- 1 - carboxylate (1 g, 77.72%) as a brown solid. LCMS: C32H43FN6O6S2 requires: 690.3, found: m / z = 691.2 [M+H]+.[000225] Step-6: Synthesis of 7V-f3-[5-(2-aminopyrimidin-4-yl)-2-(4- methylpiperidin-4-yl)-l.,3-thiazol-4-yl]-2-fluorophenvnpropane-l-sulfonaniideA mixture of tert-butyl 4-(5-{2-[(tert-butoxycarbonyl)amino]pyrimidin-4-yl}-4-[2-fluoro-3- (propane-l-sulfonamido)phenyl]-l,3-thiazol-2-yl)-4-methylpiperidine-l-carboxylate (1 g, 1.44 mmol, 1 equiv) in HCl / l,4-di oxane (10 mL, 4 M) was stirred overnight at room temperature. The resulting mixture was concentrated under reduced pressure. The residue waspurified by reverse phase flash chromatography with JtChMeCN (1 :3) to afford 7V-{3-[5-(2- aminopyrimidin-4-yl)-2-(4-methylpiperidin-4-yl)-l, 3-thi azol -4-yl]-2-fluorophenyl (propane- 1-sulfonamide (614.8 mg, 84.49%) as a yellow solid. LCMS: C22H27FN6O2S2 requires: 490.2, found: m / z = 491.1 [M+H]+.'H NMR (400 MHz, CD3OD) 5 8.11 (d, J= 6.4 Hz, 1H), 7.71 - 7.67 (m, 1H), 7.53 - 7.50 (m, 1H), 7.40 - 7.36 (m, 1H), 6.67 - 6.64 (m, 1H), 3.42 - 3.35 (m, 3H), 3.32 - 3.30 (m, 1H), 3.18- 3.14 (m, 2H), 2.56 - 2.50 (m, 2H), 2.15 - 2.08 (m, 2H), 1.90 - 1.84 (m, 2H), 1.62 (s, 3H), 1.08 - 1.04 (m, 3H).[000226] Synthesis of 7V-13- [5-(2-aminoDyrimidin-4-yl)-2-12-azasDiro [3.5] nonan-7- vn-l,3-thiazol-4-yl]-2-fluoroDhenvnDroDane-l-sulfonamide; trifluoroacetic acid salt[000227] Step-1: Synthesis o butyl 7-carbamoyl-2-azasDiro[3.5]nonane-2-carboxylate (2)To a mixture of 2-(tert-butoxycarbonyl)-2-azaspiro[3.5]nonane-7-carboxylic acid (4 g, 14.85 mmol, 1 equiv) and HATU (8.47 g, 22.28 mmol, 1.5 equiv) in DMF (40 mL) was added NH4CI (3.97 g, 74.26 mmol, 5 equiv) and the mixture was stirred for 15 min. Then, DIEA (5.76 g, 44.55 mmol, 3 equiv) was added. The resulting mixture was stirred at room temperature for one hour. The residue was purified by reverse phase flash chromatography eluted with ACbFFhO (1 : 1) to afford tert-butyl 7-carbamoyl-2-azaspiro[3.5]nonane-2-carboxylate (3.5 g, 87.82%) as a white solid. LCMS: C14H24N2O3 requires: 268.2, found: m / z = 269.3 [M+H]+.[000228] Step-2: Synthesis of tert-butyl 7-carbamothioyl-2-azaspiro[3.5]nonane-2- carboxylate (3)To a mixture of tert-butyl 7-carbamoyl-2-azaspiro[3.5]nonane-2-carboxylate (3.5 g, 13.04 mmol, 1 equiv) in THF (40 mL) was added Lawesson’s Reagent (2.64 g, 6.53 mmol, 0.5 equiv). The resulting mixture was stirred at room temperature overnight under a nitrogen atmosphere. The resulting mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography eluted with DCM:MeOH (10: 1) to afford tert-butyl 7-carbamothioyl- 2-azaspiro[3.5]nonane-2-carboxylate (2.5 g, 51.89%) as a white solid. LCMS: C14H24N2O2S requires: 284.2, found: m / z = 285.2 [M+H]+.[000229] Step-3: Synthesis of tert-butyl 7-[5-(2-chloropyrimidin-4-yl)-4-(2-fluoro-3- l[(prop-2-en-l-yloxy)carbonyl]amino}phenyl)-l.,3-thiazol-2-yl]-2-azaspiro[3.5]nonane-2- carboxylate (4)To a mixture of prop-2-en-l-yl A-{3-[2-(2-chloropyrimidin-4-yl)acetyl]-2- fluorophenyl] carbamate (3.07 g, 8.78 mmol, 1 equiv) in DMA (20 mL) was added NBS (1.56 g, 8.78 mmol, 1 equiv) and the mixture was stirred for 15 min. Then, tert-butyl 7- carbamothioyl-2-azaspiro[3.5]nonane-2-carboxylate (2.5 g, 8.79 mmol, 1 equiv) was added. The resulting mixture was stirred at 60 °C for 2 h. The residue was purified by reverse phase flash chromatography eluted with ACN / FLO (1 : 1) to afford tert-butyl 7-[5-(2-chloropyrimidin- 4-yl)-4-(2-fluoro-3-{[(prop-2-en-l-yloxy)carbonyl]amino}phenyl)-l,3-thiazol-2-yl]-2- azaspiro[3.5]nonane-2-carboxylate...

Claims

WHAT IS CLAIMED IS:

1. A compound of F ormula (I)whereinR1is alkyl, aryl, amino, alkylamino, dialkylamino, cycloalkyl, or heterocycloalkyl, each unsubstituted or substituted with one or more halogen or hydroxyl;Rlais halogen;Rih is hydrogen, haloalkyl, or halogen;R2is hydrogen, alkyl, cycloalkyl, haloalkyl, or -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM;X1is carbon or nitrogen;X2is carbon or nitrogen;X3is sulfur, nitrogen, oxygen, or carbon; the bonds among X1, X2, and X3comprise single and double bonds, and the ring containing X1, X2, and X3is aromatic;X4is carbon or nitrogen;X5is hydrogen or -NR3R4;R3is hydrogen or alkyl where alkyl is unsubstituted or substituted with hydroxyl;R4is hydrogen, alkyl, cycloalkyl, or -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM whereinAr1is arylene or heteroarylene, each unsubstituted or substituted with one or more alkyl or one or more halogen;Z1is a bond or -CH2-; n is zero or one;Z2is absent, -C(O)-, -O-, C1-10 alkylene, C1-10 alkylene-C(Me)(Me)-, three- to six-membered cycloalkylene, three- to six-membered cycloalkylene-Ci-10 alkylene, heterocycloalkylene, or -C(Me)(Me)-;Cy1is absent or heterocycloalkylene, unsubstituted or substituted with one or more alkyl or one or more halogen;Z3is absent, Ci-io alkylene, or -C(O)-;L is a linker according to -L1-L2-L3-L4- or -L4-L3-L2-L1-, wherein-L1- is absent, -N(R10)-, -C(Rn)2-, -C(O)-, -Ci-8alkylene-, -C2-8 alkynylene-, -Ce-io aryl-, -C4-10 heteroaryl-, -Q1-, or -Q2-; each -L2-, -L3-, and -L4- is independently, absent, -N(R10)-, -C(Rn)2-, -C(O)-, -O-, -(CH2CH2-O)I-8-, -C1-8 alkylene-, -C2-8 alkynylene-, -Ce-io aryl-, -C4-10 heteroaryl-, -Q1-, -Q2-, or -Q3-; each R10is independently, hydrogen or methyl; each R11is, independently, hydrogen, methyl, aryl, or heteroaryl; each -Q1- is a three- to seven-membered heterocycloalkylene comprising at least one nitrogen and is unsubstituted or substituted with one or more methyl, hydroxyl, or halogen; each -Q2- is a five- to thirteen-membered bicyclic heterocycloalkylene comprising at least one nitrogen, wherein the five- to thirteen-membered bicyclic heterocycloalkylene is optionally a spiro bicyclic heterocycloalkylene ring; each -Q3- is a three- to six-membered cycloalkylene;UBM is a ubiquitin ligase binding moiety; wherein at least one of R2or R4is -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM; or a stereoisomer and / or pharmaceutical salt thereof.

2. The compound of claim 1, having the following Formula (I)whereinR1is alkyl, aryl, amino, alkylamino, dialkylamino, cycloalkyl, or heterocycloalkyl, each unsubstituted or substituted with one or more halogen or hydroxyl;Rlais halogen;Rlbis hydrogen or halogen;R2is hydrogen, alkyl, cycloalkyl, haloalkyl, or -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM;X1is carbon or nitrogen;X2is carbon or nitrogen;X3is sulfur, nitrogen, oxygen, or carbon; the bonds among X1, X2, and X3comprise single and double bonds, and the ring containing X1, X2, and X3is aromatic;X4is carbon or nitrogen;X5is hydrogen or -NR3R4;R3is hydrogen or alkyl where alkyl is unsubstituted or substituted with hydroxyl;R4is hydrogen, alkyl, cycloalkyl, or -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM whereinAr1is arylene or heteroarylene, each unsubstituted or substituted with one or more alkyl or one or more halogen;Z1is a bond or -CH2-; n is zero or one;Z2is absent, -C(O)-, -O-, C1-10 alkylene, C1-10 alkylene-C(Me)(Me)-, three- to six-membered cycloalkylene, three- to six-membered cycloalkylene-Ci-10 alkylene, heterocycloalkylene, or -C(Me)(Me)-;Cy1is absent or heterocycloalkylene, unsubstituted or substituted with alkyl;Z3is absent, C1-10 alkylene, or -C(O)-;L is a linker according to -L4-L2-L3-L4- or -L4-L3-L2-L1-, wherein-L1- is absent, -N(R10)-, -C(Rn)2-, -C(O)-, -Ci-8alkylene-, -C2-8 alkynylene-, -Ce-io aryl-, -C4-10 heteroaryl-, -Q1-, or -Q2-; each -L2-, -L3-, and -L4- is independently, absent, -N(R10)-, -C(Rn)2-, -C(O)-, -O-, -(CH2CH2-O)I-8-, -CI-8 alkylene-, -C2-8 alkynylene-, -Ce-io aryl-, -C4-10 heteroaryl-, -Q1-, -Q2-, or -Q3-; each R10is independently, hydrogen or methyl; each R11is, independently, hydrogen, methyl, aryl, or heteroaryl; each -Q1- is a three- to seven-membered heterocycloalkylene comprising at least one nitrogen and is unsubstituted or substituted with methyl, hydroxyl, or halogen; each -Q2- is a five- to thirteen-membered bicyclic heterocycloalkylene comprising at least one nitrogen, wherein the five- to thirteen-memberedbicyclic heterocycloalkylene is optionally a spiro bicyclic heterocycloalkylene ring; each -Q3- is a three- to six-membered cycloalkylene;UBM is a ubiquitin ligase binding moiety; wherein at least one of R2or R4is -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM; or a stereoisomer and / or pharmaceutical salt thereof.

3. The compound of claim 2, wherein X1is nitrogen; X2is carbon, X3is sulfur; and X4is carbon or nitrogen.

4. The compound of claim 3, whereinR1is alkyl;Rlais fluoro;R2is -[A Z^n-Z^Cy^Z’-L-UBM; n is zero;Z2is absent; andCy1is an unsubstituted heterocycloalkylene.

5. The compound of claim 4, wherein Z3is -C(O)-.

6. The compound of claim 5, wherein L1is Q1.

7. The compound of claim 6, wherein L2is -C(O)-.

8. The compound of claim 7, wherein L3is Q1; and L4is absent.

9. The compound of any one of claims 4-8, wherein R1is -CH2CH2CH3.

10. The compound of claim 2, wherein X1is carbon or nitrogen; X2is nitrogen, and X3is carbon or nitrogen.

11. The compound of claim 10, wherein X1is carbon; X2is nitrogen, and X3is nitrogen.

12. The compound of claim 11, whereinR1is alkyl;Rlais fluoro;R2is -[A Z^n-Z^Cy^Z’-L-UBM;Z1is a bond; n is one;Z2and Z3are absent; andCy1is an unsubstituted heterocycloalkylene.

13. The compound of claim 12, wherein X4is carbon and X5is hydrogen.

14. The compound of claim 13, wherein L1is -C(Rn)2-.

15. The compound of claim 14, wherein is R11hydrogen.

16. The compound of claim 15, wherein L2is Q1; and L3and L4are absent.

17. The compound of any one of claims 11-16, wherein R1is -CH2CH2CH3.

18. The compound of claim 2, wherein X1is nitrogen; X2is carbon, X3is sulfur; and X4is nitrogen.

19. The compound of claim 18, whereinR1is alkyl;Rlais fluoro;R2is alkyl; n is zero;Z2is absent; andCy1is an unsubstituted heterocycloalkylene.

20. The compound of claim 19, wherein Z3is absent, -CH2- or -C(O)-.

21. The compound of claim 20, wherein L1is Q1, -C(Rn)2-, or -CH2CH2CH2CH2CH2-, orQ322. The compound of claim 21, wherein L2is absent, Q1, Q2, -C(Rn)2-, -C(O)-, or -O-.

23. The compound of claim 22, wherein L3is absent, Q1, or -CH2CH2CH2-; and L4is absent.

24. The compound of any one of claims 19-23, wherein R1is -CH2CH2CH3.

25. The compound of claim 2, wherein UBM binds an E3 ubiquitin ligase.

26. The compound of claim 2, wherein UBM binds SCFP-TRCP, VHL, MDM2, IAP, or CRBN.

27. The compound of claim 2, wherein UBM binds VHL.

28. The compound of claim 27, wherein UBM binds VHL and has the following chemical formulaL designates attachment to L;Z4is a bond, -CH2-, -C(O)-, -C(O)N(R12)-, or -N(R12)-, wherein R12is hydrogen or methyl;X6is C-H or nitrogen;R8is alkyl, alkenyl, alkylene, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, - S(O)(R13), or -S(O)2(R13); wherein R13is hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, aryl, heterocycle, or heteroaryl, wherein each alkyl, alkenyl, alkylene, alkynyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl is unsubstituted or substituted;R9is hydrogen, unsubstituted or substituted C1-8 alkyl, or -AA’-AA2-R14wherein each AA1and AA2is an amino acid residue, and R14is hydrogen or methyl.

29. The compound of claim 27, wherein UBM binds VHL and has the following chemical formulawhereinL designates attachment to L;Z5is a bond, -CH2-, -C(O)-, -C(O)N(R12)-, -N(R12)-, or -O-, wherein R12is hydrogen or methyl;A is phenyl or C4-heteroaryl;X7is -CH2, -NR12, oxygen, or sulfur, wherein R12is hydrogen or methyl; p is zero or one;R15is unsubstituted or substituted C1-8 alkyl, -AA4-AA2-R14, wherein each AA1and AA2is an amino acid residue, and R14is hydrogen or methyl.

30. The compound of claim 27, wherein UBM binds VHL and has the following chemical formulawhereinL designates attachment to L;Z6is a bond, -CH2., -C(O)-, -C(O)N(R12)-, or N(R12), wherein R12is hydrogen or methyl;5designates attachment to X8, wherein designates attachment to X9, and wherein,§iz6designates attachment to Z6;X8is carbon or nitrogen;X9is C-H or -CH2-;R16is hydrogen, -OH, halogen, -NH2, -C1-3 alkyl, -C2-6 alkenyl, -C2-6 alkynyl, -C1-3 alkoxy, -C1-3 thioalkyl, -C1-3 alkylamine, -Ce-io aryl, cycloalkyl, heterocycloalkyl, or heteroaryl;R17is -C(0)N(H)-C6-IO aralkyl, -C(O)CH(Cbutyl)-N(H)-C3-6 cycloalkyl,n amino acid residue and R14is hydrogen or methyl; andR18 is halogen31. The compound of claim 2, wherein UBM binds CRBN.

32. The compound of claim 31, wherein UBM binds CRBN and has the following chemical formulawhereinX6absent or NR3;X7absent or -C(O)-; andX8is arylene or heteroarylene.

33. The compound of claim 32, wherein UBM binds CRBN and is selected from the groupX9is absent or halogen; and m is one, two, three, or four.

34. A compound of Formula (II)whereinR1is alkyl, aryl, amino, alkylamino, dialkylamino, cycloalkyl, or heterocycloalkyl, each unsubstituted or substituted with one or more halogen or hydroxyl;Rlais halogen;Rlbis hydrogen or halogen;R2is -[Ar1-Z1]n-Z2-Cy1-Z3-L-UBM whereinAr1is arylene or heteroarylene, each unsubstituted or substituted with one or more alkyl or one or more halogen;Z1is a bond or -CH2-; n is zero or one;Z2is absent, -C(O)-, -O-, C1-10 alkylene, C1-10 alkylene-C(Me)(Me)-, three- to six-membered cycloalkylene, three- to six-membered cycloalkylene-Ci-10 alkylene, heterocycloalkylene, or -C(Me)(Me)-;Cy1is absent or heterocycloalkylene, unsubstituted or substituted with alkyl;Z3is absent, C1-10 alkylene, or -C(O)-;L is a linker according to -L1-L2-L3-L4- or -L4-L3-L2-L1-, wherein-L1- is absent, -N(R10)-, -C(Rn)2-, -C(O)-, -Ci-8alkylene-, -C2-8 alkynylene-, -Ce-io aryl-, -C4-10 heteroaryl-, -Q1-, or -Q2-; each -L2-, -L3-, and -L4- is independently, absent, -N(R10)-, -C(Rn)2-, -C(O)-, -O-, -(CH2CH2-O)I-8-, -CI-8alkylene-, -C2-8alkynylene-, -Ce-io aryl-, -C4-10 heteroaryl-, -Q1-, -Q2-, or -Q3-; each R10is independently, hydrogen or methyl; each R11is, independently, hydrogen, methyl, aryl, or heteroaryl; each -Q1- is a three- to seven-membered heterocycloalkylene comprising at least one nitrogen and is unsubstituted or substituted with methyl, hydroxyl, or halogen;each -Q2- is a five- to thirteen-membered bicyclic heterocycloalkylene comprising at least one nitrogen, wherein the five- to thirteen-membered bicyclic heterocycloalkylene is optionally a spiro bicyclic heterocycloalkylene ring; each -Q3- is a three- to six-membered cycloalkylene;UBM is a ubiquitin ligase binding moiety;X1is nitrogen or oxygen;X3is sulfur when X1is nitrogen; oxygen when X1is nitrogen; or nitrogen when X1is oxygen; the bonds among X1and X3comprise single and double bonds, and the ring containing X1and X3is aromatic;X4is carbon or nitrogen;X5is hydrogen or -NR3R4;R3is hydrogen or alkyl where alkyl is unsubstituted or substituted with hydroxyl;R4is hydrogen, alkyl, or cycloalkyl; or a stereoisomer and / or pharmaceutical salt thereof.

35. The compound of claim 34, wherein X1is nitrogen; X3is oxygen; and X4is carbon or nitrogen.

36. The compound of claim 34, wherein X1is oxygen; X3is nitrogen; and X4is carbon or nitrogen.

37. The compound of claim 34, wherein X1is nitrogen; X3is sulfur; and X4is carbon or nitrogen.

38. The compound of claim 37, whereinR1is alkyl;Rlais fluoro;R2is -[A Z^n-Z^Cy^Z’-L-UBM; n is zero;Z2is absent; andCy1is an unsubstituted heterocycloalkylene.

39. The compound of claim 38, wherein Z3is -C(O)-.

40. The compound of claim 39, wherein L1is Q1.

41. The compound of claim 40, wherein L2is -C(O)-.

42. The compound of claim 41, wherein L3is Q1and L4is absent.

43. The compound of any one of claims 38-42, wherein R1is -CH2CH2CH3.

44. The compound of claim 34, wherein UBM binds an E3 ubiquitin ligase.

45. The compound of claim 34, wherein UBM binds SCFP-TRCP, VHL, MDM2, IAP, orCRBN.

46. The compound of claim 45, wherein UBM binds VHL.

47. The compound of claim 46, wherein UBM binds VHL and has the following chemical formulawherein' designates attachment to L;Z4is a bond, -CH2-, -C(O)-, -C(O)N(R12)-, or -N(R12)-, wherein R12is hydrogen or methyl;X6is C-H or nitrogen;R8is alkyl, alkenyl, alkylene, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, - S(O)(R13), or -S(O)2(R13); wherein R13is hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, aryl, heterocycle, or heteroaryl, wherein each alkyl, alkenyl, alkylene, alkynyl, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl is unsubstituted or substituted;R9is hydrogen, unsubstituted or substituted C1-8 alkyl, or -AA’-AA2-R14wherein each AA1and AA2is an amino acid residue, and R14is hydrogen or methyl.

48. The compound of claim 46, wherein UBM binds VHL and has the following chemical formulawherein designates attachment to L;Z5is a bond, -CH2-, -C(O)-, -C(O)N(R12)-, -N(R12)-, or -O-, wherein R12is hydrogen or methyl;A is phenyl or C4-heteroaryl;X7is -CH2, -NR12, oxygen, or sulfur, wherein R12is hydrogen or methyl; p is zero or one;R15is unsubstituted or substituted C1-8 alkyl, -AA1-AA2-R14, wherein each AA1and AA2is an amino acid residue, and R14is hydrogen or methyl.

49. The compound of claim 46, wherein UBM binds VHL and has the following chemical formulawhereinL designates attachment to L;Z6is a bond, -CH2-, -C(O)-, -C(O)N(R12)-, or N(R12), wherein R12is hydrogen or methyl;X8X9designates attachment to X8, whereindesignates attachment to X9, and wherein, z6designates attachment to Z6;X8is carbon or nitrogen;X9is C-H or -CH2-;R16is hydrogen, -OH, halogen, -NH2, -C1-3 alkyl, -C2-6 alkenyl, -C2-6 alkynyl, -C1-3 alkoxy, -C1-3 thioalkyl, -C1-3 alkylamine, -Ce-io aryl, cycloalkyl, heterocycloalkyl, or heteroaryl; R17is -C(0)N(H)-C6-IO aralkyl, -C(O)CH(t-butyl)-N(H)-C3-6cycloalkyl,-C(O)-CH(t-butyl)-N(H)C(O)-C3-C6cycloalkyl,amino acid residue and R14is hydrogen or methyl; andR18is halogen50. The compound of claim 34, wherein UBM binds CRBN.

51. The compound of claim 50, wherein UBM binds CRBN and has the following chemical formulawhereinX6is absent or NR3;X7is absent or -C(O)-; andX8is arylene or heteroarylene.

52. The compound of claim 51, wherein UBM binds CRBN and is selected from the group consistingX9is absent or halogen; and m is one, two, three, or four.

53. The compound of claim 2 Formula (I) or claim 34 Formula (II), wherein L comprises at least one -Q1-; at least one -Q2-; at least one -Q3-; at least one -C(R11)2-; or at least one Ci-8 alkylene-.

54. The compound of claim 53, wherein L is selected from the group consisting of a. -Q1-; b. -Qi-QCO-Q1-; c. -C(R11)2-Q1-; d. -Q1-C(R11)2-Q1-; e. -C(R11)2-O-; f. -Q3-O-; g. -CCRl^-Ql-Ql-; hi. -C(Rn)2-Q2-; j. -Ci-8 alkylene-; k. -C(R11)2-Q1-CI-8 alkylene-; l. -Q3-C(R11)2-; m. -C(Rn)2-;n. -Q2-; o. -Q1-C(O)-C(R11)2-; p. -Q1-C(O)-Q3-O-; q. -Q1-C(O)-C(R11)2-Q1-; r. -Q^ R^-Q3-©-; and s. -Q1-C(R11)2-.

55. The compound of claim 54, whereinwherein R19is hydrogen, hydroxyl, halogen, or unsubstituted alkyl, n1is one or two, n2is one or two, and n3is one or two.

56. The compound of claim 55, wherein -Q1- is selected from the group consisting ofwherein R19is hydrogen, hydroxyl, fluoro, or methyl.

57. The compound of claim 54, whereinwherein n4is one or two, n5is one or two, and n6is one or two.N58. The compound of claim 57, wherein -Q2- is selected from the group consisting of59. The compound of claim 54, wherein - , wherein n7is one or two, and n8is one or two.

60. The compound of claim 59, wherein -Q3- is selected from the group consisting of61. The compound of claim 54, wherein each R11is, independently, hydrogen or methyl.

62. The compound of claim 61, wherein both R11are hydrogen; one R11is hydrogen and oneR11is methyl; or both R11are methyl.

63. The compound of claim 54, wherein -Ci-s alkylene- is selected from the group consisting of -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2-,-CH2CH2CH2CH2CH2CH2-, -CH2CH2CH2CH2CH2CH2CH2-, and-CH2CH2CH2CH2CH2CH2CH2CH2-.

64. The compound of claim 54, wherein the linker L is selected fromZ3 UBM indicates attachment to Z3, and indicates attachment to UBM.

65. The compound of any one of claims 2-9, 31-33, or 53-64 selected from the group consisting of (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(l -(l-(l-(5-(2,6-di oxopiperi din-3 -yl)pyri din-2 -yl)piperidine-4- carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(4- (2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l- (l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, and (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5- (pyridin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide.

66. The compound of any one of claims 2, 31-33, or 53-64 selected from the group consisting of (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-l,3- dioxoisoindolin-4-yl)propyl)piperazin-l-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)- 2-fluorophenyl)propane- 1 -sulfonamide, N-(3 -(5 -(2-aminopyrimidin-4-yl)-2-( 1 -(( 15,4r)-4-((6- ((5)-2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(lJ7)-yl)methyl)cyclohexane-l- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l- (l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-5-yl)piperazin-l-yl)acetyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(T-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-[l,4'-bipiperidin]-4-yl)acetyl)-4- methylpiperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidine-4-carbonyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-(2-(6- (2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(lJ7)-yl)acetyl)piperidin-4- yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N-(3-(2- (l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyridin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(r-(2-(2,6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-5-yl)-[l,4'-bipiperidin]-4-yl)acetyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(4-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperazin-l-yl)acetyl)piperidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-( 1 -( 1 -(1 -(2-(2,6-dioxopiperi din-3 -yl)- 1 ,3 -dioxoisoindolin-5-yl)piperidin-4- yl)azetidine-3-carbonyl)piperidin-4-yl)propan-2-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-((17?,4r)-4-(3-(( ?)-2,6- dioxopiperi din-3 -yl)phenoxy)cy cl ohexane-l-carbonyl)piperidin-4-yl)methyl)piperi din-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(3-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5- (2-aminopyrimidin-4-yl)-2-(l-(l-(2-(l-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)- 4-hydroxypiperidin-4-yl)acetyl)azetidin-3-yl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-(2-(l-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)acetyl)piperidin-4-yl)phenyl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-((l- (4-(2, 6-dioxopiperi din-3 -yl)phenyl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)thi azol -4- yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-(2- (l-(4-((2,6-dioxopiperi din-3 -yl)amino)phenyl)piperi din-4-yl)acetyl)piperi din-4- yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(4-(l-(l-(5-(2,6-dioxopiperi din-3-yl)pyri din-2 -yl)piperidine-4- carbonyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, N-(3- (5-(2-aminopyrimidin-4-yl)-2-(3-(((15,4r)-4-((5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)oxy)cyclohexyl)methyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(l-(4- (2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperazin-l-yl)phenyl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-5-(4-(9-(5-(2-aminopyrimidin-4-yl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-2-yl)-3-azaspiro[5.5]undecane-3-carbonyl)piperidin-l- yl)-7V-(2,6-dioxopiperidin-3-yl)picolinamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-((5)-l- (5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)-3-azaspiro[5.5]undecan-9- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)- 2-(l-(l-(2-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)acetyl)azetidin-3- yl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-(l -(5-(2,6-di oxopiperidin-3-yl)pyri din-2 -yl)piperidine-4- carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide,(5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4- carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyridin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-((l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2- (methylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N-(3 - (5-(2-aminopyrimidin-4-yl)-2-(2-(2-(l'-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)-[l,4'-bipiperidin]-4-yl)acetyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyridin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2- (l-((l-(((15,4r)-4-(4-((5)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexyl)methyl)piperidin-4- yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3- 5-(2-aminopyrimidin-4-yl)-2-(2-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidine-4-carbonyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(2-(l-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4- yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(l-(l-(l-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin- 4-yl)ethyl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3- 5-(2- aminopyrimidin-4-yl)-2-(2-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperazin-l-yl)acetyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, ( ?)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperazin-l-yl)phenyl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(l-(l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamidef, (R)-N-(3- 5-(2- aminopyrimidin-4-yl)-2-(4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, S)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-(l-(5-(2,6-dioxopiperidin-3-yl)pyri din-2-yl)piperidine-4-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(2-(l-(5- (2, 6-dioxopiperi din-3 -yl)pyri din-2 -yl)piperi din-4-yl)acetyl)piperazin- l-yl)phenyl)thi azol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(r- (2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-[l,4'-bipiperidin]-4-yl)acetyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5- (2-aminopyrimidin-4-yl)-2-(l-(l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidine-4-carbonyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(2- (isopropylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(4-(2-(2, 6-dioxopiperi din-3-yl)-l,3-dioxoisoindolin-5- yl)piperazin-l-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-((17?,4r)-4-(4-(( ?)-2,6- dioxopiperi din-3 -yl)phenoxy)cy cl ohexane-l-carbonyl)piperidin-4-yl)methyl)piperidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-(6-(2-(2, 6-dioxopiperi din-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-2- azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, 7V-(3-(2-(l-(l- (l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(2-((( ?)-l-hydroxypropan-2-yl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-((l- (5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)thiazol- 4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, rac-(37?)-3 - { 6-[4-(4-{4-[5-(2-aminopyrimidin- 4-yl)-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-2-yl]piperidine-l- carbonyl}piperidine-l-carbonyl)piperidin-l-yl]pyridin-3-yl}piperidine-2, 6-dione, rac-(37?)-3- {6-[4-(4-{4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-5-{2-[(propan-2- yl)amino]pyrimidin-4-yl } - 1 ,3 -thiazol-2-yl]piperidine- 1 -carbonyl } piperi dine- 1 - carbonyl)piperidin-l-yl]pyridin-3-yl}piperidine-2, 6-dione, (5)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(l-(l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, ( ?)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperidin-4-yl)methyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(2-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-4- methylpiperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3- 5-(2- aminopyrimidin-4-yl)-2-(3-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidine-4-carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, ( ?)-7V-(3-(2-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)- 2,7 -di azaspiro [3.5 ]nonan-7 -yl)acetyl)piperidin-4-yl)-5-(2-(methylamino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(3-(6-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5- (2-aminopyrimidin-4-yl)-2-(l-(l-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2-(methylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N-(3 - (5-(2-aminopyrimidin-4-yl)-2-(l-(l-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin- 4-yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2-(isopropylamino)pyrimidin-4-yl)thiazol- 4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-(cyclopropylamino)pyrimidin-4- yl)-2-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l- (l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-( (R)-l-(4-(())-2,6-dioxopiperidin-3- yl)phenyl)pyrrolidin-3-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(2-(2-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-2- azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(l-((l-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)piperidin-4-yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, ( ?)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(l-(l-(2,6- dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[d]imidazol-4-yl)piperidine-4- carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-7V-(3-(2-(l-(l-((l-(4-(2, 6-dioxopiperi din-3 -yl)phenyl)piperi din-4-yl)methyl)piperi dine-4- carbonyl)piperidin-4-yl)-5-(2-(methylamino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperidin-4-yl)azetidine-3- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(2-(l-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidin-4-yl)azetidine-3-carbonyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2- fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -(5-(2-aminopyrimidin-4-yl)-2-(l -( 1 -(( 1 -( 1 -(2, 6-dioxopiperi din-3 -yl)-3-methyl-2-oxo-2, 3 -dihydro- 17 / -benzo[d]imidazol-4-yl)piperi din- 4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, ( ?)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-3-azaspiro[5.5]undecan-9- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7- diazaspiro[3.5]nonan-7-yl)acetyl)piperidin-4-yl)propan-2-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, and (R)-4-((4-(5-(2-aminopyrimidin-4-yl)-4-(2-fluoro- 3 -(propylsulfonamido)phenyl)thiazol-2-yl)piperi din- l-yl)methyl)-7V-(2, 6-dioxopiperi din-3 - yl)benzamide.

67. The compound of any one of claims 2, 18-24, 31-33, or 53-64 selected from the group consisting of (R)-4-(4-((6-((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5- yl)pyrimidin-2-yl)amino)-2-azaspiro[3.3]heptan-2-yl)methyl)piperidin-l-yl)-7V-(2,6- di oxopiperi din-3 -yl)benzamide, 7V-(3-(2-(tert-butyl)-5-(2-((2-(2-((5)-l-(5-((5)-2,6- dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)-2-azaspiro[3.3]heptan-6- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3-(2- (tert-butyl)-5-(2-((2-(2-(l'-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-[l,4'- bipiperidin]-4-yl)acetyl)-2-azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((2-(l-(l-(2,6-di oxopiperidin-3-yl)-3-m ethyl -2-oxo-2, 3-dihydro- l 7 / -benzo[t / ]imidazol -4-yl )piperidine-4- carbonyl)-2-azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((2-(l-(l-(2-(2,6- dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperidin-4-yl)azetidine-3-carbonyl)-2- azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((2-(2-(2-(2-(2,6-dioxopiperi din-3 -yl)- 1,3- dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-2-azaspiro[3.3]heptan-6- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3-(2- (tert-butyl)-5-(2-((2-(6-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-2- azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((2-((l-((l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)methyl)-2-azaspiro[3.3]heptan-6- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3-(2- (tert-butyl)-5-(2-((2-(2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-4- yl)propyl)piperazin-l-yl)acetyl)-2-azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((2-(l-((l-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-4-fluoropiperidine-4-carbonyl)-2- azaspiro[3.3]heptan-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((2-((l-(l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidine-4-carbonyl)piperidin-4-yl)methyl)-2-azaspiro[3.3]heptan-6- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, S)-N-(3-(2- (tert-butyl)-5-(2-((r-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)- [ 1 ,4'-bipiperidin]-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 - sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((7-(2-(4-(4-((2,6-dioxopiperidin-3- yl)amino)phenyl)piperidin-l-yl)acetyl)-7-azaspiro[3.5]nonan-2-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((7- (((15,4r)-4-(4-((5)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexyl)methyl)-7- azaspiro[3.5]nonan-2-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((7-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2- dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-7-azaspiro[3.5]nonan-2-yl)amino)pyrimidin- 4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((7-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-7-azaspiro[3.5]nonan-2- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, and (R)-N-(3-(2-(tert-butyl)-5-(2-((7-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperazin- l-yl)acetyl)-7-azaspiro[3.5]nonan-2-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluoropheny l)prop ane- 1 - sulfonami de .

68. The compound of any one of claims 2, 31-33, or 53-64 selected from the group consisting of (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-3-yl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(2-((2-(2,6-dioxopiperidin-3-yl)-l,3- dioxoisoindolin-5-yl)oxy)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(2-((2-(2,6- dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)oxy)acetyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N- (3-(2-(te / 7-butyl)-5-(2-((4-(l-(2-(4-(4-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperazin-l- yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(2-((5)-l-(5-((, )-2,6-dioxopiperidin-3- yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-4-(4-((4-(4-((4-(2-(tert-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)phenyl)piperidin-l- yl)methyl)piperi din- l-yl)-7V-(2,6-dioxopiperi din-3 -yl)benzamide, (R)-5-(4-((4-(4-((4-(2-(7ert- butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2- yl)amino)phenyl)piperidin-l-yl)methyl)piperidin-l-yl)-7V-(2,6-dioxopiperidin-3- yl)picolinamide, 7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(((15,4r)-4-((5-((5)-2,6-dioxopiperidin-3- yl)pyridin-2-yl)oxy)cyclohexyl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol- 4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-((l-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(2- ((5)-l-(4-((5)-2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)acetyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3- (2-(tert-butyl)-5-(2-((4-(l-(2-( (R)-l-(4-((5)-2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3- yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((4-(l-( (R)-l-(5-((, )-2,6-dioxopiperidin-3- yl)pyridin-2-yl)pyrrolidine-3-carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(l-(l-(4-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N- (3-(2-(terZ-butyl)-5-(2-((4-(l-(2-(l'-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)- [l,4'-bipiperidin]-4-yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(l-(5-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, N-(3- (2-(tert-butyl)-5-(2-((4-(l-(2-((5)-l-(l-( (R)-2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3- dihydro-l / Z-benzo[ ]imidazol-5-yl)pyrrolidin-3-yl)acetyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N- (3-(2-(terZ-butyl)-5-(2-((4-(l-(l-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro- l / Z-benzo[ ]imidazol-4-yl)piperidine-4-carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(l- (l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)azetidine-3-carbonyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N- (3-(2-(terZ-butyl)-5-(2-((4-(l-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidine-4-carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(l-(2-(2-(2-(2,6- dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7- yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(6-(2-(2,6-dioxopiperidin-3-yl)-3- oxoisoindolin-5-yl)hexanoyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(l-(2-(4-(2-(2,6- dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperazin-l-yl)acetyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-5- (4-((4-(((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2- yl)amino)methyl)piperidin- 1 -yl)methyl)piperidin- 1 -yl)-7V-(2,6-dioxopiperi din-3 - yl)picolinamide, (5)-5-(4-((4-(l-((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-2-methylpropan-2- yl)piperi din- l-yl)methyl)piperi din- l-yl)-7V-(2,6-dioxopiperi din-3 -yl)picolinamide, (R)-N-(3- (2-(tert-butyl)-5-(2-(((l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidin-4-yl)methyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1 -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((2-(l-((l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)-2-methylpropyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 5-(4-(( (R)-3-(((4-(2-(tert-butyl)-4-(2- fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)methyl)pyrrolidin-l- yl)methyl)piperi din- l-yl)-7V-((5)-2,6-dioxopiperi din-3 -yl)picolinamide, 7V-(3-(2-(tert-butyl)- 5-(2-(((lr,4r)-4-((4-((l-(4-((5)-2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)methyl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-( e^butyl)-5-(2-(((l ,4 )-4-(4-(l-(5-((5')-2,6- dioxopiperi din-3 -yl)pyri din-2-yl)piperi dine-4-carbonyl)piperazin- 1- yl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, N- (3-(2-(terZ-butyl)-5-(2-(((lr,4r)-4-(4-(l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidine-4-carbonyl)piperazin-l-yl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(terZ-butyl)-5-(2-(((lr,4r)-4-(4-((l-(5-((5)-2,6- dioxopiperi din-3 -yl)pyri din-2-yl)piperi din-4-yl)methyl)piperazin- 1- yl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, N- (3-(2-(terZ-butyl)-5-(2-(((15,45)-4-(4-((l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperazin-l-yl)cyclohexyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (37?)-3-{4-[4-({4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl } amino)pyri din-3 -yl]piperazin- 1 -yl }methyl)piperidin- 1 -yl]phenyl }piperidine-2, 6-dione, (35)-3-{4-[4-({4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazin-l- yl}methyl)piperi din- l-yl]phenyl}piperidine-2, 6-dione, rac-(35)-3-{6-[4-({4-[6-({4-[2-tert- butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl } amino)pyri din-3 -yl]piperazin- 1 -yl }methyl)piperidin- 1 -yl]pyri din-3 -yl }piperidine-2,6- dione, rac-(3 S)-3 -(2- { [( 1 r,4r)-4- {4-[6-({4-[2-tert-butyl-4-(3 -{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl }amino)pyri din-3 -yl]piperazine-l -carbonyl }cy cl ohexyl]methyl}- 1,2, 3,4- tetrahydroisoquinolin-6-yl)piperidine-2, 6-dione, rac-(3S)-3-(2-{[(lr,4r)-4-{4-[6-({4-[2-tert- butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl }amino)pyri din-3 -yl]piperazine-l -carbonyl }cy cl ohexyl]methyl}- 1,2, 3,4- tetrahydroisoquinolin-7-yl)piperidine-2, 6-dione, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((2-(2-(4-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-l-yl)acetyl)-l,2,3,4-tetrahydroisoquinolin-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, ( ?)-5-(4-(6- ((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2- yl)amino)-l,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidin-l-yl)-7V-(2,6-dioxopiperidin-3- yl)picolinamide, V-(3-(2-(ferZ-butyl)-5-(2-((2-( (R)-l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine-3-carbonyl)-l,2,3,4-tetrahydroisoquinolin-6-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((2-(2- (4-(4-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperazin-l-yl)acetyl)-l, 2,3,4- tetrahydroisoquinolin-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((l-((l-(2-(6-(2,6-dioxopiperidin-3-yl)-3,4- dihydroisoquinolin-2(U7)-yl)acetyl)piperidin-4-yl)methyl)-lJH-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, N-(3-(2-(tert- butyl)-5-(2-((l-((l-((15,4r)-4-(4-((5)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexane-l- carbonyl)piperidin-4-yl)methyl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(ter -butyl)-5-(2-((l-((l-((15',4r)-4-((5-((, )-2, 6- dioxopiperi din-3 -yl)pyridin-2-yl)oxy)cy cl ohexane-l-carbonyl)piperidin-4-yl)methyl)- 1H- pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)- 7V-(3-(2-(terZ-butyl)-5-(2-((l-((l-(2-(4-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin- l-yl)acetyl)piperidin-4-yl)methyl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-5-(4-(4-((4-((4-(2-(tert-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-l / Z-pyrazol-l- yl)methyl)piperi dine- l-carbonyl)piperi din- l-yl)-7V-(2,6-dioxopiperi din-3 -yl)picolinamide, N- (3-(2-(terZ-butyl)-5-(2-((l-((l-( (R)-l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine-3-carbonyl)piperidin-4-yl)methyl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((l-((l-(2-(4-(4-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)piperazin-l-yl)acetyl)piperidin-4-yl)methyl)-lJH-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, N-(3-(2-(tert- butyl)-5-(2-((l-((l-(2-((5)-l-(4-((5)-2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3- yl)acetyl)piperidin-4-yl)methyl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(Zert-butyl)-5-(2-((l-((l-(2-( (R)-l-(4-((5)-2,6- dioxopiperi din-3 -yl)phenyl)pyrrolidin-3-yl)acetyl)piperidin-4-yl)m ethyl)- l / f-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, N-(3-(2-(tert- butyl)-5 -(2-(( 1 -( 1 -(( 15,4r)-4-(4-((5)-2, 6-dioxopiperi din-3 -yl)phenoxy)cy clohexane- 1 - carbonyl)piperidin-4-yl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, jV-(3-(2-(tert-butyl)-5-(2-((l-(l-((15,4r)-4-((5-((5)-2,6- dioxopiperidin-3-yl)pyridin-2-yl)oxy)cyclohexane-l-carbonyl)piperidin-4-yl)-lJH-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (7?)-7V-(3-(2- (tert-butyl)-5-(2-((l-(l-(2-(4-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-l- yl)acetyl)piperidin-4-yl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-5-(4-(4-(4-((4-(2-(tert-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-l / Z-pyrazol-l-yl)piperidine- l-carbonyl)piperi din- l-yl)-7V-(2,6-dioxopiperi din-3 -yl)picolinamide, 7V-(3-(2-(tert-butyl)-5- (2-((l-(l-( (R)-l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine-3- carbonyl)piperidin-4-yl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((l-(l-(2-((5)-l-(4-((5)-2,6- dioxopiperi din-3 -yl)phenyl)pyrrolidin-3 -yl)acetyl)piperi din-4-yl)- l / f-pyrazol-4- yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (S)-N-(3-(2- (tert-butyl)-5-(2-((3-(l-(2-(6-(2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(lJ7)- yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((3-(l-(2-(4-(4-((2,6-dioxopiperidin-3- yl)amino)phenyl)piperidin-l-yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane- 1 -sulfonamide, N-(3 -(2-(terZ-butyl)-5 -(2-((3 -( 1 -((R)- 1 -(5 -((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine-3-carbonyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N- (3-(2-(7erZ-butyl)-5-(2-((3-((l-(2-(6-(2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(lJ7)- yl)acetyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -(2-(terZ-butyl)-5 -(2-((3 -(( 1 -( 1 -(4-(2, 6- dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (S)-N-(3 -(2-(te / 7-buty 1 )-5 -(2-((3 -(( 1 -( 1 -(3 -(2, 6-dioxopiperi din-3 -yl)phenyl)piperidine-4- carbonyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, jV-(3-(2-(tert-butyl)-5-(2-((3-((l-((15,4r)-4-(4-((5)-2,6- dioxopiperi din-3 -yl)phenoxy)cy cl ohexane-1 -carbonyl)piperi din-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, N- (3-(2-(terZ-butyl)-5-(2-((3-((l-((15,4r)-4-((5-((,S)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)oxy)cy cl ohexane-1 -carbonyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thi azol -4- yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((3-((l-(2-(4-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-l-yl)acetyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-5-(4-(4-(3-((4-(2-(terZ-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5- yl)pyrimidin-2-yl)amino)phenoxy)piperidine-l-carbonyl)piperidin-l-yl)-7V-(2,6- dioxopiperidin-3-yl)picolinamide, 7V-(3-(2-(tert-butyl)-5-(2-((3-((l-( (R)-l-(5-((5)-2,6- dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidine-3-carbonyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((3-((l-(2-(4-(4-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperazin- l-yl)acetyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(terZ-butyl)-5-(2-((3-((l-(2-((5)-l-(4-((5)-2,6- dioxopiperidin-3-yl)phenyl)pyrrolidin-3-yl)acetyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, 7V- (3-(2-(terZ-butyl)-5-(2-((3-((l-(2-( (R)-l-(4-((5)-2,6-dioxopiperidin-3-yl)phenyl)pyrrolidin-3- yl)acetyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(l-((l-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(l- ((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N- (3-(2-(terZ-butyl)-5-(2-((4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(4-((l-(4-(2,6- dioxopiperi din-3 -yl)phenyl)piperi din-4-yl)m ethyl)piperazin- 1 -yl)-3- fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (25,47?)-l-((5)-2-(5-(4-(4-((4-(2-(terZ-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)phenyl)piperidin-l-yl)-5- oxopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-7V-((5)-l-(4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2-carboxamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((2-((l-(2-(2,6- dioxopiperi din-3-yl)- 1 -oxo-1, 2-dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)-l, 2,3,4- tetrahydroisoquinolin-6-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, 7V-(3-(2-(terZ-butyl)-5-(2-((l-((l-(((15,4r)-4-(4-((5)-2,6-dioxopiperidin-3- yl)phenoxy)cyclohexyl)methyl)piperidin-4-yl)methyl)-lJH-pyrazol-4-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N-(3 -(2-( ert-butyl)-5 -(2-(( 1 -(( 1 -((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4- yl )methyl)piperidin-4-yl)methyl)- l / / -pyrazol -4-yl )amino)pyrimidin-4-yl )thiazol -4-yl )-2- fluorophenyl)propane-l -sulfonamide, (R)-5-(4-((4-((4-((4-(2-(terZ-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-l / / -pyrazol-l- yl)methyl)piperi din- l-yl)methyl)piperi din- l-yl)-7V-(2,6-dioxopiperi din-3 -yl)picolinamide, N- (3 -(2-(terZ-butyl)-5 -(2-(( 1 -(( 1 -(2-((R)~ 1 -(5 -((5)-2, 6-dioxopiperi din-3 -yl)pyridin-2- yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)methyl)-lJ7-pyrazol-4-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((l-(l- ((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4- yl)methyl)piperidin-4-yl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-5-(4-((4-(4-((4-(2-(tert-butyl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-l / Z-pyrazol-l-yl)piperidin-l- yl)methyl)piperi din- l-yl)-7V-(2, 6-dioxopiperi din-3 -yl)picolinamide, 7V-(3-(2-(tert-butyl)-5-(2- ((l-(l-(2-( (R)-l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin- 4-yl)-lJH-pyrazol-4-yl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((l-(l-(2-((5)-l-(5-((,S)-2,6-dioxopiperidin-3- yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)-lJH-pyrazol-4-yl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((3-(l- ((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2-dihydroisoquinolin-6-yl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, N-(3 -(2-(terZ-butyl)-5 -(2-((3 -(1 -(2-((R)~ 1 -(5 -((5)-2, 6-dioxopiperi din-3 - yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane- 1 -sulfonamide, N-(3 -(2-(terZ-butyl)-5 -(2-((3 -( 1 -(2-((5)- 1 -(5 -((5)- 2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N- (3-(2-(terZ-butyl)-5-(2-((3-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidin- 4-yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(terZ-butyl)-5-(2-((3-((l-(((15,4r)-4-(4-((5)-2, 6- dioxopiperidin-3-yl)phenoxy)cyclohexyl)methyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-7V-(3-(2-(tert-butyl)-5-(2-((3-((l-((l-(2-(2,6-dioxopiperidin-3-yl)-l-oxo-l,2- dihydroisoquinolin-6-yl)piperidin-4-yl)methyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(terZ-butyl)-5-(2-((3-((l-(2-( (R)-l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, N- (3-(2-(terZ-butyl)-5-(2-((3-((l-(2-((5 -l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)pyrrolidin-3-yl)ethyl)piperidin-4-yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -(2-(tert-butyl)-5 -(2-((3 - (( 1 - (( 1 - (5 - (2 , 6- dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)methyl)piperidin-4- yl)oxy)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-5-(4-((4-(4-((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5- yl)pyrimidin-2-yl)amino)-lZZ-pyrazol-l-yl)piperidin-l-yl)methyl)piperidin-l-yl)-7V-(2,6- dioxopiperidin-3-yl)picolinamide, (R)-5-(4-((4-((4-((4-(2-(tert-butyl)-4-(2-fluoro-3-(propylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-yl)amino)-l / Z-pyrazol-l- yl)methyl)piperi din- l-yl)methyl)piperi din- l-yl)-7V-(2,6-dioxopiperi din-3 -yl)picolinamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(4-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4- carbonyl)piperazin-l-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-((4-(l-((l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)-2- methylthiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-((4-(l-((l-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4- yl)-2-methylthiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(5-(2-((5-(4-((l- (5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l-yl)pyridin-2- yl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- 7V-(3-(5-(2-((5-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazin-l- yl)pyridin-2-yl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, ( ?)-7V-(3-(5-(2-((5-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)pyri din-2 -yl)amino)pyrimi din-4-yl)-2-methylthi azol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(4-((l-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(4- ((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazin-l- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N- (3-(2-(terZ-butyl)-5-(2-((4-(4-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)piperazin-l-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, rac-(37?)-3-[6-(4-{4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl}amino)pyridin-3-yl]piperazine-l-carbonyl}piperidin-l-yl)pyridin-3-yl]piperidine-2,6- dione, (5)-7V-(3-(5-(2-((4-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((4-(4-( (R)-l-(5-( (R)-2,6- dioxopiperi din-3 -yl)pyridin-2-yl)pyrrolidine-3 -carbonyl)piperazin- 1 -y l)-3 - fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)- 7V-(3-(5-(2-((4-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((4-(4-( (R)-l-(5-( (R)-2,6- dioxopiperi din-3 -yl)pyridin-2-yl)pyrrolidine-3 -carbonyl)piperazin- 1 -y l)-3 - fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, rac- (35)-3-[6-(3-{4-[6-({4-[2-tert-butyl-4-(3-{ [ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)- l,3-thiazol-5-yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazine-l-carbonyl}azetidin-l- yl)pyri din-3 -yl]piperidine-2, 6-dione, (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(4-(2-(l-(4-((2,6- dioxopiperidin-3-yl)amino)-2-fluorophenyl)-4-hydroxypiperidin-4-yl)acetyl)piperazin-l-yl)- 3 -fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, ( ?)-7V-(3-(2-(tert-butyl)-5-(2-((4-(4-(2-(6-(2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin- 2(U7)-yl)acetyl)piperazin-l-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, 7V-(3-(2-(tert-butyl)-5-(2-((4-(4-((15,4r)-4-((5-((5)-2,6- dioxopiperi din-3 -yl)pyridin-2-yl)oxy)cy cl ohexane-1 -carbonyl)piperazin- l-yl)-3- fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)- 7V-(3-(2-(terZ-butyl)-5-(2-((4-(4-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)piperazin-l-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(4-((l-(5-(2,6- di oxopiperi din-3 -yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin- 1- yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N- (3-(2-(terZ-butyl)-5-(2-((4-(4-(2-(l-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4- yl)acetyl)piperazin-l-yl)-3-fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(terZ-butyl)-5-(2-((4-(4-((l-(5-(2,6- di oxopiperi din-3 -yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin- l-yl)-3- fluorophenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (5)- 7V-(3-(5-(2-((4-(l-(2-(l-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4-yl)acetyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, rac-(35)-3-{6-[4-({4-[6-({4-[4-(3-{ [ethyl (methyl)sulfamoyl]amino}-2-fluorophenyl)-2-methyl-l, 3-thi azol-5-yl]pyrimidin-2- yl } amino)pyri din-3 -yl]piperazin- 1 -yl }methyl)piperidin- 1 -yl]pyri din-3 -yl }piperidine-2,6- dione, rac-(35)-3-[6-(4-{4-[6-({4-[2-tert-butyl-4-(3-{ [ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-l, 3-thi azol-5-yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazine-l -carbonyl }-4- methylpiperi din- l-yl)pyri din-3 -yl]piperidine-2, 6-dione, (37?)-3-{4-[4-({4-[6-({4-[4-(3-{ [ethyl (methyl)sulfamoyl]amino}-2-fluorophenyl)-2-methyl-l, 3-thi azol-5-yl]pyrimidin-2- yl } amino)pyri din-3 -yl]piperazin- 1 -yl }methyl)piperidin- 1 -yl]phenyl }piperidine-2, 6-dione, rac-(35)-3-[6-(4-{4-[6-({4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fhrorophenyl)-2- methyl-1, 3-thi azol-5-yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazine-l -carbonyl Jpiperi din- l-yl)pyri din-3 -yl]piperidine-2, 6-dione, rac-(37?)-3-{6-[4-(2-{4-[6-({4-[4-(3-{ [ethyl (methyl)sulfamoyl]amino}-2-fluorophenyl)-2-methyl-l, 3-thi azol-5-yl]pyrimidin-2- yl}amino)pyridin-3-yl]piperazin-l-yl}-2-oxoethyl)piperidin-l-yl]pyridin-3-yl}piperidine-2,6- dione, (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(4-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine- 4-carbonyl)piperazin-l-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-(l-(4-(2,6- dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidin-4-yl)phenyl)amino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, rac-(35)-3-[4-(4-{4-[6-({4-[2-tert- butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l, 3-thi azol-5-yl]pyrimidin-2- yl}amino)pyridin-3-yl]piperazine-l-carbonyl}piperidin-l-yl)phenyl]piperidine-2, 6-dione, ( ?)-7V-(3-(2-(tert-butyl)-5-(2-((4-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-1 -sulfonamide, rac-(35)-3-{6-[4-({4-[6-({4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-2 -methyl- 1 ,3 -thiazol-5-yl]pyrimidin-2-yl } amino)pyri din-3 -yl]piperazin- 1 - yl}methyl)-4-methylpiperidin-l-yl]pyridin-3-yl}piperidine-2, 6-dione, rac-(35)-3-{4-[4-({4- [6-({4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-2 -methyl-1, 3-thi azol-5- yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazin-l-yl}methyl)-4-fluoropiperidin-l- yl]phenyl}piperidine-2, 6-dione, (5 -7V-(3-(5-(2-((4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)methyl)piperazin-l-yl)phenyl)amino)pyrimidin-4-yl)-2- methylthiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-((4-(4-((l-(4-(2,6- dioxopiperi din-3 -yl)phenyl)-4-fluoropiperidin-4-yl)methyl)piperazin-l- yl)phenyl)amino)pyrimidin-4-yl)-2-methylthiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, rac-(37?)-3-{6-[6-({4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl}amino)pyridin-3-yl]piperazin-l-yl}methyl)-2-azaspiro[3.3]heptan-2-yl]pyridin-3- yl}piperidine-2, 6-dione, (37?)-3-{6-[4-({4-[6-({4-[2-tert-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2- yl } amino)pyri din-3 -yl]piperazin- 1 -yl }methyl)piperidin- 1 -yl]pyri din-3 -yl }piperidine-2,6- dione, rac-(37?)-3-[2-(2-{4-[4-({4-[2-terZ-butyl-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-l,3-thiazol-5-yl]pyrimidin-2-yl}amino)-2-fluorophenyl]piperazin-l-yl}-2- oxoethyl)-l,2,3,4-tetrahydroisoquinolin-6-yl]piperidine-2,6-dione, and (37?)-3-{6-[4-({4-[6- ({4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-2-methyl-l,3-thiazol-5- yl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridin-3- yl}piperidine-2, 6-dione.

69. The compound of any one of claims 2, 10-17, 31-33, or 53-64 selected from the group consisting of (5)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-17 / -pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, ( ?)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-17 / -pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, and (5)-7V-(3-(l-(4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin- 4-yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-17 / -pyrazol-4-yl)-2- fluoropheny l)prop ane- 1 - sulfonami de .

70. The compound of any one of claims 2, 31-33, or 53-64 selected from the group consisting of ( ?)-7V-(3-(l-(4-(4-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4- carbonyl)piperazine-l-carbonyl)phenyl)-3-(pyridin-4-yl)-177-pyrazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidin-4-yl)methyl)piperazine-l-carbonyl)phenyl)-3-(pyridin-4-yl)-17 / -pyrazol- 4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(l-(4-(4-(l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidine-4-carbonyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-17 / -pyrazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(l-(4-((l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidin-4-yl)oxy)phenyl)-3-(pyridin-4-yl)-177- pyrazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(l-(4-(4-((l-(5-(2,6- dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidin-4-yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-l / / -pyrazol-4-yl)-2-fluorophenyl)propane- l -sulfonamide, (R)-7V-(3-(l-(4-(4- ((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazine-l-carbonyl)phenyl)-3 -(pyridin-4-yl)- lZ7-pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -( 1 -(1 -( 1 - (l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)-3-fluorophenyl)piperidin-4-yl)methyl)piperazin-l- yl)phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N- (3-(l-(4-(l-((l-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)methyl)piperidin- 4-yl)phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- 7V-(3-(l-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperi din-3 -yl)-2-fluorophenyl)piperi din-4- yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (5)-7V-(3-(l-(6-(4-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)pyri din-3 -yl)-3-(pyri din-4-yl)- 1 / 7-pyrazol -4-yl)-2- fluorophenyl)propane-l -sulfonamide, (7?)-7V-(3-(l-(4-(4-(2-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidin-4-yl)acetyl)piperazine-l-carbonyl)phenyl)-3-(pyridin-4-yl)-lJH- pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -( 1 - ( 1 - ( 1 -(( 1 - ( 5 -(2 , 6 - dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)- 3 -(pyridin-d-y^-l / f-pyrazol-d-y^-Z-fluoropheny^propane-l -sulfonamide, (5)-7V-(3-(l-(4-(4- ((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(l-(6-(4- ((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l-yl)pyridin-3- yl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(l-(4- (l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)-3- (pyridin-4-yl)- 1 J7-pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -(1 -(4-( 1 -((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)-3- (pyridin-4-yl)- 1 J7-pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -(1 -(4-( 1 -((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(l-(4-(4- ((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)-3- (pyridin-4-yl)- I / / -py razol -4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -(1-(1-(1-(1- (5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-3-(pyridin-4-yl)- IT / -pyrazol-4-yl)-2-fluorophenyl)propane- l- sulfonamide, (5)-7V-(3-(l-(4-(l-((l-(4-(2,6-dioxopiperidin-3-yl)-3-fluorophenyl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)-3-(pyridin-4-yl)- IT / -pyrazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, and (7?)-7V-(3-(l-(4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin- 4-yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-17 / -pyrazol-4-yl)-2- fluoropheny l)prop ane- 1 - sulfonami de .

71. The compound of any one of claims 34, 37-45, or 50-54 selected from the group consisting of (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)-4-methylpiperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2- aminopyrimidin-4-yl)-2-(l -(l-(l-(5-(2,6-di oxopiperi din-3 -yl)pyri din-2 -yl)piperidine-4- carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(4- (2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l- (l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, and (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5- (pyridin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide.

72. The compound of any one of claims 34, 37, 44, 45, or 50-64 selected from the group consisting of (7?)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(4-(3-(2-(2,6-dioxopiperidin-3-yl)- l,3-dioxoisoindolin-4-yl)propyl)piperazin-l-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol- 4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((15,4r)- 4-((6-((5)-2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(177)-yl)methyl)cyclohexane-l- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l- (l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-5-yl)piperazin-l-yl)acetyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(r-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-[l,4'-bipiperidin]-4-yl)acetyl)-4- methylpiperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidine-4-carbonyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-(2-(6- (2,6-dioxopiperidin-3-yl)-3,4-dihydroisoquinolin-2(U7)-yl)acetyl)piperidin-4- yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N-(3-(2- (l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(pyridin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(r-(2-(2,6-dioxopiperidin-3-yl)-1.3-dioxoisoindolin-5-yl)-[l,4'-bipiperidin]-4-yl)acetyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(4-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperazin-l-yl)acetyl)piperidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-( 1 -( 1 -(1 -(2-(2,6-dioxopiperi din-3 -yl)- 1 ,3-dioxoisoindolin-5-yl)piperidin-4- yl)azetidine-3-carbonyl)piperidin-4-yl)propan-2-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-((17?,4r)-4-(3-(( ?)-2,6- dioxopiperi din-3 -yl)phenoxy)cy cl ohexane-l-carbonyl)piperidin-4-yl)methyl)piperi din-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(3-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5- (2-aminopyrimidin-4-yl)-2-(l-(l-(2-(l-(4-((2,6-dioxopiperidin-3-yl)amino)-2-fluorophenyl)- 4-hydroxypiperidin-4-yl)acetyl)azetidin-3-yl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-(2-(l-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)acetyl)piperidin-4-yl)phenyl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-((l- (4-(2, 6-dioxopiperi din-3 -yl)phenyl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)thi azol -4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-(2- (l-(4-((2,6-dioxopiperi din-3 -yl)amino)phenyl)piperi din-4-yl)acetyl)piperi din-4- yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(4-(l-(l-(5-(2,6-dioxopiperi din-3-yl)pyri din-2 -yl)piperidine-4- carbonyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, N-(3- (5-(2-aminopyrimidin-4-yl)-2-(3-(((15,4r)-4-((5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)oxy)cyclohexyl)methyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(l-(4- (2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperazin-l-yl)phenyl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-5-(4-(9-(5-(2-aminopyrimidin-4-yl)-4-(2-fluoro-3- (propylsulfonamido)phenyl)thiazol-2-yl)-3-azaspiro[5.5]undecane-3-carbonyl)piperidin-l- yl)-7V-(2,6-dioxopiperidin-3-yl)picolinamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-((5)-l- (5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)pyrrolidin-3-yl)ethyl)-3-azaspiro[5.5]undecan-9- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)- 2-(l-(l-(2-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)acetyl)azetidin-3- yl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(3-(l -(5-(2,6-di oxopiperidin-3-yl)pyri din-2 -yl)piperidine-4- carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4- carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyridin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-((l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2- (methylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N-(3 - (5-(2-aminopyrimidin-4-yl)-2-(2-(2-(l'-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)-[l,4'-bipiperidin]-4-yl)acetyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyridin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2- (l-((l-(((15,4r)-4-(4-((5)-2,6-dioxopiperidin-3-yl)phenoxy)cyclohexyl)methyl)piperidin-4-yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3- 5- (2-aminopyrimidin-4-yl)-2-(2-(l-(2-(2, 6-dioxopiperi din-3-yl)- 1,3 -di oxoisoindolin-5- yl)piperidine-4-carbonyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(2-(l-(4-((2,6-dioxopiperidin-3-yl)amino)phenyl)piperidin-4- yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(l-(l-(l-(5- (2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin- 4-yl)ethyl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3- 5-(2- aminopyrimidin-4-yl)-2-(2-(2-(4-(2-(2, 6-dioxopiperi din-3-yl)- 1,3 -di oxoisoindolin-5- yl)piperazin-l-yl)acetyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, ( ?)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperazin-l-yl)phenyl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(l-(l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(4-(4-((l-(4-(2, 6-dioxopiperi din-3-yl)phenyl)piperidin-4- yl)methyl)piperazin-l-yl)phenyl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (S)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-(l-(5-(2,6-dioxopiperidin-3-yl)pyri din-2- yl)piperidine-4-carbonyl)piperidin-4-yl)methyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-(2-(l-(5- (2, 6-dioxopiperi din-3 -yl)pyri din-2 -yl)piperi din-4-yl)acetyl)piperazin- l-yl)phenyl)thi azol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(r- (2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-[l,4'-bipiperidin]-4-yl)acetyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5- (2-aminopyrimidin-4-yl)-2-(l-(l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4- yl)methyl)piperidine-4-carbonyl)-4-methylpiperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(4-(2,6-dioxopiperidin-3- yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)-5-(2- (isopropylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N- (3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(4-(2-(2, 6-dioxopiperi din-3-yl)-l,3-dioxoisoindolin-5- yl)piperazin-l-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-1 -sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-((l-((17?,4r)-4-(4-(( ?)-2,6- dioxopiperi din-3 -yl)phenoxy)cy cl ohexane-l-carbonyl)piperidin-4-yl)methyl)piperi din-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-(6-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-2- azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, 7V-(3-(2-(l-(l- (l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)-5-(2-((( ?)-l-hydroxypropan-2-yl)amino)pyrimidin-4-yl)thiazol-4- yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(4-(4-((l- (5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)thiazol- 4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, rac-(35)-3 - { 6- [4 - (4 - {4-[5-(2-aminopyrimidin- 4-yl)-4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-l,3-thiazol-2-yl]piperidine-l- carbonyl}piperidine-l-carbonyl)piperidin-l-yl]pyridin-3-yl}piperidine-2, 6-dione, rac-(35)-3- {6-[4-(4-{4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-5-{2-[(propan-2- yl)amino]pyrimidin-4-yl } - 1 ,3 -thiazol-2-yl]piperidine- 1 -carbonyl } piperi dine- 1 - carbonyl)piperidin-l-yl]pyridin-3-yl}piperidine-2, 6-dione, (5)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(l-(l-((l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidin-4-yl)methyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)- V-(3-(5-(2- aminopyrimidin-4-yl)-2-(l-(l-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-((l-(2-(2,6-dioxopiperidin-3-yl)-l- oxoisoindolin-5-yl)piperidin-4-yl)methyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(2-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-4- methylpiperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3- 5-(2- aminopyrimidin-4-yl)-2-(3-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidine-4-carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, ( ?)-7V-(3-(2-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)- 2,7 -di azaspiro [3.5 ]nonan-7 -yl)acetyl)piperidin-4-yl)-5-(2-(methylamino)pyrimidin-4- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(3-(6-(2-(2,6-dioxopiperidin-3-yl)-3-oxoisoindolin-5-yl)hexanoyl)-3- azaspiro[5.5 ]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3- 5- (2-aminopyrimidin-4-yl)-2-(l-(l-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)-4-methylpiperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3- yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2- (methylamino)pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- 1 -sulfonamide, (R)-N-(3 - (5-(2-aminopyrimidin-4-yl)-2-(l-(l-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin- 4-yl)acetyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (5)-7V-(3-(2-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4- carbonyl)piperidine-4-carbonyl)piperidin-4-yl)-5-(2-(isopropylamino)pyrimidin-4-yl)thiazol- 4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(5-(2-(cyclopropylamino)pyrimidin-4- yl)-2-(l-(l-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidine-4-carbonyl)piperidine-4- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (5)-7V-(3-(2-(l- (l-(l-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperidine-4-carbonyl)-4-methylpiperidine-4- carbonyl)piperidin-4-yl)-5-(pyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, 7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-( (R)-l-(4-((, )-2,6-dioxopiperidin-3- yl)phenyl)pyrrolidin-3-yl)acetyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(2-(2-(2-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-2- azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(l-((l-(2-(l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)acetyl)piperidin-4-yl)methyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l- sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)- l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)piperidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(l-(l-(2,6- dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[d]imidazol-4-yl)piperidine-4- carbonyl)-3-azaspiro[5.5]undecan-9-yl)thiazol-4-yl)-2-fluorophenyl)propane-l-sulfonamide, (R)-7V-(3-(2-(l-(l-((l-(4-(2,6-dioxopiperi din-3 -yl)phenyl)piperi din-4-yl)methyl)piperi dine-4- carbonyl)piperidin-4-yl)-5-(2-(methylamino)pyrimidin-4-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(l-(l-(l-(2- (2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)piperidin-4-yl)azetidine-3- carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-N-(3-(5-(2- aminopyrimidin-4-yl)-2-(2-(l-(l-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5- yl)piperidin-4-yl)azetidine-3-carbonyl)-2-azaspiro[3.5]nonan-7-yl)thiazol-4-yl)-2- fluorophenyl)propane- 1 -sulfonamide, (S)-N-(3 -(5-(2-aminopyrimidin-4-yl)-2-(l -( 1 -(( 1 -( 1 - (2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[ ]imidazol-4-yl)piperidin-4-yl)methyl)piperidine-4-carbonyl)piperidin-4-yl)thiazol-4-yl)-2-fluorophenyl)propane- l - sulfonamide, ( ?)-7V-(3-(5-(2-aminopyrimidin-4-yl)-2-(3-(2-(2-(2-(2,6-dioxopiperidin-3-yl)- l,3-dioxoisoindolin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)acetyl)-3-azaspiro[5.5]undecan-9- yl)thiazol-4-yl)-2-fluorophenyl)propane-l -sulfonamide, (R)-7V-(3-(5-(2-aminopyrimidin-4- yl)-2-(2-(l-(2-(2-(2-(2,6-dioxopiperidin-3-yl)-l,3-dioxoisoindolin-5-yl)-2,7- diazaspiro[3.5]nonan-7-yl)acetyl)piperidin-4-yl)propan-2-yl)thiazol-4-yl)-2- fluorophenyl)propane-l -sulfonamide, and (R)-4-((4-(5-(2-aminopyrimidin-4-yl)-4-(2-fluoro- 3-(propylsulfonamido)phenyl)thiazol-2-yl)piperidin-l-yl)methyl)-7V-(2,6-dioxopiperidin-3- yl)benzamide.

73. The compound of claim 1, wherein X1is carbon; X2is nitrogen, X3is nitrogen; X4is carbon; and X5is hydrogen.

74. The compound of claim 73, whereinR1is alkyl, dialkylamino, cycloalkyl, or heterocycloalkyl each unsubstituted or substituted with one or more halogen;Rlais halogen;Rih is hydrogen, haloalkyl or halogen;R2is -[A Z^n-Z^Cy^Z’-L-UBM;Ar1is arylene or heteroarylene, each unsubstituted or substituted with one or more halogen;Z1is a bond; n is one;Z2is absent;Cy1is absent or heterocycloalkylene, unsubstituted or substituted with one or more alkyl or one or more halogen;Z3is absent or Ci-io alkylene;L is a linker according to -L4-L2-L3-L4- or -L4-L3-L2-L1-, wherein-L1- is -Q1- or -Q2-; each -L2-, -L3-, and -L4- is independently, absent, -Ci-8 alkylene-, or -Q1-; each -Q1- is a three- to seven-membered heterocycloalkylene comprising at least one nitrogen and is unsubstituted or substituted with one or more methyl or halogen;each -Q2- is a five- to thirteen-membered bicyclic heterocycloalkylene comprising at least one nitrogen, wherein the five- to thirteen-membered bicyclic heterocycloalkylene is optionally a spiro bicyclic heterocycloalkylene ring; andUBM is a ubiquitin ligase binding moiety; or a stereoisomer and / or pharmaceutical salt thereof.

75. The compound of claim 73 or 74, wherein R1is selected from the group consisting of76. The compound of any one of claims 73-75, wherein Rlais chloro or fluoro; and Rlbis hydrogen, chloro, fluoro, or haloalkyl.

77. The compound of any one of claims 73-76, wherein Ar1is arylene or heteroarylene unsubstituted or substituted with one or two halogen.

78. The compound of any one of claims 73-77, wherein UBM binds an E3 ubiquitin ligase.

79. The compound of claim 78, wherein UBM binds SCFP-TRCP, VHL, MDM2, IAP, or CRBN.

80. The compound of claim 79, wherein UBM binds CRBN.

81. The compound of claim 80, wherein UBM binds CRBN and has the following chemical formulawhereinX6absent or NR3;X7absent or -C(O)-; andX8is arylene or heteroarylene.

82. The compound of claim 81, wherein UBM binds CRBN and is selected from the groupX9is absent or halogen; and m is one, two, three, or four.

83. The compound of any one of claims 1 or 73-82, wherein the compound is selected from the group consisting of (R)-7V-(5-chloro-3-(l-(4-(4-((l-(5-(2,4-dioxotetrahydropyrimidin- l(2J7)-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-lJT- pyrazol-4-yl)-2-fluorophenyl)-3 -fluoropyrrolidine- 1 -sulfonamide; (R)-7V-(5-chloro-3-(l-(4-(4- ((l-(5-(( ?)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l- yl)phenyl)-3 -(pyridin-4-yl)- 177-pyrazol -4-yl )-2-fl uorophenyl )-3 -fluoropyrrolidine- 1 - sulfonamide; rac-( ?)-7V-(5-chloro-3-(l-(4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-17 / -pyrazol-4-yl)-2- fluorophenyl)pyrrolidine-l -sulfonamide; rac- (R)-7V-(5-chloro-3-(l-(4-(4-((l-(5-(2,6-di oxopiperi din-3 -yl)pyri din-2-yl)piperi din-4-yl)methyl)piperazin- 1 -yl)-2-fluorophenyl)-3 - (pyridin-4-yl)-l / / -pyrazol-4-yl)-2-fluorophenyl)pyrrolidine-l -sulfonamide; rac-(7?)-7V-(3-(l- (4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin-l- yl)phenyl)-3-(pyridin-4-yl)-l / / -pyrazol-4-yl)-2,5-difluorophenyl)pyrrolidine-l -sulfonamide; 7V-(5-chloro-3-(l-(4-( (R)-4-((l-(5-((7?5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)-3-methylpiperazin-l-yl)phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2- fluorophenyl)pyrrolidine-l -sulfonamide; (7?)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)- 2-fluorophenyl)piperidin-4-yl)methyl)piperazin-l-yl)-2-fluorophenyl)-3-(pyridin-4-yl)-lJH- pyrazol-4-yl)-2,5-difluorophenyl)cyclopentanesulfonamide; rac-(7?)-7V-(3-(l-(4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperazin-l-yl)-3-fluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2,5- difluorophenyl)cyclopentanesulfonamide; rac-(7?)-7V-(5-chloro-3-(l-(4-(4-((l-(5-(2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4- yl)methyl)piperazin-l-yl)-3-fluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2- fluorophenyl)cyclopentanesulfonamide;(R)-N-(5 -chi oro-3 -( 1 -(4-(4-(( 1 -(4-(2, 6-dioxopiperi din-3 -yl)-2-fluorophenyl)piperidin-4- yl)methyl)piperazin-l-yl)-3-fluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2- fluorophenyl)cyclopentanesulfonamide;(R)-N-(5 -chi oro-3 -( 1 -(4-(4-(( 1 -(4-(2, 6-dioxopiperi din-3 -yl)-2-fluorophenyl)piperidin-4- yl)methyl)-l,4-diazepan-l-yl)-2-fluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2- fluorophenyl)pyrrolidine- 1 -sulfonamide; (R)-7V-(3-(l-(4-(4-((l-(4-(2,6-dioxopiperidin-3-yl)-2-fluorophenyl)piperidin-4-yl)methyl)-l,4- diazepan-l-yl)-2-fluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2,5- difluorophenyl)pyrrolidine-l -sulfonamide; 7V-[5-chloro-3-(l-{4-[(37?)-4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]-3-methylpiperazin-l-yl]phenyl}-3- (pyridin-4-yl)-l / / -pyrazol-4-yl)-2-fluorophenyl]propane-l-sulfonamide; 7V-[5-chloro-3-(l-{4- [(37?)-4-[(l-{5-[(37?5)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]-3- methylpiperazin-l-yl]phenyl}-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl]propane-l- sulfonamide; 7V-[5-chloro-3-(l-{4-[(37?)-4-({ l-[4-(2,4-dioxo-l,3-diazinan-l- yl)phenyl]piperidin-4-yl}methyl)-3-methylpiperazin-l-yl]phenyl}-3-(pyridin-4-yl)-lJ7- pyrazol-4-yl)-2-fluorophenyl]propane-l -sulfonamide; 7V-[5-chloro-3-(l-{4-[(35)-4-[(l-{4- [(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]-3-methylpiperazin-l- yl]phenyl} -3 -(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl]propane-l -sulfonamide; 7V-[5-chloro-3-Cl - { 4-[(3KS')-4-[( 1 - { 5-[(3 / ^S')-2,6-dioxopiperidin-3-yl]pyridin-2-yl } piperidin-4- yl)methyl]-3-methylpiperazin-l-yl]phenyl }-3-(pyridin-4-yl)-U7-pyrazol-4-yl)-2- fluorophenyl]propane-l -sulfonamide; 7V-[5-chloro-3-(l-{4-[(35)-4-({l-[4-(2,4-dioxo-l,3- diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)-3 -methylpiperazin- 1 -yl]phenyl } -3 -(pyridin-4- yl)-l / / -pyrazol-4-yl)-2-fluorophenyl]propane-l -sulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l-{4- [(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}-2-fluorophenyl)- 3-(pyridin-4-yl)-U7-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l -sulfonamide; 7V-{5-chloro-3- [l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l- yl }phenyl)-3 -(pyridin-4-yl)- 1 / / -pyrazol -4-yl ]-2-fl uorophenyl } pyrrol i dine- 1 -sulfonamide; N- [5-chloro-3-(l-{4-[4-({l-[4-(2,4-dioxo-l,3-diazinan-l-yl)phenyl]piperidin-4- yl}methyl)piperazin-l-yl]phenyl}-3-(pyridin-4-yl)-U7-pyrazol-4-yl)-2- fluorophenyl]pyrrolidine-l -sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl}-4-fluoropiperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)-l / / -pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l -sulfonamide; 7V-{5-chloro-3- [l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-1-yl}phenyl)-3-(pyridin-4-yl)-U7-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l-sulfonamide; 7V-{5-chloro-3-[l-(5-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4- yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyridin-4-yl)-U7-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; 7V-[5-chloro-3-(l-{5-[4-({l-[4-(2,4-dioxo-l,3- diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)piperazin- 1 -yl]pyri din-2 -yl } -3 -(pyridin-4-yl)- l / Z-pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; rac-7V-{5-chloro-3-[l-(5-{4-[(l- {5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyridin-4-yl)-lJ7-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l-sulfonamide; 7V-(3-(l-(4-( (R)-4-((l-(5-((7?5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)-3- methylpiperazin- 1 -yl)-2-fluorophenyl)-3 -(pyridin-4-yl)- 1 H-py razol-4-yl)-2, 5 - difluorophenyl)pyrrolidine- 1 -sulfonamide; N- { 5 -chi oro-3 - [l-(5-{4-[(l-{ 5 - [ (37?) -2 , 6 - dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2-yl)-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l-sulfonamide; (3R)-N-{5- chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4- yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-U7-pyrazol-4-yl]-2-fluorophenyl}-3- fluoropyrrolidine-1 -sulfonamide; (37?)-7V-[5-chloro-3-(l-{4-[4-({l-[4-(2,4-dioxo-l,3- diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)piperazin- 1 -yl]phenyl } -3 -(pyridin-4-yl)- 1H- pyrazol-4-yl)-2-fluorophenyl]-3 -fluoropyrrolidine- 1 -sulfonamide; (3R)-N- { 5-chl oro-3 -[ 1 -(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l- yl }phenyl)-3 -(pyridin-4-yl)- 177-pyrazol -4-yl ]-2-fl uorophenyl } -3 -fluoropyrrolidine- 1 - sulfonamide; (37?)-7V-{5-chloro-3-[l-(5-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3- yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyridin-4-yl)-lJH-pyrazol-4- yl]-2-fluorophenyl}-3-fluoropyrrolidine-l-sulfonamide; (37?)-zV-[5-chloro-3-(l-{5-[4-({ l-[4- (2,4-dioxo-l,3-diazinan-l-yl)phenyl]piperidin-4-yl}methyl)piperazin-l-yl]pyridin-2-yl}-3- (pyridin-4-yl)-l / / -pyrazol-4-yl)-2-fluorophenyl]-3-fluoropyrrolidine-l -sulfonamide; (3R)-N- {5-chloro-3-[l-(5-{4-[(l-{5-[(37?5)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyridin-4-yl)-lJ7-pyrazol-4-yl]-2-fluorophenyl}-3- fluoropyrrolidine- 1 -sulfonamide; (37?)-7V-{5-chloro-3-[l-(5-{4-[(l-{5-[(37?)-2,6- dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2-yl)-3- (pyridin-4-yl)-17 / -pyrazol-4-yl]-2-fluorophenyl [-3-fluoropyrrolidine-l -sulfonamide; (3R)-N- {5-chloro-3-[l-(5-{4-[(7-{4-[(37?5)-2,6-dioxopiperidin-3-yl]phenyl}-7-azaspiro[3.5]nonan-2- yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyridin-4-yl)-177-pyrazol-4-yl]-2-fluorophenyl}-3- fluoropyrrolidine- 1 -sulfonamide; 7V-{3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3- yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2.5-difluorophenyl}pyrrolidine-l-sulfonamide; 7V-[3-(l-{4-[4-({l-[4-(2,4-dioxo-l,3-diazinan- l-yl)phenyl]piperidin-4-yl}methyl)piperazin-l-yl]phenyl}-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2.5-difluorophenyl]pyrrolidine-l-sulfonamide; 7V-{3-[l-(4-{4-[(l-{5-[(37?)-2,6- dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4- yl)-17 / -pyrazol-4-yl]-2,5-difluorophenyl [pyrrolidine-1 -sulfonamide; (37?)-7V-{3-[l-(5-{4-[(l - {4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2-yl)- 3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2,5-difluorophenyl}-3-fluoropyrrolidine-l-sulfonamide; (37?)-7V-[3-(l-{5-[4-({l-[4-(2,4-dioxo-l,3-diazinan-l-yl)phenyl]piperidin-4- yl}methyl)piperazin-l-yl]pyridin-2-yl}-3-(pyridin-4-yl)-177-pyrazol-4-yl)-2,5- difluorophenyl]-3-fluoropyrrolidine-l-sulfonamide; (37?)-7V-{3-[l-(5-{4-[(l-{5-[(3R5)-2,6- dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2-yl)-3- (pyridin-4-yl)-177-pyrazol-4-yl]-2,5-difluorophenyl}-3-fluoropyrrolidine-l -sulfonamide; (37?)-7V-{3-[l-(5-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin-l-yl}pyridin-2-yl)-3-(pyridin-4-yl)-177-pyrazol-4-yl]-2,5- difluorophenyl } -3 -fluoropyrrolidine- 1 -sulfonamide; (3R)-3 -(4- { 4- [(4- { 4- [4 - (5 -chi oro-3 -{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-lJ7-pyrazol-l- yl]phenyl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidine-2, 6-dione; l-(4-{4-[(4-{4-[4-(5-chloro-3-{ [ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-lJ7- pyrazol-l-yl]phenyl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)-l,3-diazinane-2, 4-dione; rac-(37?)-3-(6-{4-[(4-{4-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3- (pyridin-4-yl)- 1 / / -pyrazol - 1 -yl]phenyl } piperazin- 1 -yl)methyl]piperidin- 1 -yl Jpyri din-3 - yl)piperidine-2, 6-dione; (37?)-3-(6-{4-[(4-{4-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-lJ7-pyrazol-l- yl]phenyl}piperazin-l-yl)methyl]piperidin-l-yl}pyridin-3-yl)piperidine-2, 6-dione; (37?)-3-(4- {4-[(4-{6-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)- I / / -pyrazol - 1 -yl]pyri din-3 -yl } piperazin- 1 -yl)methyl]piperidin- 1 -yl [ phenyl )pi peri di ne-2, 6- dione; l-(4-{4-[(4-{6-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3- (pyridin-4-yl)-l / / -pyrazol-l-yl]pyridin-3-yl [piperazin-l-yl)methyl]piperidin-l-yl [phenyl)-1.3-diazinane-2, 4-dione; rac-(37?)-3-(6-{4-[(4-{6-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-lJ7-pyrazol-l-yl]pyridin-3-yl}piperazin-l-yl)methyl]piperidin-l-yl}pyridin-3-yl)piperidine-2, 6-dione; l-(6-{4-[(4-{6- [4-(5-chloro-3-{ [ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-lJ7- pyrazol-l-yl]pyridin-3-yl}piperazin-l-yl)methyl]piperidin-l-yl}pyridin-3-yl)-l,3-diazinane-2.4-dione; (37?)-3-(6-{4-[(4-{6-[4-(5-chloro-3-{[ethyl(methyl)sulfamoyl]amino}-2- fluorophenyl)-3 -(pyridin-4-yl)- I / / -py razol - 1 -yl]pyri din-3 -yl } piperazin- 1 - yl)methyl]piperidin-l-yl}pyridin-3-yl)piperidine-2, 6-dione; (37?)- V-[5-chloro-3-(l-{4-[(37?)-4-({ 1 -[4-(2,4-dioxo- 1 ,3 -diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)-3 -methylpiperazin- 1 - yl]phenyl} -3 -(pyridin-4-yl)-l / / -pyrazol-4-yl)-2-fluorophenyl]-3 -fluoropyrrolidine- 1- sulfonamide; 7V-[5-chloro-3-(l-{4-[(37?)-4-[(l-{4-[(37?)-2,6-dioxopiperidin-3- yl]phenyl}piperidin-4-yl)methyl]-3-methylpiperazin-l-yl]phenyl}-3-(pyridin-4-yl)-lJ7- pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; (37?)- V-[5-chloro-3-(l-{4-[(37?)-4- [(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]-3-methylpiperazin-l- yl]phenyl} -3 -(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl]-3 -fluoropyrrolidine- 1- sulfonamide; (37?)-7V-[5-chloro-3-(l-{4-[(37?)-4-[(l-{5-[(37?5)-2,6-dioxopiperidin-3- yl]pyridin-2-yl }piperidin-4-yl)methyl]-3 -methylpiperazin- 1 -yl]phenyl } -3 -(pyridin-4-yl)- 1H- pyrazol-4-yl)-2-fluorophenyl]-3-fluoropyrrolidine-l-sulfonamide; 7V-[5-chloro-3-(l-{4-[(37?)- 4-({ 1 -[4-(2,4-dioxo- 1 ,3 -diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)-3 -methylpiperazin- 1 - yl]phenyl} -3 -(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide;(37?)-7V-[5-chloro-3-(l-{5-[(37?)-4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4- yl)methyl]-3 -methylpiperazin- 1 -yl]pyri din-2 -yl } -3 -(pyridin-4-yl)- l / 7-pyrazol-4-yl)-2-fluorophenyl]-3-fluoropyrrolidine-l-sulfonamide; (37?)-7V-[5-chloro-3-(l-{5-[(37?)-4-[(l-{5- [(37?5)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]-3-methylpiperazin-l- yl]pyridin-2-yl } -3 -(pyridin-4-yl)- 17 / -py razol -4-yl )-2-fl uorophenyl ]-3 -fluoropyrrolidine- 1 - sulfonamide; (37?)-7V-[5-chl oro-3 -(1 - { 5-[(37?)-4-({ 1 -[4-(2,4-dioxo- 1 ,3 -diazinan- 1 - yl)phenyl]piperidin-4-yl}methyl)-3-methylpiperazin-l-yl]pyridin-2-yl}-3-(pyridin-4-yl)-lJH- pyrazol-4-yl)-2-fluorophenyl]-3-fluoropyrrolidine-l-sulfonamide; 7V-[5-chloro-3-(l-{5-[(37?)- 4-[(l-{5-[(37?5)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]-3- methylpiperazin-l-yl]pyridin-2-yl}-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2- fluorophenyl]pyrrolidine- 1 -sulfonamide; 7V-[5-chloro-3 -( 1 -{ 5 - [(37?)-4-( { 1 -[4-(2,4-dioxo- 1,3- diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)-3 -methylpiperazin- 1 -yl]pyridin-2-yl }-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l-sulfonamide; 7V-[5-chloro-3-(l- {5-[(37?)-4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]-3- methylpiperazin-l-yl]pyridin-2-yl}-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2- fluorophenyl]pyrrolidine-l -sulfonamide; 7V-[5-chloro-3-(l-{5-[(37?)-4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]-3-methylpiperazin-l-yl]pyridin-2-yl}-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l-sulfonamide; (7?5)-7V-(5-chloro- 3-(l-(4-(4-((l-(5-((7?)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)piperazin- 1 -yl)phenyl)-3 -(pyridin-4-yl)- 17 / -py razol -4-yl )-2-fl uorophenyl )butane-2-sulfonami de; rac-(27?)-7V-[5-chl oro-3 -(1 - { 4- [4-({ 1 -[4-(2,4-dioxo- 1 ,3 -diazinan- 1 -yl)phenyl]piperidin-4- yl}methyl)piperazin-l-yl]phenyl}-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl]butane- 2-sulfonamide; rac- (R)-7V-(5-chloro-3-(l-(4-(4-((l-(5-((5)-2,6-dioxopiperidin-3-yl)pyridin-2- yl)piperidin-4-yl)methyl)piperazin-l-yl)phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2- fluorophenyl)butane-2-sulfonamide; (27?S)-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)- l / / -pyrazol-4-yl]-2-fluorophenyl }butane-2-sulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l-{5- [(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl]-2-fluorophenyl}-3-fluoroazetidine-l-sulfonamide; rac-7V-{5- chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2-fluorophenyl}-3- fluoroazetidine-1 -sulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3- yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2- fluorophenyl } -3 -fluoroazetidine- 1 -sulfonamide; (3R)-N- { 5 -chi oro-3 -[l-(4-{4-[(l-{5 -[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}-2-fluorophenyl)-3-(pyridin-4-yl)-l / / -pyrazol-4-yl]-2-fluorophenyl ( -3 -fluoropyrrolidine- 1 -sulfonamide; (37?)- 7V-{5-chloro-3-[l-(4-{4-[(l-{5-[(37?S)-2,6-dioxopiperidin-3-yl]pyridin-2-yl(piperidin-4- yl)methyl]piperazin-l-yl(-2-fluorophenyl)-3-(pyridin-4-yl)-177-pyrazol-4-yl]-2- fluorophenyl} -3 -fluoropyrrolidine- 1 -sulfonamide; (37?)-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)- 2,6-dioxopiperidin-3-yl]phenyl(piperidin-4-yl)methyl]piperazin-l-yl(-2-fluorophenyl)-3- (pyridin-4-yl)- l / / -pyrazol-4-yl]-2-fluorophenyl }-3-fluoropyrrolidine- l -sulfonamide; rac-7V- {5-chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl(piperidin-4- yl)methyl]piperazin-l-yl(-2-fluorophenyl)-3-(pyridin-4-yl)-177-pyrazol-4-yl]-2- fluorophenyl} -3 -fluoroazetidine- 1 -sulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl(piperidin-4-yl)methyl]piperazin-l-yl(-2-fluorophenyl)-3- (pyridin-4-yl)-177-pyrazol-4-yl]-2-fluorophenyl(-3-fluoroazetidine-l-sulfonamide; 7V-[5- chl oro-3-(l-{4-[4-({l-[4-(2,4-di oxo-1, 3-diazinan-l -yl)phenyl]piperidin-4- yl }methyl)piperazin- 1 -yl]-2-fluorophenyl ( -3 -(pyridin-4-yl)- 177-pyrazol-4-yl)-2- fluorophenyl]-3 -fluoroazetidine- 1 -sulfonamide; 7V-{3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl(piperidin-4-yl)methyl]piperazin-l-yl(-2-fluorophenyl)-3- (pyridin-4-yl)-177-pyrazol-4-yl]-2,5-difluorophenyl(pyrrolidine-l-sulfonamide; rac-7V-{3-[l- (4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl(piperidin-4-yl)methyl]piperazin-l- yl ( -2-fluorophenyl)-3 -(pyridin-4-yl)- 177-pyrazol-4-yl]-2, 5 -difluorophenyl (pyrrolidine- 1 - sulfonamide; 7V-{3-[l-(5-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl(piperidin-4- yl)methyl]piperazin-l-yl(pyrimidin-2-yl)-3-(pyridin-4-yl)-177-pyrazol-4-yl]-2,5- difluorophenyl ( pyrrolidine- 1 -sulfonamide; rac-7V- { 3 - [ 1 -(5 - { 4- [( 1 - { 5 - [(37?)-2, 6- dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}pyrimidin-2-yl)-3- (pyridin-4-yl)-177-pyrazol-4-yl]-2,5-difluorophenyl}pyrrolidine-l-sulfonamide; 7V-{5-chloro- 3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]-3-fluorophenyl}piperidin-4- yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6- dioxopiperi din-3 -yl]pyridin-2-yl }piperidin-4-yl)methyl]- 1 ,4-diazepan- 1 -yl } -2-fluorophenyl)- 3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l -sulfonamide; 7V-{5-chloro-3- [l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]-l,4-diazepan-l- yl } -2-fluorophenyl)-3 -(pyridin-4-yl)- 17 / -py razol -4-yl ]-2-fl uorophenyl (pyrrolidine- 1 - sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]-2- fluorophenyl(piperidin-4-yl)methyl]piperazin-l-yl(phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4- yl]-2-fluorophenyl(pyrrolidine-l-sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]-3-fluorophenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)-l / / -pyrazol-4-yl]-2-fluorophenyl [pyrrolidine-1 -sulfonamide; 7V-[5-(difluoromethyl)-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4- yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2- fluorophenyl]pyrrolidine-l -sulfonamide; rac-7V-[5-(difluoromethyl)-3-[l-(4-{4-[(l-{5-[(37?)- 2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)-l / / -pyrazol-4-yl]-2-fluorophenyl]pyrrolidine-l -sulfonamide; 7V-{5-chloro-3-[l- (6-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l- yl}pyridin-3-yl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l- sulfonamide; rac-7V-{5-chloro-3-[l-(6-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2- yl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-3-yl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}-2,5-difluorophenyl)-3- (pyridin-4-yl)- l / / -pyrazol-4-yl]-2-fluorophenyl J pyrrolidine-1 -sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin-l-yl}-2,5-difluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; 7V-[5-chloro-3-(l-{4-[4-({l-[5-(2,4-dioxo-l,3- diazinan- 1 -yl)pyri din-2 -y 1 ] piperi din-4-yl }methyl)piperazin- 1 -yl]phenyl } -3 -(pyridin-4-yl)- l / / -pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; 7V-[5-(difluoromethyl)-3-(l-{4- [4-({l-[4-(2,4-dioxo-l,3-diazinan-l-yl)phenyl]piperidin-4-yl}methyl)piperazin-l-yl]-2- fluorophenyl} -3 -(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; rac-7V-[5-(difluoromethyl)-3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2- yl}piperidin-4-yl)methyl]piperazin-l-yl}-2-fluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]- 2-fluorophenyl]pyrrolidine-l -sulfonamide; 7V-[5-chloro-3-(l-{5-[4-({l-[4-(2,4-dioxo-l,3- diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)piperazin- 1 -yl]pyrimidin-2-yl } -3 -(pyridin-4-yl)- l#-pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; rac-7V-{5-chloro-3-[l-(5-{4-[(l- {5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l- yl}pyrimidin-2-yl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l- sulfonamide; 7V-{5-chloro-3-[l-(5-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}pyrimidin-2-yl)-3-(pyridin-4-yl)-lJH-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l -sulfonamide; 7V-[5-chloro-3-(l-{4-[4-({l-[4-(2,4-dioxo-l,3- diazinan- 1 -yl)phenyl]piperidin-4-yl }methyl)piperazin- 1 -y 1 ] -3 -fluorophenyl } -3 -(pyridin-4- yl)-l#-pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; 7V-[5-(difluoromethyl)-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}-2- fl uorophenyl )-3 -(pyri di n-4-yl )-l / / -pyrazol -4-yl ]-2-fluorophenyl]pyrroli di ne-1 -sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4- yl)methyl]piperazin- 1 -yl } -3 -fluorophenyl)-3 -(pyridin-4-yl)- lJ7-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6- dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}-3-fluorophenyl)-3- (pyridin-4-yl)- l / / -pyrazol-4-yl]-2-fluorophenyl J pyrrolidine-1 -sulfonamide; (3R)-N-[5- chloro-3-(l-{4-[4-({l-[4-(2,4-di oxo-1, 3-diazinan-l -yl)phenyl]piperidin-4- yl } methyl)piperazin- 1 -yl] -3 -fluorophenyl } -3 -(py ridin-4-yl)- lJ7-pyrazol-4-yl)-2- fluorophenyl]-3-fluoropyrrolidine-l-sulfonamide; (37?)-7V-{5-chloro-3-[l-(4-{4-[(l-{5- [(37?5)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}-3- fluorophenyl)-3 -(pyridin-4-yl)- lZ / -pyrazol-4-yl]-2-fluorophenyl } -3 -fluoropyrrolidine- 1 - sulfonamide; (37?)-N-{5-chloro-3-[l-(4-{4-[(l-{4-[(37?)-2,6-dioxopiperidin-3- yl]phenyl }piperidin-4-yl)methyl]piperazin- 1 -yl } -3 -fluorophenyl)-3 -(pyridin-4-yl)- 1H- pyrazol-4-yl]-2-fluorophenyl}-3-fluoropyrrolidine-l-sulfonamide; 7V-[5-chloro-3-(l-{4-[4- ({1 -[5-(2,4-dioxo- 1 ,3 -diazinan- 1 -yl)pyri din-2 -y 1 ]piperi din-4-yl }methyl)piperazin- 1 - yl]phenyl} -3 -(pyridin-4-yl)- l / / -pyrazol-4-yl)-2-fluorophenyl]-3 -fluoroazetidine- 1- sulfonamide; 7V-[5-chloro-3-(l-{4-[4-({l-[5-(2,4-dioxo-l,3-diazinan-l-yl)pyridin-2- yl]piperidin-4-yl}methyl)piperazin-l-yl]-2-fluorophenyl}-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl] -3 -fluoroazetidine- 1 -sulfonamide; 7V-[5-chloro-3-(l-{4-[4-({l-[5-(2,4-dioxo- l,3-diazinan-l-yl)pyridin-2-yl]piperidin-4-yl}methyl)piperazin-l-yl]-2-fluorophenyl}-3- (pyridin-4-yl)-l / / -pyrazol-4-yl)-2-fluorophenyl]pyrrolidine-l -sulfonamide; (37?)-7V-[5-chloro-3-(l-{4-[4-({l-[5-(2,4-dioxo-l,3-diazinan-l-yl)pyridin-2-yl]piperidin-4-yl}methyl)piperazin- l-yl]-2-fluorophenyl}-3-(pyridin-4-yl)-l / / -pyrazol-4-yl)-2-fluorophenyl]-3- fluoropyrrolidine-1 -sulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6-dioxopiperidin-3- yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-lJH-pyrazol-4- yl]-2-fluorophenyl}cyclopentanesulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{5-[(37?)-2,6- dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4- yl)-l / / -pyrazol-4-yl]-2-fluorophenyl } cyclopentanesulfonamide; 7V-{5-chloro-3-[l-(4-{4-[(l- {4-[(37?)-2,6-dioxopiperidin-3-yl]phenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)-l / / -pyrazol-4-yl]-2-fluorophenyl}cyclopentanesulfonamide; (37?)-3-(6-{4-[(4- {4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2,5-difluorophenyl)-3-(pyridin-4-yl)-lJH-pyrazol-1 -yl]phenyl Jpiperazin- 1 -yl)methyl]piperidin- 1 -yl }pyri din-3 -yl)piperidine-2, 6-dione; rac-(3A)-3-(6-{4-[(4-{4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2,5-difluorophenyl)-3-(pyridin- 4-yl)- I / / -py razol - 1 -yl]phenyl } piperazin- 1 -yl)methyl]piperidin- 1 -yl Jpyri din-3 -yl)piperidine- 2, 6-dione; (37?)-3-(4-{4-[(4-{4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2,5-difluorophenyl)- 3 -(pyridin-4-yl)- 1 / / -pyrazol - 1 -yl]phenyl } piperazin- 1 -yl)methyl]piperidin- 1 - yl}phenyl)piperidine-2, 6-dione; 7V-[3-(l-{4-[(3A)-4-[(l-{4-[(3A)-2,6-dioxopiperidin-3- yl]phenyl }piperidin-4-yl)methyl]-3-methylpiperazin-l -yl]phenyl }-3-(pyridin-4-yl)-lJ7- pyrazol-4-yl)-2-fluorophenyl]propane-l -sulfonamide; (37?)-3-(6-{4-[(4-{4-[4-(3-{ [ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-lJ7-pyrazol-l-yl]-3- fluorophenyl } piperazin- 1 -yl)methyl]piperidin- 1 -yl Jpyri din-3 -yl)piperidine-2, 6-dione; (35)-3 - (6-{4-[(4-{4-[4-(3-{[ethyl(methyl)sulfamoyl]amino}-2-fluorophenyl)-3-(pyridin-4-yl)-lZ7- pyrazol-l-yl]-2-fluorophenyl}piperazin-l-yl)methyl]piperidin-l-yl}pyridin-3-yl)piperidine- 2,6-dione; rac-(7?)-N-(3-(l-(4-(4-((4-(4-(2,6-dioxopiperidin-3-yl)phenyl)piperazin-l- yl )methyl)pi peri din-l-yl)phenyl )-3-(pyri di n-4-yl)-l / 7-pyrazol -4-yl )-2-fl uorophenyl )propane-1 -sulfonamide; 7V-(5-chloro-3-(l-(4-((3A,5A)-4-((l-(5-((A5)-2,6-dioxopiperidin-3-yl)pyridin-2-yl)piperidin-4-yl)methyl)-3,5-dimethylpiperazin-l-yl)-2-fluorophenyl)-3-(pyridin-4-yl)- l / Z-pyrazol-4-yl)-2-fluorophenyl)pyrrolidine-l -sulfonamide; 7V-{5-chloro-3-[l-(5-{4-[(l-{5- [(35)-2,6-dioxopiperidin-3-yl]pyridin-2-yl}piperidin-4-yl)methyl]piperazin-l-yl}pyridin-2- yl)-3-(pyridin-4-yl)-l / / -pyrazol-4-yl]-2-fluorophenyl [pyrrolidine-1 -sulfonamide; N-{5- chloro-3-[l-(4-{4-[(l-{4-[(35)-2,6-dioxopiperidin-3-yl]-3-fluorophenyl}piperidin-4- yl)methyl]piperazin-l -yl [phenyl)-3-(pyridin-4-yl)-l / / -pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(3A)-2,6- dioxopiperidin-3-yl]-2,3-difluorophenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)- l / / -pyrazol-4-yl]-2-fluorophenyl J pyrrolidine-1 -sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(3A)-2,6-dioxopiperidin-3-yl]-2,5-difluorophenyl}piperidin-4- yl)methyl]piperazin-l-yl}phenyl)-3-(pyridin-4-yl)-l / 7-pyrazol-4-yl]-2- fluorophenyl}pyrrolidine-l-sulfonamide; rac-7V-{5-chloro-3-[l-(4-{4-[(l-{4-[(3A)-2,6- dioxopiperidin-3-yl]-3,5-difluorophenyl}piperidin-4-yl)methyl]piperazin-l-yl}phenyl)-3- (pyridin-4-yl)-lJ7-pyrazol-4-yl]-2-fluorophenyl}pyrrolidine-l-sulfonamide; and 7V-[5-chloro- 3-(l-{4-[4-({ l-[5-(2,4-dioxo-l,3-diazinan-l-yl)pyridin-2-yl]piperidin-4-yl}methyl)piperazin- l-yl]phenyl}-3-(pyridin-4-yl)-lJH-pyrazol-4-yl)-2-fluorophenyl]cyclopentanesulfonamide.

84. A pharmaceutical composition comprising the compound of any one of the previous claims and a pharmaceutically acceptable carrier, excipient, and / or diluent.

85. A method of treating a disease or disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound or composition of any one of the previous claims.

86. The method of claim 85, wherein the disease or disorder is cancer.

87. The compound or composition of any one of the previous claims for use in therapy.

88. The compound or composition of any one of the previous claims for use in the treatment of cancer.

Images